id	sid	tid	token	lemma	pos
dpc-2043	1	1	dermatology	dermatology	NOUN
dpc-2043	1	2	:	:	PUNCT
dpc-2043	1	3	practical	practical	ADJ
dpc-2043	1	4	and	and	CCONJ
dpc-2043	1	5	conceptual	conceptual	ADJ
dpc-2043	1	6	original	original	ADJ
dpc-2043	1	7	article	article	NOUN
dpc-2043	1	8	|	|	ADV
dpc-2043	1	9	dermatol	dermatol	ADJ
dpc-2043	1	10	pract	pract	NOUN
dpc-2043	1	11	concept	concept	NOUN
dpc-2043	1	12	.	.	PUNCT
dpc-2043	2	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	2	2	1	1	NUM
dpc-2043	2	3	serum	serum	NOUN
dpc-2043	2	4	copper	copper	NOUN
dpc-2043	2	5	and	and	CCONJ
dpc-2043	2	6	zinc	zinc	NOUN
dpc-2043	2	7	levels	level	NOUN
dpc-2043	2	8	among	among	ADP
dpc-2043	2	9	iranian	iranian	ADJ
dpc-2043	2	10	vitiligo	vitiligo	NOUN
dpc-2043	2	11	patients	patient	NOUN
dpc-2043	2	12	zahra	zahra	PROPN
dpc-2043	2	13	khoshdel1	khoshdel1	PROPN
dpc-2043	2	14	,	,	PUNCT
dpc-2043	2	15	naser	naser	PROPN
dpc-2043	2	16	gholijani2	gholijani2	PROPN
dpc-2043	2	17	,	,	PUNCT
dpc-2043	2	18	maryam	maryam	PROPN
dpc-2043	2	19	niknam1	niknam1	PROPN
dpc-2043	2	20	,	,	PUNCT
dpc-2043	2	21	nasim	nasim	PROPN
dpc-2043	2	22	rahmani1	rahmani1	PROPN
dpc-2043	2	23	,	,	PUNCT
dpc-2043	2	24	mohsen	mohsen	PROPN
dpc-2043	2	25	hemmati	hemmati	PROPN
dpc-2043	2	26	-	-	PROPN
dpc-2043	2	27	dinarvand1	dinarvand1	PROPN
dpc-2043	2	28	,	,	PUNCT
dpc-2043	2	29	fakhraddin	fakhraddin	VERB
dpc-2043	2	30	naghibalhossaini1,2	naghibalhossaini1,2	PROPN
dpc-2043	2	31	1	1	NUM
dpc-2043	2	32	department	department	NOUN
dpc-2043	2	33	of	of	ADP
dpc-2043	2	34	biochemistry	biochemistry	NOUN
dpc-2043	2	35	,	,	PUNCT
dpc-2043	2	36	shiraz	shiraz	PROPN
dpc-2043	2	37	university	university	PROPN
dpc-2043	2	38	of	of	ADP
dpc-2043	2	39	medical	medical	ADJ
dpc-2043	2	40	sciences	sciences	PROPN
dpc-2043	2	41	,	,	PUNCT
dpc-2043	2	42	school	school	NOUN
dpc-2043	2	43	of	of	ADP
dpc-2043	2	44	medicine	medicine	NOUN
dpc-2043	2	45	,	,	PUNCT
dpc-2043	2	46	shiraz	shiraz	PROPN
dpc-2043	2	47	,	,	PUNCT
dpc-2043	2	48	iran	iran	PROPN
dpc-2043	2	49	2	2	NUM
dpc-2043	2	50	autoimmune	autoimmune	NOUN
dpc-2043	2	51	diseases	disease	NOUN
dpc-2043	2	52	research	research	NOUN
dpc-2043	2	53	center	center	NOUN
dpc-2043	2	54	,	,	PUNCT
dpc-2043	2	55	shiraz	shiraz	PROPN
dpc-2043	2	56	university	university	PROPN
dpc-2043	2	57	of	of	ADP
dpc-2043	2	58	medical	medical	ADJ
dpc-2043	2	59	sciences	sciences	PROPN
dpc-2043	2	60	,	,	PUNCT
dpc-2043	2	61	school	school	NOUN
dpc-2043	2	62	of	of	ADP
dpc-2043	2	63	medicine	medicine	NOUN
dpc-2043	2	64	,	,	PUNCT
dpc-2043	2	65	shiraz	shiraz	PROPN
dpc-2043	2	66	,	,	PUNCT
dpc-2043	2	67	iran	iran	PROPN
dpc-2043	2	68	key	key	ADJ
dpc-2043	2	69	words	word	NOUN
dpc-2043	2	70	:	:	PUNCT
dpc-2043	2	71	vitiligo	vitiligo	NOUN
dpc-2043	2	72	,	,	PUNCT
dpc-2043	2	73	trace	trace	NOUN
dpc-2043	2	74	elements	element	NOUN
dpc-2043	2	75	,	,	PUNCT
dpc-2043	2	76	zinc	zinc	NOUN
dpc-2043	2	77	,	,	PUNCT
dpc-2043	2	78	copper	copper	NOUN
dpc-2043	2	79	citation	citation	NOUN
dpc-2043	2	80	:	:	PUNCT
dpc-2043	2	81	khoshdel	khoshdel	PROPN
dpc-2043	2	82	z	z	PROPN
dpc-2043	2	83	,	,	PUNCT
dpc-2043	2	84	gholijani	gholijani	PROPN
dpc-2043	2	85	n	n	CCONJ
dpc-2043	2	86	,	,	PUNCT
dpc-2043	2	87	niknam	niknam	PROPN
dpc-2043	2	88	m	m	PROPN
dpc-2043	2	89	,	,	PUNCT
dpc-2043	2	90	rahmani	rahmani	VERB
dpc-2043	2	91	n	n	CCONJ
dpc-2043	2	92	,	,	PUNCT
dpc-2043	2	93	hemmati	hemmati	PROPN
dpc-2043	2	94	-	-	PUNCT
dpc-2043	2	95	dinarvand	dinarvand	PROPN
dpc-2043	2	96	m	m	PROPN
dpc-2043	2	97	,	,	PUNCT
dpc-2043	2	98	naghibalhossaini	naghibalhossaini	PROPN
dpc-2043	2	99	f.	f.	PROPN
dpc-2043	2	100	serum	serum	PROPN
dpc-2043	2	101	copper	copper	PROPN
dpc-2043	2	102	and	and	CCONJ
dpc-2043	2	103	zinc	zinc	NOUN
dpc-2043	2	104	levels	level	NOUN
dpc-2043	2	105	among	among	ADP
dpc-2043	2	106	iranian	iranian	ADJ
dpc-2043	2	107	vitiligo	vitiligo	NOUN
dpc-2043	2	108	patients	patient	NOUN
dpc-2043	2	109	.	.	PUNCT
dpc-2043	3	1	dermatol	dermatol	NOUN
dpc-2043	3	2	pract	pract	PROPN
dpc-2043	3	3	concept	concept	NOUN
dpc-2043	3	4	.	.	PUNCT
dpc-2043	4	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	4	2	.	.	PUNCT
dpc-2043	4	3	doi	doi	PROPN
dpc-2043	4	4	:	:	PUNCT
dpc-2043	4	5	https://doi.org/10.5826/dpc.1204a140	https://doi.org/10.5826/dpc.1204a140	ADJ
dpc-2043	4	6	accepted	accept	VERB
dpc-2043	4	7	:	:	PUNCT
dpc-2043	4	8	january	january	PROPN
dpc-2043	4	9	2	2	NUM
dpc-2043	4	10	,	,	PUNCT
dpc-2043	4	11	2022	2022	NUM
dpc-2043	4	12	;	;	PUNCT
dpc-2043	4	13	published	publish	VERB
dpc-2043	4	14	:	:	PUNCT
dpc-2043	4	15	october	october	PROPN
dpc-2043	4	16	2022	2022	NUM
dpc-2043	5	1	copyright	copyright	NOUN
dpc-2043	5	2	:	:	PUNCT
dpc-2043	5	3	©	©	PROPN
dpc-2043	5	4	2022	2022	NUM
dpc-2043	5	5	khoshdel	khoshdel	PROPN
dpc-2043	5	6	et	et	PROPN
dpc-2043	5	7	al	al	PROPN
dpc-2043	5	8	.	.	PUNCT
dpc-2043	6	1	this	this	PRON
dpc-2043	6	2	is	be	AUX
dpc-2043	6	3	an	an	DET
dpc-2043	6	4	open	open	ADJ
dpc-2043	6	5	-	-	PUNCT
dpc-2043	6	6	access	access	NOUN
dpc-2043	6	7	article	article	NOUN
dpc-2043	6	8	distributed	distribute	VERB
dpc-2043	6	9	under	under	ADP
dpc-2043	6	10	the	the	DET
dpc-2043	6	11	terms	term	NOUN
dpc-2043	6	12	of	of	ADP
dpc-2043	6	13	the	the	DET
dpc-2043	6	14	creative	creative	ADJ
dpc-2043	6	15	commons	common	NOUN
dpc-2043	6	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2043	6	17	license	license	NOUN
dpc-2043	6	18	(	(	PUNCT
dpc-2043	6	19	by	by	ADP
dpc-2043	6	20	-	-	PUNCT
dpc-2043	6	21	nc-4.0	nc-4.0	NOUN
dpc-2043	6	22	)	)	PUNCT
dpc-2043	6	23	,	,	PUNCT
dpc-2043	6	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2043	6	25	,	,	PUNCT
dpc-2043	6	26	which	which	PRON
dpc-2043	6	27	permits	permit	VERB
dpc-2043	6	28	unrestricted	unrestricted	ADJ
dpc-2043	6	29	noncommercial	noncommercial	ADJ
dpc-2043	6	30	use	use	NOUN
dpc-2043	6	31	,	,	PUNCT
dpc-2043	6	32	distribution	distribution	NOUN
dpc-2043	6	33	,	,	PUNCT
dpc-2043	6	34	and	and	CCONJ
dpc-2043	6	35	reproduction	reproduction	NOUN
dpc-2043	6	36	in	in	ADP
dpc-2043	6	37	any	any	DET
dpc-2043	6	38	medium	medium	NOUN
dpc-2043	6	39	,	,	PUNCT
dpc-2043	6	40	provided	provide	VERB
dpc-2043	6	41	the	the	DET
dpc-2043	6	42	original	original	ADJ
dpc-2043	6	43	authors	author	NOUN
dpc-2043	6	44	and	and	CCONJ
dpc-2043	6	45	source	source	NOUN
dpc-2043	6	46	are	be	AUX
dpc-2043	6	47	credited	credit	VERB
dpc-2043	6	48	.	.	PUNCT
dpc-2043	7	1	funding	funding	NOUN
dpc-2043	7	2	:	:	PUNCT
dpc-2043	7	3	this	this	DET
dpc-2043	7	4	research	research	NOUN
dpc-2043	7	5	was	be	AUX
dpc-2043	7	6	supported	support	VERB
dpc-2043	7	7	by	by	ADP
dpc-2043	7	8	the	the	DET
dpc-2043	7	9	vice	vice	NOUN
dpc-2043	7	10	chancellor	chancellor	NOUN
dpc-2043	7	11	for	for	ADP
dpc-2043	7	12	research	research	NOUN
dpc-2043	7	13	,	,	PUNCT
dpc-2043	7	14	shiraz	shiraz	PROPN
dpc-2043	7	15	university	university	PROPN
dpc-2043	7	16	of	of	ADP
dpc-2043	7	17	medical	medical	ADJ
dpc-2043	7	18	sciences	science	NOUN
dpc-2043	7	19	through	through	ADP
dpc-2043	7	20	grant	grant	NOUN
dpc-2043	7	21	number	number	NOUN
dpc-2043	7	22	98	98	NUM
dpc-2043	7	23	-	-	SYM
dpc-2043	7	24	01	01	NUM
dpc-2043	7	25	-	-	PUNCT
dpc-2043	7	26	17	17	NUM
dpc-2043	7	27	-	-	SYM
dpc-2043	7	28	19678	19678	NUM
dpc-2043	7	29	.	.	PUNCT
dpc-2043	8	1	competing	compete	VERB
dpc-2043	8	2	interests	interest	NOUN
dpc-2043	8	3	:	:	PUNCT
dpc-2043	8	4	none	none	NOUN
dpc-2043	8	5	.	.	PUNCT
dpc-2043	9	1	authorship	authorship	NOUN
dpc-2043	9	2	:	:	PUNCT
dpc-2043	9	3	all	all	DET
dpc-2043	9	4	authors	author	NOUN
dpc-2043	9	5	have	have	AUX
dpc-2043	9	6	contributed	contribute	VERB
dpc-2043	9	7	significantly	significantly	ADV
dpc-2043	9	8	to	to	ADP
dpc-2043	9	9	this	this	DET
dpc-2043	9	10	publication	publication	NOUN
dpc-2043	9	11	.	.	PUNCT
dpc-2043	10	1	corresponding	correspond	VERB
dpc-2043	10	2	author	author	NOUN
dpc-2043	10	3	:	:	PUNCT
dpc-2043	10	4	fakhraddin	fakhraddin	VERB
dpc-2043	10	5	naghibalhossaini	naghibalhossaini	NOUN
dpc-2043	10	6	(	(	PUNCT
dpc-2043	10	7	ph	ph	PROPN
dpc-2043	10	8	.	.	PROPN
dpc-2043	10	9	d	d	NOUN
dpc-2043	10	10	)	)	PUNCT
dpc-2043	10	11	,	,	PUNCT
dpc-2043	10	12	department	department	NOUN
dpc-2043	10	13	of	of	ADP
dpc-2043	10	14	biochemistry	biochemistry	NOUN
dpc-2043	10	15	,	,	PUNCT
dpc-2043	10	16	shiraz	shiraz	PROPN
dpc-2043	10	17	university	university	PROPN
dpc-2043	10	18	of	of	ADP
dpc-2043	10	19	medical	medical	ADJ
dpc-2043	10	20	sciences	sciences	PROPN
dpc-2043	10	21	,	,	PUNCT
dpc-2043	10	22	school	school	NOUN
dpc-2043	10	23	of	of	ADP
dpc-2043	10	24	 	 	SPACE
dpc-2043	10	25	medicine	medicine	NOUN
dpc-2043	10	26	,	,	PUNCT
dpc-2043	10	27	zand	zand	PROPN
dpc-2043	10	28	street	street	PROPN
dpc-2043	10	29	,	,	PUNCT
dpc-2043	10	30	shiraz	shiraz	PROPN
dpc-2043	10	31	,	,	PUNCT
dpc-2043	10	32	7134845794	7134845794	NUM
dpc-2043	10	33	,	,	PUNCT
dpc-2043	10	34	iran	iran	PROPN
dpc-2043	10	35	,	,	PUNCT
dpc-2043	10	36	fax	fax	NOUN
dpc-2043	10	37	:	:	PUNCT
dpc-2043	10	38	+98	+98	ADJ
dpc-2043	10	39	-	-	PUNCT
dpc-2043	10	40	71	71	NUM
dpc-2043	10	41	-	-	PUNCT
dpc-2043	10	42	32303029	32303029	NUM
dpc-2043	10	43	e	e	NOUN
dpc-2043	10	44	-	-	NOUN
dpc-2043	10	45	mail	mail	NOUN
dpc-2043	10	46	:	:	PUNCT
dpc-2043	10	47	fakhraddin.naghibalhossaini@mail.mcgill.ca	fakhraddin.naghibalhossaini@mail.mcgill.ca	NOUN
dpc-2043	10	48	introduction	introduction	NOUN
dpc-2043	10	49	:	:	PUNCT
dpc-2043	10	50	vitiligo	vitiligo	PROPN
dpc-2043	10	51	is	be	AUX
dpc-2043	10	52	a	a	DET
dpc-2043	10	53	chronic	chronic	ADJ
dpc-2043	10	54	skin	skin	NOUN
dpc-2043	10	55	disease	disease	NOUN
dpc-2043	10	56	,	,	PUNCT
dpc-2043	10	57	which	which	PRON
dpc-2043	10	58	its	its	PRON
dpc-2043	10	59	etiopathogenesis	etiopathogenesis	NOUN
dpc-2043	10	60	is	be	AUX
dpc-2043	10	61	not	not	PART
dpc-2043	10	62	fully	fully	ADV
dpc-2043	10	63	understood	understand	VERB
dpc-2043	10	64	.	.	PUNCT
dpc-2043	11	1	numerous	numerous	ADJ
dpc-2043	11	2	studies	study	NOUN
dpc-2043	11	3	have	have	AUX
dpc-2043	11	4	suggested	suggest	VERB
dpc-2043	11	5	that	that	SCONJ
dpc-2043	11	6	oxidative	oxidative	ADJ
dpc-2043	11	7	stress	stress	NOUN
dpc-2043	11	8	may	may	AUX
dpc-2043	11	9	play	play	VERB
dpc-2043	11	10	a	a	DET
dpc-2043	11	11	role	role	NOUN
dpc-2043	11	12	in	in	ADP
dpc-2043	11	13	the	the	DET
dpc-2043	11	14	pathophysiology	pathophysiology	NOUN
dpc-2043	11	15	of	of	ADP
dpc-2043	11	16	vitiligo	vitiligo	NOUN
dpc-2043	11	17	.	.	PUNCT
dpc-2043	12	1	there	there	PRON
dpc-2043	12	2	are	be	VERB
dpc-2043	12	3	controversial	controversial	ADJ
dpc-2043	12	4	reports	report	NOUN
dpc-2043	12	5	as	as	ADP
dpc-2043	12	6	to	to	ADP
dpc-2043	12	7	the	the	DET
dpc-2043	12	8	changes	change	NOUN
dpc-2043	12	9	of	of	ADP
dpc-2043	12	10	serum	serum	NOUN
dpc-2043	12	11	trace	trace	NOUN
dpc-2043	12	12	elements	element	NOUN
dpc-2043	12	13	,	,	PUNCT
dpc-2043	12	14	copper	copper	NOUN
dpc-2043	12	15	(	(	PUNCT
dpc-2043	12	16	cu	cu	PROPN
dpc-2043	12	17	)	)	PUNCT
dpc-2043	12	18	and	and	CCONJ
dpc-2043	12	19	zinc	zinc	NOUN
dpc-2043	12	20	(	(	PUNCT
dpc-2043	12	21	zn	zn	NOUN
dpc-2043	12	22	)	)	PUNCT
dpc-2043	12	23	levels	level	NOUN
dpc-2043	12	24	in	in	ADP
dpc-2043	12	25	vitiligo	vitiligo	NOUN
dpc-2043	12	26	patients	patient	NOUN
dpc-2043	12	27	.	.	PUNCT
dpc-2043	13	1	objectives	objective	NOUN
dpc-2043	13	2	:	:	PUNCT
dpc-2043	13	3	we	we	PRON
dpc-2043	13	4	evaluated	evaluate	VERB
dpc-2043	13	5	the	the	DET
dpc-2043	13	6	alterations	alteration	NOUN
dpc-2043	13	7	in	in	ADP
dpc-2043	13	8	the	the	DET
dpc-2043	13	9	level	level	NOUN
dpc-2043	13	10	of	of	ADP
dpc-2043	13	11	serum	serum	NOUN
dpc-2043	13	12	cu	cu	PROPN
dpc-2043	13	13	and	and	CCONJ
dpc-2043	13	14	zn	zn	PROPN
dpc-2043	13	15	among	among	ADP
dpc-2043	13	16	a	a	DET
dpc-2043	13	17	group	group	NOUN
dpc-2043	13	18	of	of	ADP
dpc-2043	13	19	iranian	iranian	ADJ
dpc-2043	13	20	vitiligo	vitiligo	NOUN
dpc-2043	13	21	patients	patient	NOUN
dpc-2043	13	22	.	.	PUNCT
dpc-2043	14	1	methods	method	NOUN
dpc-2043	14	2	:	:	PUNCT
dpc-2043	14	3	the	the	DET
dpc-2043	14	4	levels	level	NOUN
dpc-2043	14	5	of	of	ADP
dpc-2043	14	6	serum	serum	PROPN
dpc-2043	14	7	cu	cu	PROPN
dpc-2043	14	8	and	and	CCONJ
dpc-2043	14	9	zn	zn	PROPN
dpc-2043	14	10	were	be	AUX
dpc-2043	14	11	compared	compare	VERB
dpc-2043	14	12	between	between	ADP
dpc-2043	14	13	117	117	NUM
dpc-2043	14	14	vitiligo	vitiligo	NOUN
dpc-2043	14	15	patients	patient	NOUN
dpc-2043	14	16	and	and	CCONJ
dpc-2043	14	17	137	137	NUM
dpc-2043	14	18	healthy	healthy	ADJ
dpc-2043	14	19	controls	control	NOUN
dpc-2043	14	20	using	use	VERB
dpc-2043	14	21	atomic	atomic	ADJ
dpc-2043	14	22	absorption	absorption	NOUN
dpc-2043	14	23	spectrophotometry	spectrophotometry	NOUN
dpc-2043	14	24	.	.	PUNCT
dpc-2043	15	1	results	result	NOUN
dpc-2043	15	2	:	:	PUNCT
dpc-2043	15	3	the	the	DET
dpc-2043	15	4	mean	mean	ADJ
dpc-2043	15	5	cu	cu	PROPN
dpc-2043	15	6	and	and	CCONJ
dpc-2043	15	7	zn	zn	PROPN
dpc-2043	15	8	levels	level	NOUN
dpc-2043	15	9	in	in	ADP
dpc-2043	15	10	the	the	DET
dpc-2043	15	11	cases	case	NOUN
dpc-2043	15	12	(	(	PUNCT
dpc-2043	15	13	113.57	113.57	NUM
dpc-2043	15	14	±	±	NUM
dpc-2043	15	15	59.43	59.43	NUM
dpc-2043	15	16	and	and	CCONJ
dpc-2043	15	17	95.01	95.01	NUM
dpc-2043	15	18	±	±	NUM
dpc-2043	15	19	58.95	58.95	NUM
dpc-2043	15	20	μg	μg	PROPN
dpc-2043	15	21	/	/	SYM
dpc-2043	15	22	dl	dl	PROPN
dpc-2043	15	23	,	,	PUNCT
dpc-2043	15	24	respectively	respectively	ADV
dpc-2043	15	25	)	)	PUNCT
dpc-2043	15	26	were	be	AUX
dpc-2043	15	27	significantly	significantly	ADV
dpc-2043	15	28	lower	low	ADJ
dpc-2043	15	29	than	than	ADP
dpc-2043	15	30	those	those	PRON
dpc-2043	15	31	of	of	ADP
dpc-2043	15	32	the	the	DET
dpc-2043	15	33	controls	control	NOUN
dpc-2043	15	34	(	(	PUNCT
dpc-2043	15	35	138.90	138.90	NUM
dpc-2043	15	36	±	±	NUM
dpc-2043	15	37	38.14	38.14	NUM
dpc-2043	15	38	and	and	CCONJ
dpc-2043	15	39	121.83	121.83	NUM
dpc-2043	15	40	±	±	NUM
dpc-2043	15	41	33.80	33.80	NUM
dpc-2043	15	42	μg	μg	PROPN
dpc-2043	15	43	/	/	SYM
dpc-2043	15	44	dl	dl	PROPN
dpc-2043	15	45	,	,	PUNCT
dpc-2043	15	46	respectively	respectively	ADV
dpc-2043	15	47	)	)	PUNCT
dpc-2043	16	1	(	(	PUNCT
dpc-2043	16	2	p	p	NOUN
dpc-2043	16	3	=	=	NOUN
dpc-2043	16	4	0.00	0.00	NUM
dpc-2043	16	5	)	)	PUNCT
dpc-2043	16	6	.	.	PUNCT
dpc-2043	17	1	we	we	PRON
dpc-2043	17	2	also	also	ADV
dpc-2043	17	3	observed	observe	VERB
dpc-2043	17	4	significantly	significantly	ADV
dpc-2043	17	5	lower	low	ADJ
dpc-2043	17	6	serum	serum	PROPN
dpc-2043	17	7	cu	cu	PROPN
dpc-2043	17	8	and	and	CCONJ
dpc-2043	17	9	zn	zn	PROPN
dpc-2043	17	10	concentrations	concentration	NOUN
dpc-2043	17	11	in	in	ADP
dpc-2043	17	12	young	young	ADJ
dpc-2043	17	13	(	(	PUNCT
dpc-2043	17	14	<	<	X
dpc-2043	17	15	50	50	NUM
dpc-2043	17	16	years	year	NOUN
dpc-2043	17	17	)	)	PUNCT
dpc-2043	17	18	than	than	ADP
dpc-2043	17	19	the	the	DET
dpc-2043	17	20	elderly	elderly	ADJ
dpc-2043	17	21	(	(	PUNCT
dpc-2043	17	22	≥	≥	NOUN
dpc-2043	17	23	50	50	NUM
dpc-2043	17	24	years	year	NOUN
dpc-2043	17	25	)	)	PUNCT
dpc-2043	17	26	patients	patient	NOUN
dpc-2043	17	27	(	(	PUNCT
dpc-2043	17	28	p	p	X
dpc-2043	17	29	=	=	NOUN
dpc-2043	17	30	0.00	0.00	NUM
dpc-2043	17	31	)	)	PUNCT
dpc-2043	17	32	.	.	PUNCT
dpc-2043	18	1	the	the	DET
dpc-2043	18	2	mean	mean	PROPN
dpc-2043	18	3	cu	cu	PROPN
dpc-2043	18	4	and	and	CCONJ
dpc-2043	18	5	zn	zn	PROPN
dpc-2043	18	6	levels	level	NOUN
dpc-2043	18	7	in	in	ADP
dpc-2043	18	8	the	the	DET
dpc-2043	18	9	patients	patient	NOUN
dpc-2043	18	10	with	with	ADP
dpc-2043	18	11	generalized	generalized	ADJ
dpc-2043	18	12	vitiligo	vitiligo	NOUN
dpc-2043	18	13	(	(	PUNCT
dpc-2043	18	14	111.63±54.18	111.63±54.18	NUM
dpc-2043	18	15	and	and	CCONJ
dpc-2043	18	16	93.11±59.33	93.11±59.33	NUM
dpc-2043	18	17	μg	μg	PROPN
dpc-2043	18	18	/	/	SYM
dpc-2043	18	19	dl	dl	PROPN
dpc-2043	18	20	,	,	PUNCT
dpc-2043	18	21	respectively	respectively	ADV
dpc-2043	18	22	)	)	PUNCT
dpc-2043	18	23	were	be	AUX
dpc-2043	18	24	significantly	significantly	ADV
dpc-2043	18	25	lower	low	ADJ
dpc-2043	18	26	than	than	ADP
dpc-2043	18	27	patients	patient	NOUN
dpc-2043	18	28	with	with	ADP
dpc-2043	18	29	localized	localized	ADJ
dpc-2043	18	30	vitiligo	vitiligo	NOUN
dpc-2043	18	31	(	(	PUNCT
dpc-2043	18	32	120.74	120.74	NUM
dpc-2043	18	33	±71.64	±71.64	NOUN
dpc-2043	18	34	and	and	CCONJ
dpc-2043	18	35	98.69±58.63	98.69±58.63	NUM
dpc-2043	18	36	μg	μg	PROPN
dpc-2043	18	37	/	/	SYM
dpc-2043	18	38	dl	dl	PROPN
dpc-2043	18	39	,	,	PUNCT
dpc-2043	18	40	respectively	respectively	ADV
dpc-2043	18	41	)	)	PUNCT
dpc-2043	18	42	and	and	CCONJ
dpc-2043	18	43	those	those	PRON
dpc-2043	18	44	in	in	ADP
dpc-2043	18	45	the	the	DET
dpc-2043	18	46	control	control	NOUN
dpc-2043	18	47	(	(	PUNCT
dpc-2043	18	48	p	p	X
dpc-2043	18	49	=	=	NOUN
dpc-2043	18	50	0.00	0.00	NUM
dpc-2043	18	51	)	)	PUNCT
dpc-2043	18	52	.	.	PUNCT
dpc-2043	19	1	the	the	DET
dpc-2043	19	2	serum	serum	PROPN
dpc-2043	19	3	cu	cu	PROPN
dpc-2043	19	4	/	/	SYM
dpc-2043	19	5	zn	zn	PROPN
dpc-2043	19	6	ratio	ratio	NOUN
dpc-2043	19	7	obtained	obtain	VERB
dpc-2043	19	8	in	in	ADP
dpc-2043	19	9	the	the	DET
dpc-2043	19	10	young	young	ADJ
dpc-2043	19	11	and	and	CCONJ
dpc-2043	19	12	male	male	ADJ
dpc-2043	19	13	patients	patient	NOUN
dpc-2043	19	14	was	be	AUX
dpc-2043	19	15	higher	high	ADJ
dpc-2043	19	16	than	than	ADP
dpc-2043	19	17	those	those	PRON
dpc-2043	19	18	in	in	ADP
dpc-2043	19	19	their	their	PRON
dpc-2043	19	20	matched	match	VERB
dpc-2043	19	21	controls	control	NOUN
dpc-2043	19	22	(	(	PUNCT
dpc-2043	19	23	p	p	X
dpc-2043	19	24	=	=	NOUN
dpc-2043	19	25	0.01	0.01	NUM
dpc-2043	19	26	)	)	PUNCT
dpc-2043	19	27	.	.	PUNCT
dpc-2043	20	1	conclusions	conclusion	NOUN
dpc-2043	20	2	:	:	PUNCT
dpc-2043	20	3	the	the	DET
dpc-2043	20	4	current	current	ADJ
dpc-2043	20	5	study	study	NOUN
dpc-2043	20	6	has	have	AUX
dpc-2043	20	7	shown	show	VERB
dpc-2043	20	8	that	that	SCONJ
dpc-2043	20	9	the	the	DET
dpc-2043	20	10	disturbance	disturbance	NOUN
dpc-2043	20	11	of	of	ADP
dpc-2043	20	12	serum	serum	PROPN
dpc-2043	20	13	cu	cu	PROPN
dpc-2043	20	14	and	and	CCONJ
dpc-2043	20	15	zn	zn	PROPN
dpc-2043	20	16	levels	level	NOUN
dpc-2043	20	17	is	be	AUX
dpc-2043	20	18	associated	associate	VERB
dpc-2043	20	19	with	with	ADP
dpc-2043	20	20	vitiligo	vitiligo	NOUN
dpc-2043	20	21	,	,	PUNCT
dpc-2043	20	22	and	and	CCONJ
dpc-2043	20	23	may	may	AUX
dpc-2043	20	24	play	play	VERB
dpc-2043	20	25	an	an	DET
dpc-2043	20	26	important	important	ADJ
dpc-2043	20	27	role	role	NOUN
dpc-2043	20	28	in	in	ADP
dpc-2043	20	29	the	the	DET
dpc-2043	20	30	disease	disease	NOUN
dpc-2043	20	31	development	development	NOUN
dpc-2043	20	32	of	of	ADP
dpc-2043	20	33	iranian	iranian	ADJ
dpc-2043	20	34	patients	patient	NOUN
dpc-2043	20	35	.	.	PUNCT
dpc-2043	21	1	abstract	abstract	ADJ
dpc-2043	21	2	2	2	NUM
dpc-2043	21	3	original	original	ADJ
dpc-2043	21	4	article	article	NOUN
dpc-2043	21	5	|	|	ADV
dpc-2043	21	6	dermatol	dermatol	ADJ
dpc-2043	21	7	pract	pract	NOUN
dpc-2043	21	8	concept	concept	NOUN
dpc-2043	21	9	.	.	PUNCT
dpc-2043	22	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	22	2	introduction	introduction	NOUN
dpc-2043	22	3	vitiligo	vitiligo	NOUN
dpc-2043	22	4	is	be	AUX
dpc-2043	22	5	a	a	DET
dpc-2043	22	6	multifactorial	multifactorial	ADJ
dpc-2043	22	7	hypo	hypo	ADJ
dpc-2043	22	8	-	-	PUNCT
dpc-2043	22	9	melanotic	melanotic	ADJ
dpc-2043	22	10	disorder	disorder	NOUN
dpc-2043	22	11	characterized	characterize	VERB
dpc-2043	22	12	by	by	ADP
dpc-2043	22	13	the	the	DET
dpc-2043	22	14	appearance	appearance	NOUN
dpc-2043	22	15	of	of	ADP
dpc-2043	22	16	white	white	ADJ
dpc-2043	22	17	spots	spot	NOUN
dpc-2043	22	18	of	of	ADP
dpc-2043	22	19	different	different	ADJ
dpc-2043	22	20	sizes	size	NOUN
dpc-2043	22	21	and	and	CCONJ
dpc-2043	22	22	shapes	shape	NOUN
dpc-2043	22	23	on	on	ADP
dpc-2043	22	24	the	the	DET
dpc-2043	22	25	skin	skin	NOUN
dpc-2043	22	26	.	.	PUNCT
dpc-2043	23	1	the	the	DET
dpc-2043	23	2	disease	disease	NOUN
dpc-2043	23	3	affects	affect	VERB
dpc-2043	23	4	0.1	0.1	NUM
dpc-2043	23	5	%	%	NOUN
dpc-2043	23	6	to	to	ADP
dpc-2043	23	7	8.8	8.8	NUM
dpc-2043	23	8	%	%	NOUN
dpc-2043	23	9	of	of	ADP
dpc-2043	23	10	the	the	DET
dpc-2043	23	11	world	world	NOUN
dpc-2043	23	12	’s	’s	PART
dpc-2043	23	13	population	population	NOUN
dpc-2043	23	14	,	,	PUNCT
dpc-2043	23	15	with	with	ADP
dpc-2043	23	16	a	a	DET
dpc-2043	23	17	higher	high	ADJ
dpc-2043	23	18	prevalence	prevalence	NOUN
dpc-2043	23	19	among	among	ADP
dpc-2043	23	20	pigmented	pigmented	ADJ
dpc-2043	23	21	racial	racial	ADJ
dpc-2043	23	22	groups	group	NOUN
dpc-2043	23	23	[	[	X
dpc-2043	23	24	1,2	1,2	NUM
dpc-2043	23	25	]	]	PUNCT
dpc-2043	23	26	.	.	PUNCT
dpc-2043	24	1	the	the	DET
dpc-2043	24	2	loss	loss	NOUN
dpc-2043	24	3	of	of	ADP
dpc-2043	24	4	functional	functional	ADJ
dpc-2043	24	5	melanocytes	melanocyte	NOUN
dpc-2043	24	6	has	have	AUX
dpc-2043	24	7	been	be	AUX
dpc-2043	24	8	detected	detect	VERB
dpc-2043	24	9	histochemically	histochemically	ADV
dpc-2043	24	10	in	in	ADP
dpc-2043	24	11	the	the	DET
dpc-2043	24	12	skin	skin	NOUN
dpc-2043	24	13	as	as	ADP
dpc-2043	24	14	well	well	ADV
dpc-2043	24	15	mucous	mucous	ADJ
dpc-2043	24	16	membranes	membrane	NOUN
dpc-2043	24	17	,	,	PUNCT
dpc-2043	24	18	hair	hair	NOUN
dpc-2043	24	19	,	,	PUNCT
dpc-2043	24	20	and	and	CCONJ
dpc-2043	24	21	the	the	DET
dpc-2043	24	22	retina	retina	NOUN
dpc-2043	24	23	of	of	ADP
dpc-2043	24	24	vitiligo	vitiligo	ADJ
dpc-2043	24	25	patients	patient	NOUN
dpc-2043	24	26	[	[	X
dpc-2043	24	27	3	3	NUM
dpc-2043	24	28	]	]	PUNCT
dpc-2043	24	29	.	.	PUNCT
dpc-2043	25	1	many	many	ADJ
dpc-2043	25	2	different	different	ADJ
dpc-2043	25	3	factors	factor	NOUN
dpc-2043	25	4	,	,	PUNCT
dpc-2043	25	5	including	include	VERB
dpc-2043	25	6	genetics	genetic	NOUN
dpc-2043	25	7	,	,	PUNCT
dpc-2043	25	8	oxidative	oxidative	ADJ
dpc-2043	25	9	stress	stress	NOUN
dpc-2043	25	10	,	,	PUNCT
dpc-2043	25	11	environment	environment	NOUN
dpc-2043	25	12	,	,	PUNCT
dpc-2043	25	13	metabolic	metabolic	NOUN
dpc-2043	25	14	abnormalities	abnormality	NOUN
dpc-2043	25	15	,	,	PUNCT
dpc-2043	25	16	autoimmunity	autoimmunity	NOUN
dpc-2043	25	17	mediated	mediate	VERB
dpc-2043	25	18	by	by	ADP
dpc-2043	25	19	autoreactive	autoreactive	PROPN
dpc-2043	25	20	cd8	cd8	PROPN
dpc-2043	25	21	+	+	PROPN
dpc-2043	25	22	t	t	PROPN
dpc-2043	25	23	lymphocytes	lymphocyte	NOUN
dpc-2043	25	24	,	,	PUNCT
dpc-2043	25	25	and	and	CCONJ
dpc-2043	25	26	interferon	interferon	ADJ
dpc-2043	25	27	-	-	PUNCT
dpc-2043	25	28	γ	γ	NOUN
dpc-2043	25	29	cxcl10	cxcl10	NOUN
dpc-2043	25	30	cytokine	cytokine	ADJ
dpc-2043	25	31	signaling	signal	VERB
dpc-2043	25	32	pathway	pathway	NOUN
dpc-2043	25	33	may	may	AUX
dpc-2043	25	34	be	be	AUX
dpc-2043	25	35	involved	involve	VERB
dpc-2043	25	36	in	in	ADP
dpc-2043	25	37	the	the	DET
dpc-2043	25	38	pathogenesis	pathogenesis	NOUN
dpc-2043	25	39	of	of	ADP
dpc-2043	25	40	the	the	DET
dpc-2043	25	41	disease	disease	NOUN
dpc-2043	25	42	[	[	X
dpc-2043	25	43	4	4	NUM
dpc-2043	25	44	-	-	SYM
dpc-2043	25	45	6	6	NUM
dpc-2043	25	46	]	]	PUNCT
dpc-2043	25	47	.	.	PUNCT
dpc-2043	26	1	the	the	DET
dpc-2043	26	2	exact	exact	ADJ
dpc-2043	26	3	mechanisms	mechanism	NOUN
dpc-2043	26	4	and	and	CCONJ
dpc-2043	26	5	interactions	interaction	NOUN
dpc-2043	26	6	of	of	ADP
dpc-2043	26	7	these	these	DET
dpc-2043	26	8	factors	factor	NOUN
dpc-2043	26	9	in	in	ADP
dpc-2043	26	10	the	the	DET
dpc-2043	26	11	etiology	etiology	NOUN
dpc-2043	26	12	of	of	ADP
dpc-2043	26	13	vitiligo	vitiligo	NOUN
dpc-2043	26	14	are	be	AUX
dpc-2043	26	15	unclear	unclear	ADJ
dpc-2043	26	16	.	.	PUNCT
dpc-2043	27	1	previous	previous	ADJ
dpc-2043	27	2	studies	study	NOUN
dpc-2043	27	3	have	have	AUX
dpc-2043	27	4	suggested	suggest	VERB
dpc-2043	27	5	that	that	SCONJ
dpc-2043	27	6	oxidant	oxidant	ADJ
dpc-2043	27	7	/	/	SYM
dpc-2043	27	8	antioxidant	antioxidant	NOUN
dpc-2043	27	9	imbalance	imbalance	NOUN
dpc-2043	27	10	and	and	CCONJ
dpc-2043	27	11	oxidative	oxidative	ADJ
dpc-2043	27	12	stress	stress	NOUN
dpc-2043	27	13	may	may	AUX
dpc-2043	27	14	also	also	ADV
dpc-2043	27	15	play	play	VERB
dpc-2043	27	16	important	important	ADJ
dpc-2043	27	17	roles	role	NOUN
dpc-2043	27	18	in	in	ADP
dpc-2043	27	19	the	the	DET
dpc-2043	27	20	pathogenesis	pathogenesis	NOUN
dpc-2043	27	21	of	of	ADP
dpc-2043	27	22	vitiligo	vitiligo	NOUN
dpc-2043	28	1	[	[	X
dpc-2043	28	2	7,8	7,8	NUM
dpc-2043	28	3	]	]	PUNCT
dpc-2043	28	4	.	.	PUNCT
dpc-2043	29	1	antioxidant	antioxidant	ADJ
dpc-2043	29	2	deficiency	deficiency	NOUN
dpc-2043	29	3	and	and	CCONJ
dpc-2043	29	4	the	the	DET
dpc-2043	29	5	accumulation	accumulation	NOUN
dpc-2043	29	6	of	of	ADP
dpc-2043	29	7	reactive	reactive	ADJ
dpc-2043	29	8	oxygen	oxygen	NOUN
dpc-2043	29	9	species	specie	NOUN
dpc-2043	29	10	in	in	ADP
dpc-2043	29	11	the	the	DET
dpc-2043	29	12	epidermal	epidermal	ADJ
dpc-2043	29	13	lesions	lesion	NOUN
dpc-2043	29	14	of	of	ADP
dpc-2043	29	15	vitiligo	vitiligo	ADJ
dpc-2043	29	16	patients	patient	NOUN
dpc-2043	29	17	have	have	AUX
dpc-2043	29	18	been	be	AUX
dpc-2043	29	19	also	also	ADV
dpc-2043	29	20	reported	report	VERB
dpc-2043	29	21	.	.	PUNCT
dpc-2043	30	1	epidermal	epidermal	ADJ
dpc-2043	30	2	lesions	lesion	NOUN
dpc-2043	30	3	of	of	ADP
dpc-2043	30	4	vitiliginous	vitiliginous	ADJ
dpc-2043	30	5	skin	skin	NOUN
dpc-2043	30	6	show	show	NOUN
dpc-2043	30	7	decreased	decrease	VERB
dpc-2043	30	8	catalase	catalase	NOUN
dpc-2043	30	9	activity	activity	NOUN
dpc-2043	30	10	and	and	CCONJ
dpc-2043	30	11	increased	increase	VERB
dpc-2043	30	12	h2o2	h2o2	NOUN
dpc-2043	30	13	and	and	CCONJ
dpc-2043	30	14	nitric	nitric	ADJ
dpc-2043	30	15	oxide	oxide	NOUN
dpc-2043	30	16	levels	level	NOUN
dpc-2043	30	17	[	[	X
dpc-2043	30	18	8,9	8,9	NUM
dpc-2043	30	19	]	]	PUNCT
dpc-2043	30	20	.	.	PUNCT
dpc-2043	31	1	previous	previous	ADJ
dpc-2043	31	2	studies	study	NOUN
dpc-2043	31	3	have	have	AUX
dpc-2043	31	4	indicated	indicate	VERB
dpc-2043	31	5	that	that	SCONJ
dpc-2043	31	6	both	both	DET
dpc-2043	31	7	localized	localized	ADJ
dpc-2043	31	8	and	and	CCONJ
dpc-2043	31	9	generalized	generalized	ADJ
dpc-2043	31	10	vitiligo	vitiligo	NOUN
dpc-2043	31	11	were	be	AUX
dpc-2043	31	12	associated	associate	VERB
dpc-2043	31	13	with	with	ADP
dpc-2043	31	14	low	low	ADJ
dpc-2043	31	15	total	total	ADJ
dpc-2043	31	16	antioxidant	antioxidant	NOUN
dpc-2043	31	17	and	and	CCONJ
dpc-2043	31	18	high	high	ADJ
dpc-2043	31	19	total	total	ADJ
dpc-2043	31	20	oxidant	oxidant	ADJ
dpc-2043	31	21	status	status	NOUN
dpc-2043	31	22	,	,	PUNCT
dpc-2043	31	23	as	as	SCONJ
dpc-2043	31	24	compared	compare	VERB
dpc-2043	31	25	with	with	ADP
dpc-2043	31	26	healthy	healthy	ADJ
dpc-2043	31	27	controls	control	NOUN
dpc-2043	31	28	[	[	X
dpc-2043	31	29	10	10	NUM
dpc-2043	31	30	]	]	PUNCT
dpc-2043	31	31	.	.	PUNCT
dpc-2043	32	1	oxidative	oxidative	ADJ
dpc-2043	32	2	stress	stress	NOUN
dpc-2043	32	3	inhibits	inhibit	VERB
dpc-2043	32	4	melanin	melanin	NOUN
dpc-2043	32	5	production	production	NOUN
dpc-2043	32	6	by	by	ADP
dpc-2043	32	7	interfering	interfere	VERB
dpc-2043	32	8	with	with	ADP
dpc-2043	32	9	tyrosinase	tyrosinase	ADJ
dpc-2043	32	10	activity	activity	NOUN
dpc-2043	32	11	in	in	ADP
dpc-2043	32	12	the	the	DET
dpc-2043	32	13	epidermis	epidermis	NOUN
dpc-2043	32	14	,	,	PUNCT
dpc-2043	32	15	thereby	thereby	ADV
dpc-2043	32	16	exerting	exert	VERB
dpc-2043	32	17	the	the	DET
dpc-2043	32	18	cytotoxicity	cytotoxicity	NOUN
dpc-2043	32	19	of	of	ADP
dpc-2043	32	20	melanocytes	melanocyte	NOUN
dpc-2043	32	21	[	[	X
dpc-2043	32	22	11	11	NUM
dpc-2043	32	23	]	]	PUNCT
dpc-2043	32	24	.	.	PUNCT
dpc-2043	33	1	melanin	melanin	NOUN
dpc-2043	33	2	,	,	PUNCT
dpc-2043	33	3	a	a	DET
dpc-2043	33	4	dark	dark	ADJ
dpc-2043	33	5	biopigment	biopigment	NOUN
dpc-2043	33	6	found	find	VERB
dpc-2043	33	7	in	in	ADP
dpc-2043	33	8	the	the	DET
dpc-2043	33	9	skin	skin	NOUN
dpc-2043	33	10	has	have	VERB
dpc-2043	33	11	a	a	DET
dpc-2043	33	12	high	high	ADJ
dpc-2043	33	13	affinity	affinity	NOUN
dpc-2043	33	14	for	for	ADP
dpc-2043	33	15	binding	bind	VERB
dpc-2043	33	16	and	and	CCONJ
dpc-2043	33	17	sequestering	sequester	VERB
dpc-2043	33	18	zinc	zinc	NOUN
dpc-2043	33	19	,	,	PUNCT
dpc-2043	33	20	copper	copper	NOUN
dpc-2043	33	21	,	,	PUNCT
dpc-2043	33	22	and	and	CCONJ
dpc-2043	33	23	other	other	ADJ
dpc-2043	33	24	metal	metal	NOUN
dpc-2043	33	25	ions	ion	NOUN
dpc-2043	33	26	[	[	X
dpc-2043	33	27	12	12	NUM
dpc-2043	33	28	]	]	PUNCT
dpc-2043	33	29	.	.	PUNCT
dpc-2043	34	1	zn	zn	PROPN
dpc-2043	34	2	and	and	CCONJ
dpc-2043	34	3	cu	cu	PROPN
dpc-2043	34	4	trace	trace	NOUN
dpc-2043	34	5	elements	element	NOUN
dpc-2043	34	6	are	be	AUX
dpc-2043	34	7	required	require	VERB
dpc-2043	34	8	as	as	ADP
dpc-2043	34	9	cofactors	cofactor	NOUN
dpc-2043	34	10	by	by	ADP
dpc-2043	34	11	tyrosinase	tyrosinase	NOUN
dpc-2043	34	12	,	,	PUNCT
dpc-2043	34	13	and	and	CCONJ
dpc-2043	34	14	many	many	ADJ
dpc-2043	34	15	other	other	ADJ
dpc-2043	34	16	metalloenzymes	metalloenzyme	NOUN
dpc-2043	34	17	involved	involve	VERB
dpc-2043	34	18	in	in	ADP
dpc-2043	34	19	melanin	melanin	NOUN
dpc-2043	34	20	biogenesis	biogenesis	NOUN
dpc-2043	34	21	[	[	X
dpc-2043	34	22	13,14	13,14	NUM
dpc-2043	34	23	]	]	PUNCT
dpc-2043	34	24	.	.	PUNCT
dpc-2043	35	1	they	they	PRON
dpc-2043	35	2	are	be	AUX
dpc-2043	35	3	also	also	ADV
dpc-2043	35	4	essential	essential	ADJ
dpc-2043	35	5	cofactors	cofactor	NOUN
dpc-2043	35	6	for	for	ADP
dpc-2043	35	7	the	the	DET
dpc-2043	35	8	activity	activity	NOUN
dpc-2043	35	9	of	of	ADP
dpc-2043	35	10	superoxide	superoxide	NOUN
dpc-2043	35	11	dismutase	dismutase	NOUN
dpc-2043	35	12	,	,	PUNCT
dpc-2043	35	13	an	an	DET
dpc-2043	35	14	antioxidant	antioxidant	ADJ
dpc-2043	35	15	enzyme	enzyme	NOUN
dpc-2043	35	16	that	that	PRON
dpc-2043	35	17	protects	protect	VERB
dpc-2043	35	18	skin	skin	NOUN
dpc-2043	35	19	against	against	ADP
dpc-2043	35	20	reactive	reactive	ADJ
dpc-2043	35	21	oxygen	oxygen	NOUN
dpc-2043	35	22	species	specie	NOUN
dpc-2043	35	23	[	[	X
dpc-2043	35	24	15	15	NUM
dpc-2043	35	25	]	]	PUNCT
dpc-2043	35	26	.	.	PUNCT
dpc-2043	36	1	although	although	SCONJ
dpc-2043	36	2	these	these	DET
dpc-2043	36	3	trace	trace	NOUN
dpc-2043	36	4	elements	element	NOUN
dpc-2043	36	5	are	be	AUX
dpc-2043	36	6	essential	essential	ADJ
dpc-2043	36	7	for	for	ADP
dpc-2043	36	8	human	human	ADJ
dpc-2043	36	9	health	health	NOUN
dpc-2043	36	10	,	,	PUNCT
dpc-2043	36	11	the	the	DET
dpc-2043	36	12	imbalance	imbalance	NOUN
dpc-2043	36	13	of	of	ADP
dpc-2043	36	14	the	the	DET
dpc-2043	36	15	cu	cu	PROPN
dpc-2043	36	16	/	/	SYM
dpc-2043	36	17	zn	zn	PROPN
dpc-2043	36	18	ratio	ratio	NOUN
dpc-2043	36	19	suggested	suggest	VERB
dpc-2043	36	20	being	be	AUX
dpc-2043	36	21	associated	associate	VERB
dpc-2043	36	22	with	with	ADP
dpc-2043	36	23	many	many	ADJ
dpc-2043	36	24	human	human	ADJ
dpc-2043	36	25	diseases	disease	NOUN
dpc-2043	36	26	[	[	X
dpc-2043	36	27	16,17	16,17	NUM
dpc-2043	36	28	]	]	PUNCT
dpc-2043	36	29	.	.	PUNCT
dpc-2043	37	1	zinc	zinc	NOUN
dpc-2043	37	2	may	may	AUX
dpc-2043	37	3	play	play	VERB
dpc-2043	37	4	a	a	DET
dpc-2043	37	5	role	role	NOUN
dpc-2043	37	6	in	in	ADP
dpc-2043	37	7	the	the	DET
dpc-2043	37	8	etiology	etiology	NOUN
dpc-2043	37	9	of	of	ADP
dpc-2043	37	10	vitiligo	vitiligo	NOUN
dpc-2043	37	11	through	through	ADP
dpc-2043	37	12	zn	zn	PROPN
dpc-2043	37	13	-	-	PUNCT
dpc-2043	37	14	α2	α2	VERB
dpc-2043	37	15	-	-	PUNCT
dpc-2043	37	16	glycoprotein	glycoprotein	NOUN
dpc-2043	37	17	(	(	PUNCT
dpc-2043	37	18	zag	zag	NOUN
dpc-2043	37	19	)	)	PUNCT
dpc-2043	37	20	,	,	PUNCT
dpc-2043	37	21	a	a	DET
dpc-2043	37	22	major	major	ADJ
dpc-2043	37	23	plasma	plasma	NOUN
dpc-2043	37	24	protein	protein	NOUN
dpc-2043	37	25	involved	involve	VERB
dpc-2043	37	26	in	in	ADP
dpc-2043	37	27	melanocyte	melanocyte	NOUN
dpc-2043	37	28	growth	growth	NOUN
dpc-2043	37	29	and	and	CCONJ
dpc-2043	37	30	differentiation	differentiation	NOUN
dpc-2043	37	31	.	.	PUNCT
dpc-2043	38	1	studies	study	NOUN
dpc-2043	38	2	have	have	AUX
dpc-2043	38	3	shown	show	VERB
dpc-2043	38	4	that	that	SCONJ
dpc-2043	38	5	zag	zag	NOUN
dpc-2043	38	6	deficiency	deficiency	NOUN
dpc-2043	38	7	is	be	AUX
dpc-2043	38	8	involved	involve	VERB
dpc-2043	38	9	in	in	ADP
dpc-2043	38	10	the	the	DET
dpc-2043	38	11	pathogenesis	pathogenesis	NOUN
dpc-2043	38	12	of	of	ADP
dpc-2043	38	13	vitiligo	vitiligo	NOUN
dpc-2043	38	14	through	through	ADP
dpc-2043	38	15	the	the	DET
dpc-2043	38	16	shedding	shedding	NOUN
dpc-2043	38	17	and	and	CCONJ
dpc-2043	38	18	loss	loss	NOUN
dpc-2043	38	19	of	of	ADP
dpc-2043	38	20	melanocytes	melanocyte	NOUN
dpc-2043	38	21	[	[	X
dpc-2043	38	22	18	18	NUM
dpc-2043	38	23	]	]	PUNCT
dpc-2043	38	24	.	.	PUNCT
dpc-2043	39	1	the	the	DET
dpc-2043	39	2	relationship	relationship	NOUN
dpc-2043	39	3	between	between	ADP
dpc-2043	39	4	changes	change	NOUN
dpc-2043	39	5	in	in	ADP
dpc-2043	39	6	the	the	DET
dpc-2043	39	7	levels	level	NOUN
dpc-2043	39	8	of	of	ADP
dpc-2043	39	9	cu	cu	PROPN
dpc-2043	39	10	and	and	CCONJ
dpc-2043	39	11	zn	zn	NOUN
dpc-2043	39	12	trace	trace	NOUN
dpc-2043	39	13	elements	element	NOUN
dpc-2043	39	14	in	in	ADP
dpc-2043	39	15	tissues	tissue	NOUN
dpc-2043	39	16	or	or	CCONJ
dpc-2043	39	17	serum	serum	NOUN
dpc-2043	39	18	and	and	CCONJ
dpc-2043	39	19	the	the	DET
dpc-2043	39	20	pathogenesis	pathogenesis	NOUN
dpc-2043	39	21	of	of	ADP
dpc-2043	39	22	vitiligo	vitiligo	NOUN
dpc-2043	39	23	is	be	AUX
dpc-2043	39	24	controversial	controversial	ADJ
dpc-2043	39	25	.	.	PUNCT
dpc-2043	40	1	some	some	DET
dpc-2043	40	2	studies	study	NOUN
dpc-2043	40	3	have	have	AUX
dpc-2043	40	4	shown	show	VERB
dpc-2043	40	5	that	that	DET
dpc-2043	40	6	oral	oral	ADJ
dpc-2043	40	7	supplementation	supplementation	NOUN
dpc-2043	40	8	or	or	CCONJ
dpc-2043	40	9	topical	topical	ADJ
dpc-2043	40	10	treatment	treatment	NOUN
dpc-2043	40	11	of	of	ADP
dpc-2043	40	12	cu	cu	PROPN
dpc-2043	40	13	and	and	CCONJ
dpc-2043	40	14	zn	zn	PROPN
dpc-2043	40	15	may	may	AUX
dpc-2043	40	16	improve	improve	VERB
dpc-2043	40	17	the	the	DET
dpc-2043	40	18	clinical	clinical	ADJ
dpc-2043	40	19	symptoms	symptom	NOUN
dpc-2043	40	20	of	of	ADP
dpc-2043	40	21	vitiligo	vitiligo	NOUN
dpc-2043	40	22	[	[	X
dpc-2043	40	23	19,20	19,20	NUM
dpc-2043	40	24	]	]	PUNCT
dpc-2043	40	25	.	.	PUNCT
dpc-2043	41	1	both	both	PRON
dpc-2043	41	2	increased	increase	VERB
dpc-2043	41	3	and	and	CCONJ
dpc-2043	41	4	decreased	decrease	VERB
dpc-2043	41	5	serum	serum	NOUN
dpc-2043	41	6	levels	level	NOUN
dpc-2043	41	7	of	of	ADP
dpc-2043	41	8	these	these	DET
dpc-2043	41	9	trace	trace	NOUN
dpc-2043	41	10	elements	element	NOUN
dpc-2043	41	11	in	in	ADP
dpc-2043	41	12	vitiligo	vitiligo	ADJ
dpc-2043	41	13	patients	patient	NOUN
dpc-2043	41	14	have	have	AUX
dpc-2043	41	15	been	be	AUX
dpc-2043	41	16	reported	report	VERB
dpc-2043	41	17	[	[	PUNCT
dpc-2043	41	18	19,21	19,21	NUM
dpc-2043	41	19	-	-	SYM
dpc-2043	41	20	23	23	NUM
dpc-2043	41	21	]	]	PUNCT
dpc-2043	41	22	.	.	PUNCT
dpc-2043	42	1	in	in	ADP
dpc-2043	42	2	a	a	DET
dpc-2043	42	3	study	study	NOUN
dpc-2043	42	4	of	of	ADP
dpc-2043	42	5	50	50	NUM
dpc-2043	42	6	sudanese	sudanese	ADJ
dpc-2043	42	7	vitiligo	vitiligo	NOUN
dpc-2043	42	8	patients	patient	NOUN
dpc-2043	42	9	,	,	PUNCT
dpc-2043	42	10	a	a	DET
dpc-2043	42	11	significant	significant	ADJ
dpc-2043	42	12	increase	increase	NOUN
dpc-2043	42	13	in	in	ADP
dpc-2043	42	14	the	the	DET
dpc-2043	42	15	mean	mean	ADJ
dpc-2043	42	16	serum	serum	NOUN
dpc-2043	42	17	concentration	concentration	NOUN
dpc-2043	42	18	of	of	ADP
dpc-2043	42	19	cu	cu	NOUN
dpc-2043	42	20	level	level	NOUN
dpc-2043	42	21	was	be	AUX
dpc-2043	42	22	observed	observe	VERB
dpc-2043	42	23	[	[	X
dpc-2043	42	24	24	24	NUM
dpc-2043	42	25	]	]	PUNCT
dpc-2043	42	26	.	.	PUNCT
dpc-2043	43	1	it	it	PRON
dpc-2043	43	2	has	have	AUX
dpc-2043	43	3	been	be	AUX
dpc-2043	43	4	suggested	suggest	VERB
dpc-2043	43	5	that	that	SCONJ
dpc-2043	43	6	melanocytes	melanocyte	VERB
dpc-2043	43	7	degeneration	degeneration	NOUN
dpc-2043	43	8	and	and	CCONJ
dpc-2043	43	9	lower	low	ADJ
dpc-2043	43	10	melanin	melanin	NOUN
dpc-2043	43	11	biosynthesis	biosynthesis	NOUN
dpc-2043	43	12	in	in	ADP
dpc-2043	43	13	vitiligo	vitiligo	ADJ
dpc-2043	43	14	patients	patient	NOUN
dpc-2043	43	15	may	may	AUX
dpc-2043	43	16	result	result	VERB
dpc-2043	43	17	in	in	ADP
dpc-2043	43	18	increased	increase	VERB
dpc-2043	43	19	serum	serum	PROPN
dpc-2043	43	20	cu	cu	PROPN
dpc-2043	43	21	and	and	CCONJ
dpc-2043	43	22	zn	zn	PROPN
dpc-2043	43	23	levels	level	NOUN
dpc-2043	43	24	.	.	PUNCT
dpc-2043	44	1	hence	hence	ADV
dpc-2043	44	2	,	,	PUNCT
dpc-2043	44	3	the	the	DET
dpc-2043	44	4	high	high	ADJ
dpc-2043	44	5	serum	serum	NOUN
dpc-2043	44	6	levels	level	NOUN
dpc-2043	44	7	of	of	ADP
dpc-2043	44	8	these	these	DET
dpc-2043	44	9	elements	element	NOUN
dpc-2043	44	10	in	in	ADP
dpc-2043	44	11	vitiligo	vitiligo	NOUN
dpc-2043	44	12	are	be	AUX
dpc-2043	44	13	the	the	DET
dpc-2043	44	14	result	result	NOUN
dpc-2043	44	15	of	of	ADP
dpc-2043	44	16	the	the	DET
dpc-2043	44	17	disease	disease	NOUN
dpc-2043	44	18	rather	rather	ADV
dpc-2043	44	19	than	than	ADP
dpc-2043	44	20	its	its	PRON
dpc-2043	44	21	underlying	underlie	VERB
dpc-2043	44	22	cause	cause	NOUN
dpc-2043	44	23	[	[	X
dpc-2043	44	24	25	25	NUM
dpc-2043	44	25	]	]	PUNCT
dpc-2043	44	26	.	.	PUNCT
dpc-2043	45	1	several	several	ADJ
dpc-2043	45	2	other	other	ADJ
dpc-2043	45	3	studies	study	NOUN
dpc-2043	45	4	have	have	AUX
dpc-2043	45	5	reported	report	VERB
dpc-2043	45	6	significantly	significantly	ADV
dpc-2043	45	7	decreased	decrease	VERB
dpc-2043	45	8	serum	serum	NOUN
dpc-2043	45	9	levels	level	NOUN
dpc-2043	45	10	of	of	ADP
dpc-2043	45	11	cu	cu	PROPN
dpc-2043	45	12	and/or	and/or	CCONJ
dpc-2043	45	13	zn	zn	PROPN
dpc-2043	45	14	among	among	ADP
dpc-2043	45	15	vitiligo	vitiligo	NOUN
dpc-2043	45	16	patients	patient	NOUN
dpc-2043	45	17	[	[	X
dpc-2043	45	18	21,26	21,26	NUM
dpc-2043	45	19	-	-	SYM
dpc-2043	45	20	29	29	NUM
dpc-2043	45	21	]	]	PUNCT
dpc-2043	45	22	.	.	PUNCT
dpc-2043	46	1	objectives	objective	NOUN
dpc-2043	46	2	in	in	ADP
dpc-2043	46	3	view	view	NOUN
dpc-2043	46	4	of	of	ADP
dpc-2043	46	5	this	this	DET
dpc-2043	46	6	controversy	controversy	NOUN
dpc-2043	46	7	,	,	PUNCT
dpc-2043	46	8	the	the	DET
dpc-2043	46	9	purpose	purpose	NOUN
dpc-2043	46	10	of	of	ADP
dpc-2043	46	11	the	the	DET
dpc-2043	46	12	present	present	ADJ
dpc-2043	46	13	study	study	NOUN
dpc-2043	46	14	was	be	AUX
dpc-2043	46	15	to	to	PART
dpc-2043	46	16	investigate	investigate	VERB
dpc-2043	46	17	the	the	DET
dpc-2043	46	18	changes	change	NOUN
dpc-2043	46	19	in	in	ADP
dpc-2043	46	20	serum	serum	PROPN
dpc-2043	46	21	cu	cu	PROPN
dpc-2043	46	22	and	and	CCONJ
dpc-2043	46	23	zn	zn	PROPN
dpc-2043	46	24	concentrations	concentration	NOUN
dpc-2043	46	25	among	among	ADP
dpc-2043	46	26	iranian	iranian	ADJ
dpc-2043	46	27	vitiligo	vitiligo	NOUN
dpc-2043	46	28	patients	patient	NOUN
dpc-2043	46	29	.	.	PUNCT
dpc-2043	47	1	methods	method	NOUN
dpc-2043	47	2	experiment	experiment	NOUN
dpc-2043	47	3	groups	group	NOUN
dpc-2043	47	4	one	one	NUM
dpc-2043	47	5	hundred	hundred	NUM
dpc-2043	47	6	and	and	CCONJ
dpc-2043	47	7	seventeen	seventeen	NUM
dpc-2043	47	8	sera	sera	NOUN
dpc-2043	47	9	were	be	AUX
dpc-2043	47	10	obtained	obtain	VERB
dpc-2043	47	11	from	from	ADP
dpc-2043	47	12	the	the	DET
dpc-2043	47	13	previously	previously	ADV
dpc-2043	47	14	collected	collect	VERB
dpc-2043	47	15	serum	serum	NOUN
dpc-2043	47	16	samples	sample	NOUN
dpc-2043	47	17	of	of	ADP
dpc-2043	47	18	vitiligo	vitiligo	ADJ
dpc-2043	47	19	patients	patient	NOUN
dpc-2043	47	20	(	(	PUNCT
dpc-2043	47	21	48	48	NUM
dpc-2043	47	22	  	  	SPACE
dpc-2043	47	23	men	man	NOUN
dpc-2043	47	24	and	and	CCONJ
dpc-2043	47	25	69	69	NUM
dpc-2043	47	26	women	woman	NOUN
dpc-2043	47	27	)	)	PUNCT
dpc-2043	47	28	from	from	ADP
dpc-2043	47	29	the	the	DET
dpc-2043	47	30	biobank	biobank	NOUN
dpc-2043	47	31	of	of	ADP
dpc-2043	47	32	the	the	DET
dpc-2043	47	33	autoimmune	autoimmune	ADJ
dpc-2043	47	34	diseases	disease	NOUN
dpc-2043	47	35	research	research	NOUN
dpc-2043	47	36	center	center	NOUN
dpc-2043	47	37	of	of	ADP
dpc-2043	47	38	shiraz	shiraz	PROPN
dpc-2043	47	39	university	university	PROPN
dpc-2043	47	40	of	of	ADP
dpc-2043	47	41	medical	medical	ADJ
dpc-2043	47	42	sciences	sciences	PROPN
dpc-2043	47	43	(	(	PUNCT
dpc-2043	47	44	sums	sum	NOUN
dpc-2043	47	45	)	)	PUNCT
dpc-2043	47	46	.	.	PUNCT
dpc-2043	48	1	the	the	DET
dpc-2043	48	2	control	control	PROPN
dpc-2043	48	3	group	group	NOUN
dpc-2043	48	4	consisted	consist	VERB
dpc-2043	48	5	of	of	ADP
dpc-2043	48	6	137	137	NUM
dpc-2043	48	7	healthy	healthy	ADJ
dpc-2043	48	8	blood	blood	NOUN
dpc-2043	48	9	donors	donor	NOUN
dpc-2043	48	10	(	(	PUNCT
dpc-2043	48	11	62	62	NUM
dpc-2043	48	12	males	male	NOUN
dpc-2043	48	13	and	and	CCONJ
dpc-2043	48	14	75	75	NUM
dpc-2043	48	15	females	female	NOUN
dpc-2043	48	16	)	)	PUNCT
dpc-2043	48	17	with	with	ADP
dpc-2043	48	18	no	no	DET
dpc-2043	48	19	signs	sign	NOUN
dpc-2043	48	20	of	of	ADP
dpc-2043	48	21	skin	skin	NOUN
dpc-2043	48	22	or	or	CCONJ
dpc-2043	48	23	systemic	systemic	ADJ
dpc-2043	48	24	disease	disease	NOUN
dpc-2043	48	25	.	.	PUNCT
dpc-2043	49	1	according	accord	VERB
dpc-2043	49	2	to	to	ADP
dpc-2043	49	3	the	the	DET
dpc-2043	49	4	dermatology	dermatology	NOUN
dpc-2043	49	5	and	and	CCONJ
dpc-2043	49	6	wood	wood	NOUN
dpc-2043	49	7	lamp	lamp	NOUN
dpc-2043	49	8	examination	examination	NOUN
dpc-2043	49	9	,	,	PUNCT
dpc-2043	49	10	84	84	NUM
dpc-2043	49	11	%	%	NOUN
dpc-2043	49	12	of	of	ADP
dpc-2043	49	13	patients	patient	NOUN
dpc-2043	49	14	had	have	VERB
dpc-2043	49	15	generalized/	generalized/	NUM
dpc-2043	49	16	universal	universal	ADJ
dpc-2043	49	17	and	and	CCONJ
dpc-2043	49	18	16	16	NUM
dpc-2043	49	19	%	%	NOUN
dpc-2043	49	20	of	of	ADP
dpc-2043	49	21	localized	localized	ADJ
dpc-2043	49	22	/	/	SYM
dpc-2043	49	23	segmental	segmental	ADJ
dpc-2043	49	24	stable	stable	ADJ
dpc-2043	49	25	vitiligo	vitiligo	NOUN
dpc-2043	49	26	.	.	PUNCT
dpc-2043	50	1	the	the	DET
dpc-2043	50	2	university	university	NOUN
dpc-2043	50	3	ethics	ethic	NOUN
dpc-2043	50	4	committee	committee	PROPN
dpc-2043	50	5	approved	approve	VERB
dpc-2043	50	6	the	the	DET
dpc-2043	50	7	protocol	protocol	NOUN
dpc-2043	50	8	for	for	ADP
dpc-2043	50	9	this	this	DET
dpc-2043	50	10	study	study	NOUN
dpc-2043	50	11	(	(	PUNCT
dpc-2043	50	12	approval	approval	NOUN
dpc-2043	50	13	number	number	NOUN
dpc-2043	50	14	:	:	PUNCT
dpc-2043	50	15	ir.sums	ir.sum	NOUN
dpc-2043	50	16	.	.	PUNCT
dpc-2043	51	1	rec.1398.629	rec.1398.629	NOUN
dpc-2043	51	2	)	)	PUNCT
dpc-2043	51	3	,	,	PUNCT
dpc-2043	51	4	and	and	CCONJ
dpc-2043	51	5	the	the	DET
dpc-2043	51	6	informed	informed	ADJ
dpc-2043	51	7	consent	consent	NOUN
dpc-2043	51	8	was	be	AUX
dpc-2043	51	9	obtained	obtain	VERB
dpc-2043	51	10	from	from	ADP
dpc-2043	51	11	all	all	DET
dpc-2043	51	12	study	study	NOUN
dpc-2043	51	13	participants	participant	NOUN
dpc-2043	51	14	.	.	PUNCT
dpc-2043	52	1	preparation	preparation	NOUN
dpc-2043	52	2	of	of	ADP
dpc-2043	52	3	the	the	DET
dpc-2043	52	4	samples	sample	NOUN
dpc-2043	52	5	and	and	CCONJ
dpc-2043	52	6	analytical	analytical	ADJ
dpc-2043	52	7	methods	method	NOUN
dpc-2043	52	8	the	the	DET
dpc-2043	52	9	methods	method	NOUN
dpc-2043	52	10	for	for	ADP
dpc-2043	52	11	the	the	DET
dpc-2043	52	12	preparation	preparation	NOUN
dpc-2043	52	13	of	of	ADP
dpc-2043	52	14	samples	sample	NOUN
dpc-2043	52	15	and	and	CCONJ
dpc-2043	52	16	their	their	PRON
dpc-2043	52	17	analysis	analysis	NOUN
dpc-2043	52	18	have	have	AUX
dpc-2043	52	19	been	be	AUX
dpc-2043	52	20	described	describe	VERB
dpc-2043	52	21	previously	previously	ADV
dpc-2043	52	22	[	[	X
dpc-2043	52	23	16	16	NUM
dpc-2043	52	24	]	]	PUNCT
dpc-2043	52	25	.	.	PUNCT
dpc-2043	53	1	briefly	briefly	NOUN
dpc-2043	53	2	,	,	PUNCT
dpc-2043	53	3	blood	blood	NOUN
dpc-2043	53	4	samples	sample	NOUN
dpc-2043	53	5	were	be	AUX
dpc-2043	53	6	collected	collect	VERB
dpc-2043	53	7	from	from	ADP
dpc-2043	53	8	participants	participant	NOUN
dpc-2043	53	9	,	,	PUNCT
dpc-2043	53	10	and	and	CCONJ
dpc-2043	53	11	allowed	allow	VERB
dpc-2043	53	12	to	to	PART
dpc-2043	53	13	clot	clot	VERB
dpc-2043	53	14	,	,	PUNCT
dpc-2043	53	15	and	and	CCONJ
dpc-2043	53	16	serum	serum	NOUN
dpc-2043	53	17	was	be	AUX
dpc-2043	53	18	separated	separate	VERB
dpc-2043	53	19	and	and	CCONJ
dpc-2043	53	20	stored	store	VERB
dpc-2043	53	21	in	in	ADP
dpc-2043	53	22	plastic	plastic	ADJ
dpc-2043	53	23	tubes	tube	NOUN
dpc-2043	53	24	at	at	ADP
dpc-2043	53	25	-80	-80	NOUN
dpc-2043	53	26	°	°	ADP
dpc-2043	53	27	c	c	NOUN
dpc-2043	53	28	until	until	ADP
dpc-2043	53	29	analysis	analysis	NOUN
dpc-2043	53	30	.	.	PUNCT
dpc-2043	54	1	the	the	DET
dpc-2043	54	2	concentrations	concentration	NOUN
dpc-2043	54	3	of	of	ADP
dpc-2043	54	4	cu	cu	PROPN
dpc-2043	54	5	and	and	CCONJ
dpc-2043	54	6	zn	zn	PROPN
dpc-2043	54	7	in	in	ADP
dpc-2043	54	8	the	the	DET
dpc-2043	54	9	samples	sample	NOUN
dpc-2043	54	10	were	be	AUX
dpc-2043	54	11	measured	measure	VERB
dpc-2043	54	12	using	use	VERB
dpc-2043	54	13	a	a	DET
dpc-2043	54	14	flame	flame	ADJ
dpc-2043	54	15	atomic	atomic	ADJ
dpc-2043	54	16	absorption	absorption	NOUN
dpc-2043	54	17	spectrometer	spectrometer	NOUN
dpc-2043	54	18	(	(	PUNCT
dpc-2043	54	19	perkinelmer	perkinelmer	NOUN
dpc-2043	54	20	model	model	NOUN
dpc-2043	54	21	analyst	analyst	NOUN
dpc-2043	54	22	300	300	NUM
dpc-2043	54	23	)	)	PUNCT
dpc-2043	54	24	.	.	PUNCT
dpc-2043	55	1	stock	stock	PROPN
dpc-2043	55	2	standard	standard	PROPN
dpc-2043	55	3	solutions	solution	NOUN
dpc-2043	55	4	of	of	ADP
dpc-2043	55	5	zn	zn	PROPN
dpc-2043	55	6	and	and	CCONJ
dpc-2043	55	7	cu	cu	PROPN
dpc-2043	55	8	were	be	AUX
dpc-2043	55	9	prepared	prepare	VERB
dpc-2043	55	10	by	by	ADP
dpc-2043	55	11	1:1	1:1	NUM
dpc-2043	55	12	dilution	dilution	NOUN
dpc-2043	55	13	of	of	ADP
dpc-2043	55	14	either	either	DET
dpc-2043	55	15	trace	trace	NOUN
dpc-2043	55	16	element	element	NOUN
dpc-2043	55	17	(	(	PUNCT
dpc-2043	55	18	merck	merck	NOUN
dpc-2043	55	19	)	)	PUNCT
dpc-2043	55	20	solutions	solution	NOUN
dpc-2043	55	21	(	(	PUNCT
dpc-2043	55	22	2	2	NUM
dpc-2043	55	23	mg	mg	NUM
dpc-2043	55	24	/	/	SYM
dpc-2043	55	25	ml	ml	X
dpc-2043	55	26	in	in	ADP
dpc-2043	55	27	hcl	hcl	PROPN
dpc-2043	55	28	)	)	PUNCT
dpc-2043	55	29	with	with	ADP
dpc-2043	55	30	deionized	deionize	VERB
dpc-2043	55	31	water	water	NOUN
dpc-2043	55	32	.	.	PUNCT
dpc-2043	56	1	the	the	DET
dpc-2043	56	2	stock	stock	NOUN
dpc-2043	56	3	solutions	solution	NOUN
dpc-2043	56	4	of	of	ADP
dpc-2043	56	5	zn	zn	NOUN
dpc-2043	56	6	or	or	CCONJ
dpc-2043	56	7	cu	cu	PROPN
dpc-2043	56	8	were	be	AUX
dpc-2043	56	9	diluted	dilute	VERB
dpc-2043	56	10	with	with	ADP
dpc-2043	56	11	glycerol	glycerol	NOUN
dpc-2043	56	12	(	(	PUNCT
dpc-2043	56	13	5	5	NUM
dpc-2043	56	14	%	%	NOUN
dpc-2043	56	15	or	or	CCONJ
dpc-2043	56	16	10	10	NUM
dpc-2043	56	17	%	%	NOUN
dpc-2043	56	18	,	,	PUNCT
dpc-2043	56	19	respectively	respectively	ADV
dpc-2043	56	20	)	)	PUNCT
dpc-2043	56	21	and	and	CCONJ
dpc-2043	56	22	used	use	VERB
dpc-2043	56	23	as	as	ADP
dpc-2043	56	24	working	work	VERB
dpc-2043	56	25	solutions	solution	NOUN
dpc-2043	56	26	to	to	PART
dpc-2043	56	27	calibrate	calibrate	VERB
dpc-2043	56	28	the	the	DET
dpc-2043	56	29	instrument	instrument	NOUN
dpc-2043	56	30	.	.	PUNCT
dpc-2043	57	1	the	the	DET
dpc-2043	57	2	absorbance	absorbance	NOUN
dpc-2043	57	3	of	of	ADP
dpc-2043	57	4	cu	cu	PROPN
dpc-2043	57	5	and	and	CCONJ
dpc-2043	57	6	zn	zn	PROPN
dpc-2043	57	7	was	be	AUX
dpc-2043	57	8	read	read	VERB
dpc-2043	57	9	at	at	ADP
dpc-2043	57	10	324.7	324.7	NUM
dpc-2043	57	11	and	and	CCONJ
dpc-2043	57	12	213.9	213.9	NUM
dpc-2043	57	13	nm	nm	NOUN
dpc-2043	57	14	,	,	PUNCT
dpc-2043	57	15	respectively	respectively	ADV
dpc-2043	57	16	.	.	PUNCT
dpc-2043	58	1	the	the	DET
dpc-2043	58	2	concentrations	concentration	NOUN
dpc-2043	58	3	of	of	ADP
dpc-2043	58	4	trace	trace	NOUN
dpc-2043	58	5	elements	element	NOUN
dpc-2043	58	6	in	in	ADP
dpc-2043	58	7	samples	sample	NOUN
dpc-2043	58	8	were	be	AUX
dpc-2043	58	9	calculated	calculate	VERB
dpc-2043	58	10	using	use	VERB
dpc-2043	58	11	perkinelmer	perkinelmer	NOUN
dpc-2043	58	12	aa	aa	PROPN
dpc-2043	58	13	winlab	winlab	PROPN
dpc-2043	58	14	software	software	NOUN
dpc-2043	58	15	.	.	PUNCT
dpc-2043	59	1	statistical	statistical	ADJ
dpc-2043	59	2	analysis	analysis	NOUN
dpc-2043	59	3	the	the	DET
dpc-2043	59	4	statistical	statistical	ADJ
dpc-2043	59	5	analyses	analysis	NOUN
dpc-2043	59	6	of	of	ADP
dpc-2043	59	7	data	datum	NOUN
dpc-2043	59	8	were	be	AUX
dpc-2043	59	9	performed	perform	VERB
dpc-2043	59	10	using	use	VERB
dpc-2043	59	11	the	the	DET
dpc-2043	59	12	spss	spss	PROPN
dpc-2043	59	13	software	software	NOUN
dpc-2043	59	14	package	package	NOUN
dpc-2043	59	15	(	(	PUNCT
dpc-2043	59	16	version	version	NOUN
dpc-2043	59	17	16	16	NUM
dpc-2043	59	18	;	;	PUNCT
dpc-2043	59	19	spss	spss	PROPN
dpc-2043	59	20	inc	inc	PROPN
dpc-2043	59	21	.	.	PROPN
dpc-2043	59	22	)	)	PUNCT
dpc-2043	59	23	.	.	PUNCT
dpc-2043	60	1	the	the	DET
dpc-2043	60	2	results	result	NOUN
dpc-2043	60	3	were	be	AUX
dpc-2043	60	4	original	original	ADJ
dpc-2043	60	5	article	article	NOUN
dpc-2043	60	6	|	|	ADV
dpc-2043	60	7	dermatol	dermatol	ADJ
dpc-2043	60	8	pract	pract	NOUN
dpc-2043	60	9	concept	concept	NOUN
dpc-2043	60	10	.	.	PUNCT
dpc-2043	61	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	61	2	3	3	NUM
dpc-2043	61	3	expressed	express	VERB
dpc-2043	61	4	as	as	ADP
dpc-2043	61	5	mean	mean	NOUN
dpc-2043	61	6	±	±	NUM
dpc-2043	61	7	standard	standard	ADJ
dpc-2043	61	8	deviation	deviation	NOUN
dpc-2043	61	9	(	(	PUNCT
dpc-2043	61	10	sd	sd	NOUN
dpc-2043	61	11	)	)	PUNCT
dpc-2043	61	12	.	.	PUNCT
dpc-2043	62	1	differences	difference	NOUN
dpc-2043	62	2	between	between	ADP
dpc-2043	62	3	cases	case	NOUN
dpc-2043	62	4	and	and	CCONJ
dpc-2043	62	5	controls	control	NOUN
dpc-2043	62	6	were	be	AUX
dpc-2043	62	7	tested	test	VERB
dpc-2043	62	8	by	by	ADP
dpc-2043	62	9	kruskal	kruskal	PROPN
dpc-2043	62	10	–	–	PUNCT
dpc-2043	62	11	wallis	wallis	PROPN
dpc-2043	62	12	test	test	NOUN
dpc-2043	62	13	,	,	PUNCT
dpc-2043	62	14	and	and	CCONJ
dpc-2043	62	15	the	the	DET
dpc-2043	62	16	influence	influence	NOUN
dpc-2043	62	17	of	of	ADP
dpc-2043	62	18	sex	sex	NOUN
dpc-2043	62	19	and	and	CCONJ
dpc-2043	62	20	age	age	NOUN
dpc-2043	62	21	on	on	ADP
dpc-2043	62	22	the	the	DET
dpc-2043	62	23	serum	serum	NOUN
dpc-2043	62	24	levels	level	NOUN
dpc-2043	62	25	of	of	ADP
dpc-2043	62	26	trace	trace	NOUN
dpc-2043	62	27	elements	element	NOUN
dpc-2043	62	28	was	be	AUX
dpc-2043	62	29	evaluated	evaluate	VERB
dpc-2043	62	30	using	use	VERB
dpc-2043	62	31	the	the	DET
dpc-2043	62	32	mann	mann	PROPN
dpc-2043	62	33	–	–	PUNCT
dpc-2043	62	34	whitney	whitney	PROPN
dpc-2043	62	35	u	u	NOUN
dpc-2043	62	36	-	-	NOUN
dpc-2043	62	37	test	test	NOUN
dpc-2043	62	38	.	.	PUNCT
dpc-2043	63	1	the	the	DET
dpc-2043	63	2	spearman	spearman	NOUN
dpc-2043	63	3	rank	rank	NOUN
dpc-2043	63	4	correlation	correlation	NOUN
dpc-2043	63	5	test	test	NOUN
dpc-2043	63	6	was	be	AUX
dpc-2043	63	7	used	use	VERB
dpc-2043	63	8	to	to	PART
dpc-2043	63	9	analyze	analyze	VERB
dpc-2043	63	10	the	the	DET
dpc-2043	63	11	correlation	correlation	NOUN
dpc-2043	63	12	between	between	ADP
dpc-2043	63	13	quantitative	quantitative	ADJ
dpc-2043	63	14	variables	variable	NOUN
dpc-2043	63	15	.	.	PUNCT
dpc-2043	64	1	a	a	DET
dpc-2043	64	2	p	p	NOUN
dpc-2043	64	3	equal	equal	ADJ
dpc-2043	64	4	or	or	CCONJ
dpc-2043	64	5	lower	low	ADJ
dpc-2043	64	6	than	than	ADP
dpc-2043	64	7	0.05	0.05	NUM
dpc-2043	64	8	was	be	AUX
dpc-2043	64	9	considered	consider	VERB
dpc-2043	64	10	statistically	statistically	ADV
dpc-2043	64	11	significant	significant	ADJ
dpc-2043	64	12	.	.	PUNCT
dpc-2043	65	1	results	result	VERB
dpc-2043	65	2	a	a	DET
dpc-2043	65	3	total	total	NOUN
dpc-2043	65	4	of	of	ADP
dpc-2043	65	5	117	117	NUM
dpc-2043	65	6	subjects	subject	NOUN
dpc-2043	65	7	with	with	ADP
dpc-2043	65	8	vitiligo	vitiligo	NOUN
dpc-2043	65	9	and	and	CCONJ
dpc-2043	65	10	137	137	NUM
dpc-2043	65	11	healthy	healthy	ADJ
dpc-2043	65	12	volunteers	volunteer	NOUN
dpc-2043	65	13	were	be	AUX
dpc-2043	65	14	included	include	VERB
dpc-2043	65	15	in	in	ADP
dpc-2043	65	16	this	this	DET
dpc-2043	65	17	study	study	NOUN
dpc-2043	65	18	.	.	PUNCT
dpc-2043	66	1	tables	table	NOUN
dpc-2043	66	2	1	1	NUM
dpc-2043	66	3	and	and	CCONJ
dpc-2043	66	4	2	2	NUM
dpc-2043	66	5	show	show	VERB
dpc-2043	66	6	the	the	DET
dpc-2043	66	7	demographic	demographic	ADJ
dpc-2043	66	8	characteristics	characteristic	NOUN
dpc-2043	66	9	and	and	CCONJ
dpc-2043	66	10	serum	serum	NOUN
dpc-2043	66	11	levels	level	NOUN
dpc-2043	66	12	of	of	ADP
dpc-2043	66	13	cu	cu	PROPN
dpc-2043	66	14	and	and	CCONJ
dpc-2043	66	15	zn	zn	PROPN
dpc-2043	66	16	in	in	ADP
dpc-2043	66	17	patients	patient	NOUN
dpc-2043	66	18	with	with	ADP
dpc-2043	66	19	vitiligo	vitiligo	NOUN
dpc-2043	66	20	and	and	CCONJ
dpc-2043	66	21	the	the	DET
dpc-2043	66	22	control	control	NOUN
dpc-2043	66	23	group	group	NOUN
dpc-2043	66	24	.	.	PUNCT
dpc-2043	67	1	ninety	ninety	NUM
dpc-2043	67	2	-	-	PUNCT
dpc-2043	67	3	seven	seven	NUM
dpc-2043	67	4	patients	patient	NOUN
dpc-2043	67	5	had	have	VERB
dpc-2043	67	6	generalized	generalize	VERB
dpc-2043	67	7	vitiligo	vitiligo	NOUN
dpc-2043	67	8	and	and	CCONJ
dpc-2043	67	9	20	20	NUM
dpc-2043	67	10	had	have	VERB
dpc-2043	67	11	localized	localize	VERB
dpc-2043	67	12	vitiligo	vitiligo	NOUN
dpc-2043	67	13	(	(	PUNCT
dpc-2043	67	14	table	table	NOUN
dpc-2043	67	15	2	2	NUM
dpc-2043	67	16	)	)	PUNCT
dpc-2043	67	17	.	.	PUNCT
dpc-2043	68	1	the	the	DET
dpc-2043	68	2	skin	skin	NOUN
dpc-2043	68	3	phototypes	phototype	NOUN
dpc-2043	68	4	were	be	AUX
dpc-2043	68	5	type	type	NOUN
dpc-2043	68	6	iii	iii	X
dpc-2043	68	7	(	(	PUNCT
dpc-2043	68	8	70	70	NUM
dpc-2043	68	9	%	%	NOUN
dpc-2043	68	10	)	)	PUNCT
dpc-2043	68	11	and	and	CCONJ
dpc-2043	68	12	type	type	NOUN
dpc-2043	68	13	iv	iv	NUM
dpc-2043	68	14	(	(	PUNCT
dpc-2043	68	15	30	30	NUM
dpc-2043	68	16	%	%	NOUN
dpc-2043	68	17	)	)	PUNCT
dpc-2043	68	18	.	.	PUNCT
dpc-2043	69	1	the	the	DET
dpc-2043	69	2	duration	duration	NOUN
dpc-2043	69	3	of	of	ADP
dpc-2043	69	4	the	the	DET
dpc-2043	69	5	disease	disease	NOUN
dpc-2043	69	6	ranged	range	VERB
dpc-2043	69	7	from	from	ADP
dpc-2043	69	8	1	1	NUM
dpc-2043	69	9	-	-	SYM
dpc-2043	69	10	11	11	NUM
dpc-2043	69	11	years	year	NOUN
dpc-2043	69	12	,	,	PUNCT
dpc-2043	69	13	with	with	ADP
dpc-2043	69	14	a	a	DET
dpc-2043	69	15	mean	mean	NOUN
dpc-2043	69	16	of	of	ADP
dpc-2043	69	17	9.57±	9.57±	NOUN
dpc-2043	69	18	9.25	9.25	NUM
dpc-2043	69	19	years	year	NOUN
dpc-2043	69	20	.	.	PUNCT
dpc-2043	70	1	in	in	ADP
dpc-2043	70	2	this	this	DET
dpc-2043	70	3	study	study	NOUN
dpc-2043	70	4	,	,	PUNCT
dpc-2043	70	5	the	the	DET
dpc-2043	70	6	serum	serum	NOUN
dpc-2043	70	7	cu	cu	PROPN
dpc-2043	70	8	level	level	NOUN
dpc-2043	70	9	in	in	ADP
dpc-2043	70	10	patients	patient	NOUN
dpc-2043	70	11	ranged	range	VERB
dpc-2043	70	12	from	from	ADP
dpc-2043	70	13	6.11	6.11	NUM
dpc-2043	70	14	to	to	ADP
dpc-2043	70	15	289.36	289.36	NUM
dpc-2043	70	16	μg	μg	PROPN
dpc-2043	70	17	/	/	SYM
dpc-2043	70	18	dl	dl	PROPN
dpc-2043	70	19	(	(	PUNCT
dpc-2043	70	20	mean	mean	NOUN
dpc-2043	70	21	:	:	PUNCT
dpc-2043	70	22	113.57	113.57	NUM
dpc-2043	70	23	±	±	NUM
dpc-2043	70	24	59.43	59.43	NUM
dpc-2043	70	25	μg	μg	PROPN
dpc-2043	70	26	/	/	SYM
dpc-2043	70	27	dl	dl	PROPN
dpc-2043	70	28	)	)	PUNCT
dpc-2043	70	29	and	and	CCONJ
dpc-2043	70	30	that	that	SCONJ
dpc-2043	70	31	for	for	ADP
dpc-2043	70	32	the	the	DET
dpc-2043	70	33	control	control	NOUN
dpc-2043	70	34	group	group	NOUN
dpc-2043	70	35	was	be	AUX
dpc-2043	70	36	71.21	71.21	NUM
dpc-2043	70	37	to	to	ADP
dpc-2043	70	38	231	231	NUM
dpc-2043	70	39	μg	μg	PROPN
dpc-2043	70	40	/	/	SYM
dpc-2043	70	41	dl	dl	PROPN
dpc-2043	70	42	(	(	PUNCT
dpc-2043	70	43	mean	mean	VERB
dpc-2043	70	44	:	:	PUNCT
dpc-2043	70	45	 	 	SPACE
dpc-2043	70	46	138.90	138.90	NUM
dpc-2043	70	47	 	 	SPACE
dpc-2043	70	48	±	±	NUM
dpc-2043	70	49	38.14	38.14	NUM
dpc-2043	70	50	μg	μg	PROPN
dpc-2043	70	51	/	/	SYM
dpc-2043	70	52	dl	dl	PROPN
dpc-2043	70	53	)	)	PUNCT
dpc-2043	70	54	.	.	PUNCT
dpc-2043	71	1	serum	serum	PROPN
dpc-2043	71	2	zinc	zinc	NOUN
dpc-2043	71	3	concentrations	concentration	NOUN
dpc-2043	71	4	in	in	ADP
dpc-2043	71	5	patients	patient	NOUN
dpc-2043	71	6	with	with	ADP
dpc-2043	71	7	vitiligo	vitiligo	NOUN
dpc-2043	71	8	ranged	range	VERB
dpc-2043	71	9	from	from	ADP
dpc-2043	71	10	6.15	6.15	NUM
dpc-2043	71	11	to	to	ADP
dpc-2043	71	12	273	273	NUM
dpc-2043	71	13	μg	μg	PROPN
dpc-2043	71	14	/	/	SYM
dpc-2043	71	15	dl	dl	PROPN
dpc-2043	71	16	(	(	PUNCT
dpc-2043	71	17	mean	mean	NOUN
dpc-2043	71	18	:	:	PUNCT
dpc-2043	71	19	95.01	95.01	NUM
dpc-2043	71	20	±	±	NUM
dpc-2043	71	21	58.95	58.95	NUM
dpc-2043	71	22	μg	μg	PROPN
dpc-2043	71	23	/	/	SYM
dpc-2043	71	24	dl	dl	PROPN
dpc-2043	71	25	)	)	PUNCT
dpc-2043	71	26	and	and	CCONJ
dpc-2043	71	27	that	that	SCONJ
dpc-2043	71	28	for	for	ADP
dpc-2043	71	29	the	the	DET
dpc-2043	71	30	control	control	NOUN
dpc-2043	71	31	group	group	NOUN
dpc-2043	71	32	was	be	AUX
dpc-2043	71	33	32.64	32.64	NUM
dpc-2043	71	34	to	to	ADP
dpc-2043	71	35	190.20	190.20	NUM
dpc-2043	71	36	μg	μg	PROPN
dpc-2043	71	37	/	/	SYM
dpc-2043	71	38	dl	dl	PROPN
dpc-2043	71	39	(	(	PUNCT
dpc-2043	71	40	mean	mean	NOUN
dpc-2043	71	41	:	:	PUNCT
dpc-2043	71	42	121.83	121.83	NUM
dpc-2043	71	43	±	±	NUM
dpc-2043	71	44	33.80	33.80	NUM
dpc-2043	71	45	μg	μg	PROPN
dpc-2043	71	46	/	/	SYM
dpc-2043	71	47	dl	dl	PROPN
dpc-2043	71	48	)	)	PUNCT
dpc-2043	71	49	.	.	PUNCT
dpc-2043	72	1	statistical	statistical	ADJ
dpc-2043	72	2	analysis	analysis	NOUN
dpc-2043	72	3	showed	show	VERB
dpc-2043	72	4	that	that	SCONJ
dpc-2043	72	5	compared	compare	VERB
dpc-2043	72	6	with	with	ADP
dpc-2043	72	7	healthy	healthy	ADJ
dpc-2043	72	8	controls	control	NOUN
dpc-2043	72	9	,	,	PUNCT
dpc-2043	72	10	there	there	PRON
dpc-2043	72	11	were	be	VERB
dpc-2043	72	12	significant	significant	ADJ
dpc-2043	72	13	differences	difference	NOUN
dpc-2043	72	14	in	in	ADP
dpc-2043	72	15	serum	serum	NOUN
dpc-2043	72	16	copper	copper	NOUN
dpc-2043	72	17	and	and	CCONJ
dpc-2043	72	18	zinc	zinc	NOUN
dpc-2043	72	19	levels	level	NOUN
dpc-2043	72	20	in	in	ADP
dpc-2043	72	21	patients	patient	NOUN
dpc-2043	72	22	with	with	ADP
dpc-2043	72	23	vitiligo	vitiligo	NOUN
dpc-2043	72	24	(	(	PUNCT
dpc-2043	72	25	p	p	X
dpc-2043	72	26	=	=	NOUN
dpc-2043	72	27	0.00	0.00	NUM
dpc-2043	72	28	)	)	PUNCT
dpc-2043	72	29	(	(	PUNCT
dpc-2043	72	30	table	table	NOUN
dpc-2043	72	31	1	1	NUM
dpc-2043	72	32	)	)	PUNCT
dpc-2043	72	33	.	.	PUNCT
dpc-2043	73	1	the	the	DET
dpc-2043	73	2	age	age	NOUN
dpc-2043	73	3	of	of	ADP
dpc-2043	73	4	patients	patient	NOUN
dpc-2043	73	5	ranged	range	VERB
dpc-2043	73	6	from	from	ADP
dpc-2043	73	7	19	19	NUM
dpc-2043	73	8	to	to	PART
dpc-2043	73	9	66	66	NUM
dpc-2043	73	10	years	year	NOUN
dpc-2043	73	11	old	old	ADJ
dpc-2043	73	12	(	(	PUNCT
dpc-2043	73	13	mean	mean	NOUN
dpc-2043	73	14	:	:	PUNCT
dpc-2043	73	15	37.64	37.64	NUM
dpc-2043	73	16	±	±	NUM
dpc-2043	73	17	13.01	13.01	NUM
dpc-2043	73	18	years	year	NOUN
dpc-2043	73	19	)	)	PUNCT
dpc-2043	73	20	and	and	CCONJ
dpc-2043	73	21	that	that	PRON
dpc-2043	73	22	of	of	ADP
dpc-2043	73	23	control	control	NOUN
dpc-2043	73	24	26	26	NUM
dpc-2043	73	25	to	to	PART
dpc-2043	73	26	60	60	NUM
dpc-2043	73	27	years	year	NOUN
dpc-2043	73	28	old	old	ADJ
dpc-2043	73	29	(	(	PUNCT
dpc-2043	73	30	mean	mean	NOUN
dpc-2043	73	31	:	:	PUNCT
dpc-2043	73	32	47.19	47.19	NUM
dpc-2043	73	33	±	±	NUM
dpc-2043	73	34	8.03	8.03	NUM
dpc-2043	73	35	years	year	NOUN
dpc-2043	73	36	)	)	PUNCT
dpc-2043	73	37	.	.	PUNCT
dpc-2043	74	1	in	in	ADP
dpc-2043	74	2	terms	term	NOUN
dpc-2043	74	3	of	of	ADP
dpc-2043	74	4	the	the	DET
dpc-2043	74	5	prevalence	prevalence	NOUN
dpc-2043	74	6	of	of	ADP
dpc-2043	74	7	disease	disease	NOUN
dpc-2043	74	8	,	,	PUNCT
dpc-2043	74	9	the	the	DET
dpc-2043	74	10	highest	high	ADJ
dpc-2043	74	11	rate	rate	NOUN
dpc-2043	74	12	was	be	AUX
dpc-2043	74	13	in	in	ADP
dpc-2043	74	14	the	the	DET
dpc-2043	74	15	25	25	NUM
dpc-2043	74	16	to	to	PART
dpc-2043	74	17	28	28	NUM
dpc-2043	74	18	year	year	NOUN
dpc-2043	74	19	age	age	NOUN
dpc-2043	74	20	group	group	NOUN
dpc-2043	74	21	(	(	PUNCT
dpc-2043	74	22	17	17	NUM
dpc-2043	74	23	%	%	NOUN
dpc-2043	74	24	)	)	PUNCT
dpc-2043	74	25	.	.	PUNCT
dpc-2043	75	1	the	the	DET
dpc-2043	75	2	median	median	ADJ
dpc-2043	75	3	age	age	NOUN
dpc-2043	75	4	of	of	ADP
dpc-2043	75	5	vitiligo	vitiligo	ADJ
dpc-2043	75	6	patients	patient	NOUN
dpc-2043	75	7	was	be	AUX
dpc-2043	75	8	about	about	ADV
dpc-2043	75	9	34	34	NUM
dpc-2043	75	10	years	year	NOUN
dpc-2043	75	11	.	.	PUNCT
dpc-2043	76	1	since	since	SCONJ
dpc-2043	76	2	the	the	DET
dpc-2043	76	3	serum	serum	NOUN
dpc-2043	76	4	levels	level	NOUN
dpc-2043	76	5	of	of	ADP
dpc-2043	76	6	zn	zn	PROPN
dpc-2043	76	7	and	and	CCONJ
dpc-2043	76	8	cu	cu	PROPN
dpc-2043	76	9	have	have	AUX
dpc-2043	76	10	been	be	AUX
dpc-2043	76	11	reported	report	VERB
dpc-2043	76	12	to	to	PART
dpc-2043	76	13	increase	increase	VERB
dpc-2043	76	14	by	by	ADP
dpc-2043	76	15	age	age	NOUN
dpc-2043	76	16	[	[	X
dpc-2043	76	17	30	30	NUM
dpc-2043	76	18	]	]	PUNCT
dpc-2043	76	19	,	,	PUNCT
dpc-2043	76	20	we	we	PRON
dpc-2043	76	21	divided	divide	VERB
dpc-2043	76	22	the	the	DET
dpc-2043	76	23	subjects	subject	NOUN
dpc-2043	76	24	into	into	ADP
dpc-2043	76	25	two	two	NUM
dpc-2043	76	26	groups	group	NOUN
dpc-2043	76	27	of	of	ADP
dpc-2043	76	28	young	young	ADJ
dpc-2043	76	29	(	(	PUNCT
dpc-2043	76	30	<	<	X
dpc-2043	76	31	50	50	NUM
dpc-2043	76	32	years	year	NOUN
dpc-2043	76	33	)	)	PUNCT
dpc-2043	76	34	and	and	CCONJ
dpc-2043	76	35	old	old	ADJ
dpc-2043	76	36	(	(	PUNCT
dpc-2043	76	37	≥	≥	NUM
dpc-2043	76	38	50	50	NUM
dpc-2043	76	39	years	year	NOUN
dpc-2043	76	40	)	)	PUNCT
dpc-2043	76	41	groups	group	NOUN
dpc-2043	76	42	.	.	PUNCT
dpc-2043	77	1	we	we	PRON
dpc-2043	77	2	found	find	VERB
dpc-2043	77	3	significantly	significantly	ADV
dpc-2043	77	4	lower	low	ADJ
dpc-2043	77	5	serum	serum	PROPN
dpc-2043	77	6	cu	cu	PROPN
dpc-2043	77	7	and	and	CCONJ
dpc-2043	77	8	zn	zn	PROPN
dpc-2043	77	9	concentration	concentration	NOUN
dpc-2043	77	10	among	among	ADP
dpc-2043	77	11	young	young	ADJ
dpc-2043	77	12	patients	patient	NOUN
dpc-2043	77	13	(	(	PUNCT
dpc-2043	77	14	107.12	107.12	NUM
dpc-2043	77	15	±	±	NUM
dpc-2043	77	16	61.18	61.18	NUM
dpc-2043	77	17	and	and	CCONJ
dpc-2043	77	18	82.47	82.47	NUM
dpc-2043	77	19	±	±	NUM
dpc-2043	77	20	47.40	47.40	NUM
dpc-2043	77	21	μg	μg	PROPN
dpc-2043	77	22	/	/	SYM
dpc-2043	77	23	dl	dl	PROPN
dpc-2043	77	24	,	,	PUNCT
dpc-2043	77	25	respectively	respectively	ADV
dpc-2043	77	26	)	)	PUNCT
dpc-2043	77	27	than	than	ADP
dpc-2043	77	28	the	the	DET
dpc-2043	77	29	elderly	elderly	ADJ
dpc-2043	77	30	group	group	NOUN
dpc-2043	77	31	(	(	PUNCT
dpc-2043	77	32	122.53	122.53	NUM
dpc-2043	77	33	±56.30	±56.30	NOUN
dpc-2043	77	34	and	and	CCONJ
dpc-2043	77	35	114.37	114.37	NUM
dpc-2043	77	36	±	±	NUM
dpc-2043	77	37	67.27	67.27	NUM
dpc-2043	77	38	μg	μg	PROPN
dpc-2043	77	39	/	/	SYM
dpc-2043	77	40	dl	dl	PROPN
dpc-2043	77	41	,	,	PUNCT
dpc-2043	77	42	respectively	respectively	ADV
dpc-2043	77	43	)	)	PUNCT
dpc-2043	77	44	(	(	PUNCT
dpc-2043	77	45	p	p	NOUN
dpc-2043	77	46	=	=	NOUN
dpc-2043	77	47	0.00	0.00	NUM
dpc-2043	77	48	)	)	PUNCT
dpc-2043	77	49	(	(	PUNCT
dpc-2043	77	50	table	table	NOUN
dpc-2043	77	51	1	1	NUM
dpc-2043	77	52	)	)	PUNCT
dpc-2043	77	53	.	.	PUNCT
dpc-2043	78	1	in	in	ADP
dpc-2043	78	2	the	the	DET
dpc-2043	78	3	case	case	NOUN
dpc-2043	78	4	-	-	PUNCT
dpc-2043	78	5	control	control	NOUN
dpc-2043	78	6	comparison	comparison	NOUN
dpc-2043	78	7	of	of	ADP
dpc-2043	78	8	two	two	NUM
dpc-2043	78	9	age	age	NOUN
dpc-2043	78	10	groups	group	NOUN
dpc-2043	78	11	,	,	PUNCT
dpc-2043	78	12	we	we	PRON
dpc-2043	78	13	found	find	VERB
dpc-2043	78	14	that	that	SCONJ
dpc-2043	78	15	the	the	DET
dpc-2043	78	16	serum	serum	NOUN
dpc-2043	78	17	copper	copper	NOUN
dpc-2043	78	18	concentrations	concentration	NOUN
dpc-2043	78	19	of	of	ADP
dpc-2043	78	20	cases	case	NOUN
dpc-2043	78	21	were	be	AUX
dpc-2043	78	22	lower	low	ADJ
dpc-2043	78	23	than	than	ADP
dpc-2043	78	24	those	those	PRON
dpc-2043	78	25	in	in	ADP
dpc-2043	78	26	the	the	DET
dpc-2043	78	27	respective	respective	ADJ
dpc-2043	78	28	control	control	NOUN
dpc-2043	78	29	group	group	NOUN
dpc-2043	78	30	(	(	PUNCT
dpc-2043	78	31	p	p	NOUN
dpc-2043	78	32	≤	≤	NOUN
dpc-2043	78	33	 	 	SPACE
dpc-2043	78	34	0.05	0.05	NUM
dpc-2043	78	35	)	)	PUNCT
dpc-2043	78	36	.	.	PUNCT
dpc-2043	79	1	the	the	DET
dpc-2043	79	2	mean	mean	ADJ
dpc-2043	79	3	serum	serum	PROPN
dpc-2043	79	4	zn	zn	PROPN
dpc-2043	79	5	levels	level	NOUN
dpc-2043	79	6	of	of	ADP
dpc-2043	79	7	young	young	ADJ
dpc-2043	79	8	cases	case	NOUN
dpc-2043	79	9	were	be	AUX
dpc-2043	79	10	also	also	ADV
dpc-2043	79	11	lower	low	ADJ
dpc-2043	79	12	than	than	ADP
dpc-2043	79	13	the	the	DET
dpc-2043	79	14	corresponding	corresponding	ADJ
dpc-2043	79	15	value	value	NOUN
dpc-2043	79	16	in	in	ADP
dpc-2043	79	17	the	the	DET
dpc-2043	79	18	respective	respective	ADJ
dpc-2043	79	19	controls	control	NOUN
dpc-2043	79	20	(	(	PUNCT
dpc-2043	79	21	p	p	X
dpc-2043	79	22	  	  	SPACE
dpc-2043	79	23	=	=	NOUN
dpc-2043	79	24	  	  	SPACE
dpc-2043	79	25	0.00	0.00	NUM
dpc-2043	79	26	)	)	PUNCT
dpc-2043	79	27	while	while	SCONJ
dpc-2043	79	28	there	there	PRON
dpc-2043	79	29	was	be	VERB
dpc-2043	79	30	no	no	DET
dpc-2043	79	31	significant	significant	ADJ
dpc-2043	79	32	difference	difference	NOUN
dpc-2043	79	33	between	between	ADP
dpc-2043	79	34	the	the	DET
dpc-2043	79	35	mean	mean	ADJ
dpc-2043	79	36	serum	serum	NOUN
dpc-2043	79	37	zn	zn	PROPN
dpc-2043	79	38	concentrations	concentration	NOUN
dpc-2043	79	39	of	of	ADP
dpc-2043	79	40	the	the	DET
dpc-2043	79	41	elderly	elderly	ADJ
dpc-2043	79	42	subjects	subject	NOUN
dpc-2043	79	43	and	and	CCONJ
dpc-2043	79	44	controls	control	NOUN
dpc-2043	79	45	(	(	PUNCT
dpc-2043	79	46	p	p	X
dpc-2043	79	47	=	=	NOUN
dpc-2043	79	48	0.535	0.535	NUM
dpc-2043	79	49	)	)	PUNCT
dpc-2043	79	50	.	.	PUNCT
dpc-2043	80	1	although	although	SCONJ
dpc-2043	80	2	,	,	PUNCT
dpc-2043	80	3	in	in	ADP
dpc-2043	80	4	the	the	DET
dpc-2043	80	5	case	case	NOUN
dpc-2043	80	6	-	-	PUNCT
dpc-2043	80	7	case	case	NOUN
dpc-2043	80	8	comparison	comparison	NOUN
dpc-2043	80	9	of	of	ADP
dpc-2043	80	10	two	two	NUM
dpc-2043	80	11	age	age	NOUN
dpc-2043	80	12	groups	group	NOUN
dpc-2043	80	13	,	,	PUNCT
dpc-2043	80	14	a	a	DET
dpc-2043	80	15	higher	high	ADJ
dpc-2043	80	16	cu	cu	PROPN
dpc-2043	80	17	/	/	SYM
dpc-2043	80	18	zn	zn	PROPN
dpc-2043	80	19	ratio	ratio	NOUN
dpc-2043	80	20	was	be	AUX
dpc-2043	80	21	found	find	VERB
dpc-2043	80	22	in	in	ADP
dpc-2043	80	23	the	the	DET
dpc-2043	80	24	young	young	ADJ
dpc-2043	80	25	cases	case	NOUN
dpc-2043	80	26	than	than	ADP
dpc-2043	80	27	elderly	elderly	ADJ
dpc-2043	80	28	patients	patient	NOUN
dpc-2043	80	29	(	(	PUNCT
dpc-2043	80	30	1.96	1.96	NUM
dpc-2043	80	31	±	±	NUM
dpc-2043	80	32	2.09	2.09	NUM
dpc-2043	80	33	vs	vs	ADP
dpc-2043	80	34	1.64	1.64	NUM
dpc-2043	80	35	±	±	NUM
dpc-2043	80	36	1.67	1.67	NUM
dpc-2043	80	37	)	)	PUNCT
dpc-2043	80	38	,	,	PUNCT
dpc-2043	80	39	the	the	DET
dpc-2043	80	40	difference	difference	NOUN
dpc-2043	80	41	did	do	AUX
dpc-2043	80	42	n’t	not	PART
dpc-2043	80	43	reach	reach	VERB
dpc-2043	80	44	the	the	DET
dpc-2043	80	45	level	level	NOUN
dpc-2043	80	46	of	of	ADP
dpc-2043	80	47	significance	significance	NOUN
dpc-2043	80	48	(	(	PUNCT
dpc-2043	80	49	p	p	NOUN
dpc-2043	80	50	=	=	NOUN
dpc-2043	80	51	 	 	SPACE
dpc-2043	80	52	0.406	0.406	NUM
dpc-2043	80	53	)	)	PUNCT
dpc-2043	80	54	.	.	PUNCT
dpc-2043	81	1	there	there	PRON
dpc-2043	81	2	was	be	VERB
dpc-2043	81	3	no	no	DET
dpc-2043	81	4	significant	significant	ADJ
dpc-2043	81	5	difference	difference	NOUN
dpc-2043	81	6	in	in	ADP
dpc-2043	81	7	serum	serum	NOUN
dpc-2043	81	8	copper	copper	NOUN
dpc-2043	81	9	and	and	CCONJ
dpc-2043	81	10	zinc	zinc	NOUN
dpc-2043	81	11	levels	level	NOUN
dpc-2043	81	12	between	between	ADP
dpc-2043	81	13	table	table	NOUN
dpc-2043	81	14	1	1	NUM
dpc-2043	81	15	.	.	PUNCT
dpc-2043	81	16	serum	serum	PROPN
dpc-2043	81	17	copper	copper	NOUN
dpc-2043	81	18	and	and	CCONJ
dpc-2043	81	19	zinc	zinc	NOUN
dpc-2043	81	20	levels	level	NOUN
dpc-2043	81	21	among	among	ADP
dpc-2043	81	22	vitiligo	vitiligo	PROPN
dpc-2043	81	23	patients	patient	NOUN
dpc-2043	81	24	group	group	NOUN
dpc-2043	81	25	cu	cu	PROPN
dpc-2043	81	26	(	(	PUNCT
dpc-2043	81	27	μg/	μg/	NOUN
dpc-2043	81	28	dl	dl	NOUN
dpc-2043	81	29	)	)	PUNCT
dpc-2043	81	30	median	median	PROPN
dpc-2043	81	31	cu	cu	PROPN
dpc-2043	81	32	(	(	PUNCT
dpc-2043	81	33	μg	μg	PROPN
dpc-2043	81	34	/	/	SYM
dpc-2043	81	35	dl	dl	PROPN
dpc-2043	81	36	)	)	PUNCT
dpc-2043	81	37	mean	mean	VERB
dpc-2043	81	38	±	±	NUM
dpc-2043	81	39	sd	sd	ADP
dpc-2043	81	40	pa	pa	PROPN
dpc-2043	81	41	pb	pb	ADP
dpc-2043	81	42	zn	zn	PROPN
dpc-2043	81	43	(	(	PUNCT
dpc-2043	81	44	μg/	μg/	NOUN
dpc-2043	81	45	dl	dl	NOUN
dpc-2043	81	46	)	)	PUNCT
dpc-2043	81	47	median	median	NOUN
dpc-2043	81	48	zn	zn	PROPN
dpc-2043	81	49	(	(	PUNCT
dpc-2043	81	50	μg	μg	PROPN
dpc-2043	81	51	/	/	SYM
dpc-2043	81	52	dl	dl	PROPN
dpc-2043	81	53	)	)	PUNCT
dpc-2043	81	54	mean	mean	VERB
dpc-2043	81	55	±	±	NUM
dpc-2043	81	56	sd	sd	ADP
dpc-2043	81	57	pa	pa	PROPN
dpc-2043	81	58	pb	pb	X
dpc-2043	82	1	[	[	X
dpc-2043	82	2	cu]/[zn	cu]/[zn	X
dpc-2043	82	3	]	]	X
dpc-2043	82	4	pa	pa	NOUN
dpc-2043	82	5	pb	pb	ADP
dpc-2043	82	6	cases	case	NOUN
dpc-2043	82	7	(	(	PUNCT
dpc-2043	82	8	n	n	CCONJ
dpc-2043	82	9	)	)	PUNCT
dpc-2043	82	10	total	total	NOUN
dpc-2043	82	11	(	(	PUNCT
dpc-2043	82	12	117	117	NUM
dpc-2043	82	13	)	)	PUNCT
dpc-2043	82	14	103.41	103.41	NUM
dpc-2043	82	15	113.57	113.57	NUM
dpc-2043	82	16	±	±	NUM
dpc-2043	82	17	59.43	59.43	NUM
dpc-2043	82	18	0.000	0.000	NUM
dpc-2043	82	19	76.17	76.17	NUM
dpc-2043	82	20	95.01	95.01	NUM
dpc-2043	82	21	±	±	NUM
dpc-2043	82	22	58.95	58.95	NUM
dpc-2043	82	23	0.00	0.00	NUM
dpc-2043	82	24	1.81	1.81	NUM
dpc-2043	82	25	±	±	NUM
dpc-2043	82	26	1.90	1.90	NUM
dpc-2043	82	27	0.488	0.488	NUM
dpc-2043	82	28	age	age	NOUN
dpc-2043	82	29	<	<	X
dpc-2043	82	30	50	50	NUM
dpc-2043	82	31	y	y	NOUN
dpc-2043	82	32	(	(	PUNCT
dpc-2043	82	33	68	68	NUM
dpc-2043	82	34	)	)	PUNCT
dpc-2043	82	35	≥50	≥50	X
dpc-2043	82	36	y	y	PROPN
dpc-2043	82	37	(	(	PUNCT
dpc-2043	82	38	49	49	NUM
dpc-2043	82	39	)	)	PUNCT
dpc-2043	82	40	95.07	95.07	NUM
dpc-2043	82	41	128.67	128.67	NUM
dpc-2043	82	42	107.12	107.12	NUM
dpc-2043	82	43	±	±	NUM
dpc-2043	82	44	61.18	61.18	NUM
dpc-2043	82	45	122.53	122.53	NUM
dpc-2043	82	46	±	±	NUM
dpc-2043	82	47	56.30	56.30	NUM
dpc-2043	82	48	0.000	0.000	NUM
dpc-2043	82	49	0.050	0.050	NUM
dpc-2043	82	50	0.003	0.003	NUM
dpc-2043	82	51	72.01	72.01	NUM
dpc-2043	82	52	101.06	101.06	NUM
dpc-2043	82	53	82.47	82.47	NUM
dpc-2043	82	54	±	±	NUM
dpc-2043	82	55	47.40	47.40	NUM
dpc-2043	82	56	114.37	114.37	NUM
dpc-2043	82	57	±	±	NOUN
dpc-2043	82	58	67.27	67.27	NUM
dpc-2043	82	59	0.00	0.00	NUM
dpc-2043	82	60	0.535	0.535	NUM
dpc-2043	82	61	0.000	0.000	NUM
dpc-2043	82	62	1.96	1.96	NUM
dpc-2043	82	63	±	±	NUM
dpc-2043	82	64	2.09	2.09	NUM
dpc-2043	82	65	1.64	1.64	NUM
dpc-2043	82	66	±	±	NUM
dpc-2043	82	67	1.67	1.67	NUM
dpc-2043	82	68	0.018	0.018	NUM
dpc-2043	82	69	0.161	0.161	NUM
dpc-2043	82	70	0.406	0.406	NUM
dpc-2043	82	71	sex	sex	NOUN
dpc-2043	82	72	male	male	NOUN
dpc-2043	82	73	(	(	PUNCT
dpc-2043	82	74	48	48	NUM
dpc-2043	82	75	)	)	PUNCT
dpc-2043	82	76	female	female	NOUN
dpc-2043	82	77	(	(	PUNCT
dpc-2043	82	78	69	69	NUM
dpc-2043	82	79	)	)	PUNCT
dpc-2043	82	80	108.94	108.94	NUM
dpc-2043	82	81	110.68	110.68	NUM
dpc-2043	82	82	114.65	114.65	NUM
dpc-2043	82	83	±	±	NOUN
dpc-2043	82	84	63.88	63.88	NUM
dpc-2043	82	85	112.95	112.95	NUM
dpc-2043	82	86	±	±	NOUN
dpc-2043	82	87	56.32	56.32	NUM
dpc-2043	82	88	0.015	0.015	NUM
dpc-2043	82	89	0.00	0.00	NUM
dpc-2043	82	90	0.992	0.992	NUM
dpc-2043	82	91	76.34	76.34	NUM
dpc-2043	82	92	75.09	75.09	NUM
dpc-2043	82	93	99.12	99.12	NUM
dpc-2043	82	94	±	±	NUM
dpc-2043	82	95	62.10	62.10	NUM
dpc-2043	82	96	92.25	92.25	NUM
dpc-2043	82	97	±	±	NUM
dpc-2043	82	98	56.83	56.83	NUM
dpc-2043	82	99	0.000	0.000	NUM
dpc-2043	82	100	0.000	0.000	NUM
dpc-2043	82	101	0.429	0.429	NUM
dpc-2043	82	102	1.67	1.67	NUM
dpc-2043	82	103	±	±	NUM
dpc-2043	82	104	1.48	1.48	NUM
dpc-2043	82	105	1.90	1.90	NUM
dpc-2043	82	106	±	±	NUM
dpc-2043	82	107	2.15	2.15	NUM
dpc-2043	82	108	0.011	0.011	NUM
dpc-2043	82	109	0.087	0.087	NUM
dpc-2043	82	110	0.559	0.559	NUM
dpc-2043	82	111	controls	control	NOUN
dpc-2043	82	112	,	,	PUNCT
dpc-2043	82	113	(	(	PUNCT
dpc-2043	82	114	n	n	CCONJ
dpc-2043	82	115	)	)	PUNCT
dpc-2043	82	116	total	total	NOUN
dpc-2043	82	117	(	(	PUNCT
dpc-2043	82	118	137	137	NUM
dpc-2043	82	119	)	)	PUNCT
dpc-2043	82	120	138.58	138.58	NUM
dpc-2043	82	121	138.90	138.90	NUM
dpc-2043	82	122	±	±	NUM
dpc-2043	82	123	38.14	38.14	NUM
dpc-2043	82	124	118.42	118.42	NUM
dpc-2043	82	125	121.83	121.83	NUM
dpc-2043	82	126	±	±	NUM
dpc-2043	82	127	33.80	33.80	NUM
dpc-2043	82	128	1.28	1.28	NUM
dpc-2043	82	129	±	±	NOUN
dpc-2043	82	130	0.56	0.56	NUM
dpc-2043	82	131	age	age	NOUN
dpc-2043	82	132	<	<	X
dpc-2043	82	133	50	50	NUM
dpc-2043	82	134	y	y	NOUN
dpc-2043	82	135	(	(	PUNCT
dpc-2043	82	136	71	71	NUM
dpc-2043	82	137	)	)	PUNCT
dpc-2043	82	138	≥50	≥50	X
dpc-2043	82	139	y	y	PROPN
dpc-2043	82	140	(	(	PUNCT
dpc-2043	82	141	66	66	NUM
dpc-2043	82	142	)	)	PUNCT
dpc-2043	82	143	138.97	138.97	NUM
dpc-2043	82	144	138.74	138.74	NUM
dpc-2043	82	145	143.82	143.82	NUM
dpc-2043	82	146	±	±	NUM
dpc-2043	82	147	30.73	30.73	NUM
dpc-2043	82	148	138.70	138.70	NUM
dpc-2043	82	149	±	±	NUM
dpc-2043	82	150	31.59	31.59	NUM
dpc-2043	82	151	0.338	0.338	NUM
dpc-2043	82	152	122.14	122.14	NUM
dpc-2043	82	153	117.02	117.02	NUM
dpc-2043	82	154	124.80	124.80	NUM
dpc-2043	82	155	±	±	NUM
dpc-2043	82	156	33.05	33.05	NUM
dpc-2043	82	157	118.84	118.84	NUM
dpc-2043	82	158	±	±	NUM
dpc-2043	82	159	34.59	34.59	NUM
dpc-2043	82	160	0.321	0.321	NUM
dpc-2043	82	161	1.24	1.24	NUM
dpc-2043	82	162	±	±	NUM
dpc-2043	82	163	0.43	0.43	NUM
dpc-2043	82	164	1.32	1.32	NUM
dpc-2043	82	165	±	±	NUM
dpc-2043	82	166	0.66	0.66	NUM
dpc-2043	82	167	0.001	0.001	NUM
dpc-2043	82	168	sex	sex	NOUN
dpc-2043	82	169	male	male	NOUN
dpc-2043	82	170	(	(	PUNCT
dpc-2043	82	171	62	62	NUM
dpc-2043	82	172	)	)	PUNCT
dpc-2043	82	173	female	female	NOUN
dpc-2043	82	174	(	(	PUNCT
dpc-2043	82	175	75	75	NUM
dpc-2043	82	176	)	)	PUNCT
dpc-2043	82	177	137.08	137.08	NUM
dpc-2043	82	178	142.38	142.38	NUM
dpc-2043	82	179	135.46	135.46	NUM
dpc-2043	82	180	±	±	NUM
dpc-2043	82	181	25.13	25.13	NUM
dpc-2043	82	182	146.22	146.22	NUM
dpc-2043	82	183	±	±	NUM
dpc-2043	82	184	34.76	34.76	NUM
dpc-2043	82	185	0.044	0.044	NUM
dpc-2043	82	186	126.10	126.10	NUM
dpc-2043	82	187	111.40	111.40	NUM
dpc-2043	82	188	126.87	126.87	NUM
dpc-2043	82	189	±	±	NUM
dpc-2043	82	190	29.28	29.28	NUM
dpc-2043	82	191	112.53	112.53	NUM
dpc-2043	82	192	±	±	NUM
dpc-2043	82	193	33.78	33.78	NUM
dpc-2043	82	194	0.113	0.113	NUM
dpc-2043	82	195	1.14	1.14	NUM
dpc-2043	82	196	±	±	NUM
dpc-2043	82	197	0.3	0.3	NUM
dpc-2043	82	198	1.39	1.39	NUM
dpc-2043	82	199	±	±	NUM
dpc-2043	82	200	0.69	0.69	NUM
dpc-2043	82	201	0.008	0.008	NUM
dpc-2043	82	202	cu	cu	NOUN
dpc-2043	82	203	=	=	PROPN
dpc-2043	82	204	copper	copper	NOUN
dpc-2043	82	205	;	;	PUNCT
dpc-2043	82	206	sd	sd	NOUN
dpc-2043	82	207	=	=	SYM
dpc-2043	82	208	standard	standard	ADJ
dpc-2043	82	209	deviation	deviation	NOUN
dpc-2043	82	210	;	;	PUNCT
dpc-2043	82	211	y	y	PROPN
dpc-2043	82	212	=	=	SYM
dpc-2043	82	213	years	year	NOUN
dpc-2043	82	214	;	;	PUNCT
dpc-2043	82	215	zn	zn	PROPN
dpc-2043	82	216	=	=	SYM
dpc-2043	82	217	zinc	zinc	PROPN
dpc-2043	82	218	.	.	PUNCT
dpc-2043	83	1	a	a	DET
dpc-2043	83	2	values	value	NOUN
dpc-2043	83	3	for	for	ADP
dpc-2043	83	4	case	case	NOUN
dpc-2043	83	5	–	–	PUNCT
dpc-2043	83	6	control	control	NOUN
dpc-2043	83	7	comparisons	comparison	NOUN
dpc-2043	83	8	from	from	ADP
dpc-2043	83	9	kruskal	kruskal	ADJ
dpc-2043	83	10	–	–	PUNCT
dpc-2043	83	11	wallis	wallis	PROPN
dpc-2043	83	12	or	or	CCONJ
dpc-2043	83	13	mann	mann	PROPN
dpc-2043	83	14	–	–	PUNCT
dpc-2043	83	15	whitney	whitney	PROPN
dpc-2043	83	16	u	u	PROPN
dpc-2043	83	17	test	test	NOUN
dpc-2043	83	18	where	where	SCONJ
dpc-2043	83	19	appropriate	appropriate	ADJ
dpc-2043	83	20	b	b	NOUN
dpc-2043	83	21	values	value	NOUN
dpc-2043	83	22	for	for	ADP
dpc-2043	83	23	case	case	NOUN
dpc-2043	83	24	–	–	PUNCT
dpc-2043	83	25	case	case	NOUN
dpc-2043	83	26	or	or	CCONJ
dpc-2043	83	27	control	control	NOUN
dpc-2043	83	28	-	-	PUNCT
dpc-2043	83	29	control	control	NOUN
dpc-2043	83	30	comparisons	comparison	NOUN
dpc-2043	83	31	from	from	ADP
dpc-2043	83	32	kruskal	kruskal	ADJ
dpc-2043	83	33	–	–	PUNCT
dpc-2043	83	34	wallis	wallis	PROPN
dpc-2043	83	35	or	or	CCONJ
dpc-2043	83	36	mann	mann	PROPN
dpc-2043	83	37	–	–	PUNCT
dpc-2043	83	38	whitney	whitney	PROPN
dpc-2043	83	39	u	u	PROPN
dpc-2043	83	40	test	test	NOUN
dpc-2043	83	41	where	where	SCONJ
dpc-2043	83	42	appropriate	appropriate	ADJ
dpc-2043	83	43	4	4	NUM
dpc-2043	83	44	original	original	ADJ
dpc-2043	83	45	article	article	NOUN
dpc-2043	83	46	|	|	ADV
dpc-2043	83	47	dermatol	dermatol	ADJ
dpc-2043	83	48	pract	pract	NOUN
dpc-2043	83	49	concept	concept	NOUN
dpc-2043	83	50	.	.	PUNCT
dpc-2043	84	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	84	2	cu	cu	PROPN
dpc-2043	84	3	level	level	NOUN
dpc-2043	84	4	of	of	ADP
dpc-2043	84	5	these	these	DET
dpc-2043	84	6	patients	patient	NOUN
dpc-2043	84	7	(	(	PUNCT
dpc-2043	84	8	117.04±	117.04±	NUM
dpc-2043	84	9	59.95	59.95	NUM
dpc-2043	84	10	μg	μg	PROPN
dpc-2043	84	11	/	/	SYM
dpc-2043	84	12	dl	dl	PROPN
dpc-2043	84	13	)	)	PUNCT
dpc-2043	84	14	and	and	CCONJ
dpc-2043	84	15	that	that	PRON
dpc-2043	84	16	of	of	ADP
dpc-2043	84	17	patients	patient	NOUN
dpc-2043	84	18	with	with	ADP
dpc-2043	84	19	type	type	NOUN
dpc-2043	84	20	iii	iii	NOUN
dpc-2043	84	21	skin	skin	NOUN
dpc-2043	84	22	(	(	PUNCT
dpc-2043	84	23	112.67±59.66	112.67±59.66	NUM
dpc-2043	84	24	μg	μg	PROPN
dpc-2043	84	25	/	/	SYM
dpc-2043	84	26	dl	dl	PROPN
dpc-2043	84	27	)	)	PUNCT
dpc-2043	84	28	(	(	PUNCT
dpc-2043	84	29	p	p	X
dpc-2043	84	30	>	>	X
dpc-2043	84	31	0.05	0.05	NUM
dpc-2043	84	32	)	)	PUNCT
dpc-2043	84	33	.	.	PUNCT
dpc-2043	85	1	the	the	DET
dpc-2043	85	2	patients	patient	NOUN
dpc-2043	85	3	with	with	ADP
dpc-2043	85	4	a	a	DET
dpc-2043	85	5	history	history	NOUN
dpc-2043	85	6	of	of	ADP
dpc-2043	85	7	other	other	ADJ
dpc-2043	85	8	autoimmune	autoimmune	ADJ
dpc-2043	85	9	diseases	disease	NOUN
dpc-2043	85	10	had	have	VERB
dpc-2043	85	11	a	a	DET
dpc-2043	85	12	higher	high	ADJ
dpc-2043	85	13	serum	serum	NOUN
dpc-2043	85	14	cu	cu	PROPN
dpc-2043	85	15	,	,	PUNCT
dpc-2043	85	16	zn	zn	PROPN
dpc-2043	85	17	,	,	PUNCT
dpc-2043	85	18	and	and	CCONJ
dpc-2043	85	19	cu	cu	PROPN
dpc-2043	85	20	/	/	SYM
dpc-2043	85	21	zn	zn	PROPN
dpc-2043	85	22	ratio	ratio	NOUN
dpc-2043	85	23	than	than	ADP
dpc-2043	85	24	patients	patient	NOUN
dpc-2043	85	25	without	without	ADP
dpc-2043	85	26	a	a	DET
dpc-2043	85	27	history	history	NOUN
dpc-2043	85	28	of	of	ADP
dpc-2043	85	29	autoimmune	autoimmune	ADJ
dpc-2043	85	30	disease	disease	NOUN
dpc-2043	85	31	(	(	PUNCT
dpc-2043	85	32	p	p	X
dpc-2043	85	33	<	<	X
dpc-2043	85	34	0.01	0.01	NUM
dpc-2043	85	35	)	)	PUNCT
dpc-2043	85	36	(	(	PUNCT
dpc-2043	85	37	table	table	NOUN
dpc-2043	85	38	 	 	SPACE
dpc-2043	85	39	2	2	NUM
dpc-2043	85	40	)	)	PUNCT
dpc-2043	85	41	.	.	PUNCT
dpc-2043	86	1	we	we	PRON
dpc-2043	86	2	divided	divide	VERB
dpc-2043	86	3	the	the	DET
dpc-2043	86	4	patients	patient	NOUN
dpc-2043	86	5	into	into	ADP
dpc-2043	86	6	two	two	NUM
dpc-2043	86	7	groups	group	NOUN
dpc-2043	86	8	of	of	ADP
dpc-2043	86	9	early	early	ADJ
dpc-2043	86	10	-	-	PUNCT
dpc-2043	86	11	onset	onset	NOUN
dpc-2043	86	12	(	(	PUNCT
dpc-2043	86	13	the	the	DET
dpc-2043	86	14	first	first	ADJ
dpc-2043	86	15	onset	onset	NOUN
dpc-2043	86	16	before	before	ADP
dpc-2043	86	17	the	the	DET
dpc-2043	86	18	age	age	NOUN
dpc-2043	86	19	50	50	NUM
dpc-2043	86	20	)	)	PUNCT
dpc-2043	86	21	and	and	CCONJ
dpc-2043	86	22	late	late	ADJ
dpc-2043	86	23	-	-	PUNCT
dpc-2043	86	24	onset	onset	NOUN
dpc-2043	86	25	(	(	PUNCT
dpc-2043	86	26	the	the	DET
dpc-2043	86	27	first	first	ADJ
dpc-2043	86	28	onset	onset	NOUN
dpc-2043	86	29	after	after	ADP
dpc-2043	86	30	the	the	DET
dpc-2043	86	31	age	age	NOUN
dpc-2043	86	32	50	50	NUM
dpc-2043	86	33	)	)	PUNCT
dpc-2043	86	34	.	.	PUNCT
dpc-2043	87	1	patients	patient	NOUN
dpc-2043	87	2	with	with	ADP
dpc-2043	87	3	an	an	DET
dpc-2043	87	4	early	early	ADJ
dpc-2043	87	5	-	-	PUNCT
dpc-2043	87	6	onset	onset	NOUN
dpc-2043	87	7	of	of	ADP
dpc-2043	87	8	vitiligo	vitiligo	NOUN
dpc-2043	87	9	had	have	VERB
dpc-2043	87	10	lower	low	ADJ
dpc-2043	87	11	serum	serum	NOUN
dpc-2043	87	12	cu	cu	PROPN
dpc-2043	87	13	(	(	PUNCT
dpc-2043	87	14	107.12	107.12	NUM
dpc-2043	87	15	±	±	NUM
dpc-2043	87	16	61.17	61.17	NUM
dpc-2043	87	17	μg	μg	PROPN
dpc-2043	87	18	/	/	SYM
dpc-2043	87	19	dl	dl	PROPN
dpc-2043	87	20	,	,	PUNCT
dpc-2043	87	21	p	p	X
dpc-2043	87	22	=	=	NOUN
dpc-2043	87	23	0.035	0.035	NUM
dpc-2043	87	24	)	)	PUNCT
dpc-2043	87	25	and	and	CCONJ
dpc-2043	87	26	zn	zn	PROPN
dpc-2043	87	27	(	(	PUNCT
dpc-2043	87	28	83.06	83.06	NUM
dpc-2043	87	29	±	±	NUM
dpc-2043	87	30	49.89	49.89	NUM
dpc-2043	87	31	μg	μg	PROPN
dpc-2043	87	32	/	/	SYM
dpc-2043	87	33	dl	dl	PROPN
dpc-2043	87	34	,	,	PUNCT
dpc-2043	87	35	p	p	NOUN
dpc-2043	87	36	=	=	NOUN
dpc-2043	87	37	0.001	0.001	NUM
dpc-2043	87	38	)	)	PUNCT
dpc-2043	87	39	than	than	ADP
dpc-2043	87	40	those	those	PRON
dpc-2043	87	41	in	in	ADP
dpc-2043	87	42	patients	patient	NOUN
dpc-2043	87	43	with	with	ADP
dpc-2043	87	44	late	late	ADJ
dpc-2043	87	45	onset	onset	NOUN
dpc-2043	87	46	(	(	PUNCT
dpc-2043	87	47	122.53	122.53	NUM
dpc-2043	87	48	±56.30	±56.30	NOUN
dpc-2043	87	49	and	and	CCONJ
dpc-2043	87	50	112.81±	112.81±	NUM
dpc-2043	87	51	67.19	67.19	NUM
dpc-2043	87	52	μg	μg	PROPN
dpc-2043	87	53	/	/	SYM
dpc-2043	87	54	dl	dl	PROPN
dpc-2043	87	55	,	,	PUNCT
dpc-2043	87	56	respectively	respectively	ADV
dpc-2043	87	57	)	)	PUNCT
dpc-2043	87	58	(	(	PUNCT
dpc-2043	87	59	table	table	NOUN
dpc-2043	87	60	2	2	NUM
dpc-2043	87	61	)	)	PUNCT
dpc-2043	87	62	.	.	PUNCT
dpc-2043	88	1	in	in	ADP
dpc-2043	88	2	patients	patient	NOUN
dpc-2043	88	3	with	with	ADP
dpc-2043	88	4	early	early	ADJ
dpc-2043	88	5	-	-	PUNCT
dpc-2043	88	6	onset	onset	NOUN
dpc-2043	88	7	vitiligo	vitiligo	NOUN
dpc-2043	88	8	,	,	PUNCT
dpc-2043	88	9	the	the	DET
dpc-2043	88	10	male	male	ADJ
dpc-2043	88	11	subjects	subject	NOUN
dpc-2043	88	12	had	have	VERB
dpc-2043	88	13	significantly	significantly	ADV
dpc-2043	88	14	higher	high	ADJ
dpc-2043	88	15	serum	serum	PROPN
dpc-2043	88	16	zn	zn	PROPN
dpc-2043	88	17	,	,	PUNCT
dpc-2043	88	18	but	but	CCONJ
dpc-2043	88	19	a	a	DET
dpc-2043	88	20	lower	low	ADJ
dpc-2043	88	21	cu	cu	PROPN
dpc-2043	88	22	/	/	SYM
dpc-2043	88	23	zn	zn	PROPN
dpc-2043	88	24	ratio	ratio	NOUN
dpc-2043	88	25	than	than	ADP
dpc-2043	88	26	female	female	ADJ
dpc-2043	88	27	subjects	subject	NOUN
dpc-2043	88	28	(	(	PUNCT
dpc-2043	88	29	p	p	X
dpc-2043	88	30	<	<	X
dpc-2043	88	31	0.01	0.01	NUM
dpc-2043	88	32	)	)	PUNCT
dpc-2043	88	33	(	(	PUNCT
dpc-2043	88	34	table	table	NOUN
dpc-2043	88	35	2	2	NUM
dpc-2043	88	36	)	)	PUNCT
dpc-2043	88	37	.	.	PUNCT
dpc-2043	89	1	among	among	ADP
dpc-2043	89	2	the	the	DET
dpc-2043	89	3	patients	patient	NOUN
dpc-2043	89	4	with	with	ADP
dpc-2043	89	5	the	the	DET
dpc-2043	89	6	late	late	ADJ
dpc-2043	89	7	-	-	PUNCT
dpc-2043	89	8	onset	onset	NOUN
dpc-2043	89	9	vitiligo	vitiligo	NOUN
dpc-2043	89	10	,	,	PUNCT
dpc-2043	89	11	the	the	DET
dpc-2043	89	12	serum	serum	NOUN
dpc-2043	89	13	copper	copper	NOUN
dpc-2043	89	14	concentration	concentration	NOUN
dpc-2043	89	15	and	and	CCONJ
dpc-2043	89	16	the	the	DET
dpc-2043	89	17	copper	copper	NOUN
dpc-2043	89	18	-	-	PUNCT
dpc-2043	89	19	zinc	zinc	NOUN
dpc-2043	89	20	ratio	ratio	NOUN
dpc-2043	89	21	male	male	ADJ
dpc-2043	89	22	and	and	CCONJ
dpc-2043	89	23	female	female	ADJ
dpc-2043	89	24	patients	patient	NOUN
dpc-2043	89	25	.	.	PUNCT
dpc-2043	90	1	however	however	ADV
dpc-2043	90	2	,	,	PUNCT
dpc-2043	90	3	in	in	ADP
dpc-2043	90	4	male	male	ADJ
dpc-2043	90	5	and	and	CCONJ
dpc-2043	90	6	female	female	ADJ
dpc-2043	90	7	cases	case	NOUN
dpc-2043	90	8	,	,	PUNCT
dpc-2043	90	9	the	the	DET
dpc-2043	90	10	average	average	ADJ
dpc-2043	90	11	serum	serum	NOUN
dpc-2043	90	12	copper	copper	NOUN
dpc-2043	90	13	and	and	CCONJ
dpc-2043	90	14	zinc	zinc	NOUN
dpc-2043	90	15	levels	level	NOUN
dpc-2043	90	16	were	be	AUX
dpc-2043	90	17	significantly	significantly	ADV
dpc-2043	90	18	lower	low	ADJ
dpc-2043	90	19	than	than	ADP
dpc-2043	90	20	their	their	PRON
dpc-2043	90	21	matched	match	VERB
dpc-2043	90	22	control	control	NOUN
dpc-2043	90	23	group	group	NOUN
dpc-2043	90	24	(	(	PUNCT
dpc-2043	90	25	p<0.02	p<0.02	PROPN
dpc-2043	90	26	)	)	PUNCT
dpc-2043	90	27	(	(	PUNCT
dpc-2043	90	28	table	table	NOUN
dpc-2043	90	29	1	1	NUM
dpc-2043	90	30	)	)	PUNCT
dpc-2043	90	31	.	.	PUNCT
dpc-2043	91	1	the	the	DET
dpc-2043	91	2	patients	patient	NOUN
dpc-2043	91	3	with	with	ADP
dpc-2043	91	4	generalized	generalized	ADJ
dpc-2043	91	5	vitiligo	vitiligo	NOUN
dpc-2043	91	6	had	have	VERB
dpc-2043	91	7	significantly	significantly	ADV
dpc-2043	91	8	lower	low	ADJ
dpc-2043	91	9	serum	serum	PROPN
dpc-2043	91	10	cu	cu	PROPN
dpc-2043	91	11	levels	level	NOUN
dpc-2043	91	12	(	(	PUNCT
dpc-2043	91	13	111.63±54.18	111.63±54.18	NUM
dpc-2043	91	14	μg	μg	PROPN
dpc-2043	91	15	/	/	SYM
dpc-2043	91	16	dl	dl	PROPN
dpc-2043	91	17	)	)	PUNCT
dpc-2043	91	18	than	than	ADP
dpc-2043	91	19	patients	patient	NOUN
dpc-2043	91	20	with	with	ADP
dpc-2043	91	21	localized	localized	ADJ
dpc-2043	91	22	vitiligo	vitiligo	NOUN
dpc-2043	91	23	(	(	PUNCT
dpc-2043	91	24	120.74	120.74	NUM
dpc-2043	91	25	±71.64	±71.64	NOUN
dpc-2043	91	26	μg	μg	PROPN
dpc-2043	91	27	/	/	SYM
dpc-2043	91	28	dl	dl	PROPN
dpc-2043	91	29	)	)	PUNCT
dpc-2043	91	30	(	(	PUNCT
dpc-2043	91	31	p	p	X
dpc-2043	91	32	 	 	SPACE
dpc-2043	91	33	≤	≤	NOUN
dpc-2043	91	34	 	 	SPACE
dpc-2043	91	35	0.04	0.04	NUM
dpc-2043	91	36	)	)	PUNCT
dpc-2043	91	37	and	and	CCONJ
dpc-2043	91	38	healthy	healthy	ADJ
dpc-2043	91	39	controls	control	NOUN
dpc-2043	91	40	(	(	PUNCT
dpc-2043	91	41	138.98	138.98	NUM
dpc-2043	91	42	±	±	NUM
dpc-2043	91	43	28.12	28.12	NUM
dpc-2043	91	44	μg	μg	PROPN
dpc-2043	91	45	/	/	SYM
dpc-2043	91	46	dl	dl	PROPN
dpc-2043	91	47	)	)	PUNCT
dpc-2043	91	48	(	(	PUNCT
dpc-2043	91	49	p	p	X
dpc-2043	91	50	 	 	SPACE
dpc-2043	91	51	=	=	NOUN
dpc-2043	91	52	 	 	SPACE
dpc-2043	91	53	0.00	0.00	NUM
dpc-2043	91	54	)	)	PUNCT
dpc-2043	91	55	.	.	PUNCT
dpc-2043	92	1	the	the	DET
dpc-2043	92	2	mean	mean	ADJ
dpc-2043	92	3	serum	serum	NOUN
dpc-2043	92	4	zn	zn	PROPN
dpc-2043	92	5	level	level	NOUN
dpc-2043	92	6	of	of	ADP
dpc-2043	92	7	the	the	DET
dpc-2043	92	8	patients	patient	NOUN
dpc-2043	92	9	with	with	ADP
dpc-2043	92	10	the	the	DET
dpc-2043	92	11	generalized	generalize	VERB
dpc-2043	92	12	vitiligo	vitiligo	NOUN
dpc-2043	92	13	(	(	PUNCT
dpc-2043	92	14	93.11±59.33	93.11±59.33	NUM
dpc-2043	92	15	μg	μg	PROPN
dpc-2043	92	16	/	/	SYM
dpc-2043	92	17	dl	dl	PROPN
dpc-2043	92	18	)	)	PUNCT
dpc-2043	92	19	also	also	ADV
dpc-2043	92	20	differed	differ	VERB
dpc-2043	92	21	significantly	significantly	ADV
dpc-2043	92	22	with	with	ADP
dpc-2043	92	23	those	those	PRON
dpc-2043	92	24	with	with	ADP
dpc-2043	92	25	the	the	DET
dpc-2043	92	26	localized	localize	VERB
dpc-2043	92	27	vitiligo	vitiligo	NOUN
dpc-2043	92	28	(	(	PUNCT
dpc-2043	92	29	98.69±58.63	98.69±58.63	NUM
dpc-2043	92	30	μg	μg	PROPN
dpc-2043	92	31	/	/	SYM
dpc-2043	92	32	dl	dl	PROPN
dpc-2043	92	33	)	)	PUNCT
dpc-2043	92	34	and	and	CCONJ
dpc-2043	92	35	the	the	DET
dpc-2043	92	36	control	control	NOUN
dpc-2043	92	37	group	group	NOUN
dpc-2043	92	38	(	(	PUNCT
dpc-2043	92	39	p	p	X
dpc-2043	92	40	=	=	NOUN
dpc-2043	92	41	0.00	0.00	NUM
dpc-2043	92	42	)	)	PUNCT
dpc-2043	92	43	.	.	PUNCT
dpc-2043	93	1	we	we	PRON
dpc-2043	93	2	found	find	VERB
dpc-2043	93	3	significantly	significantly	ADV
dpc-2043	93	4	lower	low	ADJ
dpc-2043	93	5	serum	serum	PROPN
dpc-2043	93	6	zn	zn	PROPN
dpc-2043	93	7	,	,	PUNCT
dpc-2043	93	8	but	but	CCONJ
dpc-2043	93	9	higher	high	ADJ
dpc-2043	93	10	cu	cu	PROPN
dpc-2043	93	11	/	/	SYM
dpc-2043	93	12	zn	zn	PROPN
dpc-2043	93	13	ratio	ratio	NOUN
dpc-2043	93	14	in	in	ADP
dpc-2043	93	15	patients	patient	NOUN
dpc-2043	93	16	with	with	ADP
dpc-2043	93	17	skin	skin	NOUN
dpc-2043	93	18	type	type	NOUN
dpc-2043	93	19	iv	iv	NUM
dpc-2043	93	20	(	(	PUNCT
dpc-2043	93	21	86	86	NUM
dpc-2043	93	22	.	.	PUNCT
dpc-2043	94	1	16±60.62	16±60.62	NUM
dpc-2043	94	2	μg	μg	PROPN
dpc-2043	94	3	/	/	SYM
dpc-2043	94	4	dl	dl	PROPN
dpc-2043	94	5	and	and	CCONJ
dpc-2043	94	6	2.45±2.75	2.45±2.75	PROPN
dpc-2043	94	7	,	,	PUNCT
dpc-2043	94	8	respectively	respectively	ADV
dpc-2043	94	9	)	)	PUNCT
dpc-2043	94	10	than	than	ADP
dpc-2043	94	11	in	in	ADP
dpc-2043	94	12	patients	patient	NOUN
dpc-2043	94	13	with	with	ADP
dpc-2043	94	14	skin	skin	NOUN
dpc-2043	94	15	type	type	NOUN
dpc-2043	94	16	iii	iii	PROPN
dpc-2043	94	17	(	(	PUNCT
dpc-2043	94	18	99.24±	99.24±	NUM
dpc-2043	94	19	59.91	59.91	NUM
dpc-2043	94	20	μg	μg	PROPN
dpc-2043	94	21	/	/	SYM
dpc-2043	94	22	dl	dl	PROPN
dpc-2043	94	23	and	and	CCONJ
dpc-2043	94	24	1.48±	1.48±	NUM
dpc-2043	94	25	1.16	1.16	NUM
dpc-2043	94	26	,	,	PUNCT
dpc-2043	94	27	respectively	respectively	ADV
dpc-2043	94	28	)	)	PUNCT
dpc-2043	94	29	(	(	PUNCT
dpc-2043	94	30	p	p	X
dpc-2043	94	31	<	<	X
dpc-2043	94	32	0.02	0.02	NUM
dpc-2043	94	33	,	,	PUNCT
dpc-2043	94	34	table	table	NOUN
dpc-2043	94	35	2	2	NUM
dpc-2043	94	36	)	)	PUNCT
dpc-2043	94	37	.	.	PUNCT
dpc-2043	95	1	however	however	ADV
dpc-2043	95	2	,	,	PUNCT
dpc-2043	95	3	there	there	PRON
dpc-2043	95	4	was	be	VERB
dpc-2043	95	5	no	no	DET
dpc-2043	95	6	significant	significant	ADJ
dpc-2043	95	7	difference	difference	NOUN
dpc-2043	95	8	between	between	ADP
dpc-2043	95	9	the	the	DET
dpc-2043	95	10	mean	mean	ADJ
dpc-2043	95	11	serum	serum	NOUN
dpc-2043	95	12	table	table	NOUN
dpc-2043	95	13	2	2	NUM
dpc-2043	95	14	.	.	NUM
dpc-2043	95	15	selected	select	VERB
dpc-2043	95	16	clinical	clinical	ADJ
dpc-2043	95	17	features	feature	NOUN
dpc-2043	95	18	of	of	ADP
dpc-2043	95	19	vitiligo	vitiligo	ADJ
dpc-2043	95	20	patients	patient	NOUN
dpc-2043	95	21	and	and	CCONJ
dpc-2043	95	22	serum	serum	PROPN
dpc-2043	95	23	cu	cu	PROPN
dpc-2043	95	24	and	and	CCONJ
dpc-2043	95	25	zn	zn	PROPN
dpc-2043	95	26	levels	level	NOUN
dpc-2043	95	27	group	group	PROPN
dpc-2043	95	28	cu	cu	PROPN
dpc-2043	95	29	(	(	PUNCT
dpc-2043	96	1	µg/	µg/	PROPN
dpc-2043	96	2	dl	dl	PROPN
dpc-2043	96	3	)	)	PUNCT
dpc-2043	96	4	median	median	PROPN
dpc-2043	96	5	cu	cu	PROPN
dpc-2043	96	6	(	(	PUNCT
dpc-2043	96	7	µg	µg	PROPN
dpc-2043	96	8	/	/	SYM
dpc-2043	96	9	dl	dl	NOUN
dpc-2043	96	10	)	)	PUNCT
dpc-2043	96	11	mean	mean	VERB
dpc-2043	96	12	±	±	NUM
dpc-2043	96	13	sd	sd	ADP
dpc-2043	96	14	pa	pa	PROPN
dpc-2043	96	15	zn	zn	PROPN
dpc-2043	96	16	(	(	PUNCT
dpc-2043	96	17	µg/	µg/	PROPN
dpc-2043	96	18	dl	dl	PROPN
dpc-2043	96	19	)	)	PUNCT
dpc-2043	96	20	median	median	PROPN
dpc-2043	96	21	zn	zn	PROPN
dpc-2043	96	22	(	(	PUNCT
dpc-2043	96	23	µg	µg	PROPN
dpc-2043	96	24	/	/	SYM
dpc-2043	96	25	dl	dl	NOUN
dpc-2043	96	26	)	)	PUNCT
dpc-2043	96	27	mean	mean	VERB
dpc-2043	96	28	±	±	NUM
dpc-2043	96	29	sd	sd	ADP
dpc-2043	97	1	pa	pa	PROPN
dpc-2043	98	1	[	[	X
dpc-2043	98	2	cu]/[zn	cu]/[zn	X
dpc-2043	98	3	]	]	X
dpc-2043	98	4	pa	pa	PROPN
dpc-2043	98	5	early	early	ADV
dpc-2043	98	6	onset	onset	VERB
dpc-2043	98	7	<	<	X
dpc-2043	98	8	50	50	NUM
dpc-2043	98	9	(	(	PUNCT
dpc-2043	98	10	59.83	59.83	NUM
dpc-2043	98	11	%	%	NOUN
dpc-2043	98	12	)	)	PUNCT
dpc-2043	98	13	late	late	ADJ
dpc-2043	98	14	onset	onset	NOUN
dpc-2043	98	15	>	>	PUNCT
dpc-2043	98	16	50	50	NUM
dpc-2043	98	17	(	(	PUNCT
dpc-2043	98	18	40.17	40.17	NUM
dpc-2043	98	19	%	%	NOUN
dpc-2043	98	20	)	)	PUNCT
dpc-2043	98	21	95.07	95.07	NUM
dpc-2043	98	22	138.37	138.37	NUM
dpc-2043	98	23	107.12	107.12	NUM
dpc-2043	98	24	±	±	NOUN
dpc-2043	98	25	61.17	61.17	NUM
dpc-2043	98	26	122.53	122.53	NUM
dpc-2043	98	27	±56.30	±56.30	VERB
dpc-2043	98	28	0.035	0.035	NUM
dpc-2043	98	29	72.56	72.56	NUM
dpc-2043	98	30	100.23	100.23	NUM
dpc-2043	98	31	83.06	83.06	NUM
dpc-2043	98	32	±	±	NUM
dpc-2043	98	33	49.89	49.89	NUM
dpc-2043	98	34	112.81±	112.81±	NUM
dpc-2043	98	35	67.19	67.19	NUM
dpc-2043	98	36	0.001	0.001	NUM
dpc-2043	98	37	1.96	1.96	NUM
dpc-2043	98	38	±	±	NUM
dpc-2043	98	39	1.44	1.44	NUM
dpc-2043	98	40	1.72	1.72	NUM
dpc-2043	98	41	±	±	NUM
dpc-2043	98	42	2.13	2.13	NUM
dpc-2043	98	43	0.164	0.164	NUM
dpc-2043	98	44	early	early	ADJ
dpc-2043	98	45	-	-	PUNCT
dpc-2043	98	46	onset	onset	NOUN
dpc-2043	98	47	(	(	PUNCT
dpc-2043	98	48	<	<	X
dpc-2043	98	49	50	50	NUM
dpc-2043	98	50	y	y	NOUN
dpc-2043	98	51	)	)	PUNCT
dpc-2043	98	52	male	male	NOUN
dpc-2043	98	53	(	(	PUNCT
dpc-2043	98	54	23.9	23.9	NUM
dpc-2043	98	55	%	%	NOUN
dpc-2043	98	56	)	)	PUNCT
dpc-2043	98	57	female	female	NOUN
dpc-2043	98	58	(	(	PUNCT
dpc-2043	98	59	35.8	35.8	NUM
dpc-2043	98	60	%	%	NOUN
dpc-2043	98	61	)	)	PUNCT
dpc-2043	99	1	98.41	98.41	NUM
dpc-2043	99	2	90.04	90.04	NUM
dpc-2043	99	3	110.78±	110.78±	NUM
dpc-2043	99	4	62.80	62.80	NUM
dpc-2043	99	5	116.54±54.15	116.54±54.15	NUM
dpc-2043	99	6	0.189	0.189	DET
dpc-2043	99	7	76.92	76.92	NUM
dpc-2043	99	8	68.96	68.96	NUM
dpc-2043	99	9	89.70±45.13	89.70±45.13	NUM
dpc-2043	99	10	78.63±52.90	78.63±52.90	NUM
dpc-2043	99	11	0.008	0.008	NUM
dpc-2043	99	12	1.73±	1.73±	NUM
dpc-2043	99	13	1.61	1.61	NUM
dpc-2043	99	14	1.77±	1.77±	NUM
dpc-2043	99	15	2.00	2.00	NUM
dpc-2043	99	16	0.00	0.00	NUM
dpc-2043	99	17	late	late	ADJ
dpc-2043	99	18	-	-	PUNCT
dpc-2043	99	19	onset	onset	NOUN
dpc-2043	99	20	(	(	PUNCT
dpc-2043	99	21	>	>	SYM
dpc-2043	99	22	50	50	NUM
dpc-2043	99	23	y	y	NOUN
dpc-2043	99	24	)	)	PUNCT
dpc-2043	99	25	male	male	NOUN
dpc-2043	99	26	(	(	PUNCT
dpc-2043	99	27	17.1	17.1	NUM
dpc-2043	99	28	%	%	NOUN
dpc-2043	99	29	)	)	PUNCT
dpc-2043	99	30	female	female	NOUN
dpc-2043	99	31	(	(	PUNCT
dpc-2043	99	32	24.7	24.7	NUM
dpc-2043	99	33	%	%	NOUN
dpc-2043	99	34	)	)	PUNCT
dpc-2043	99	35	131.69	131.69	NUM
dpc-2043	99	36	128.67	128.67	NUM
dpc-2043	99	37	119.65±57.57	119.65±57.57	NUM
dpc-2043	99	38	124.52±56.34	124.52±56.34	NUM
dpc-2043	99	39	0.017	0.017	NUM
dpc-2043	99	40	88.58	88.58	NUM
dpc-2043	99	41	100.23	100.23	NUM
dpc-2043	99	42	113.54±78.26	113.54±78.26	NUM
dpc-2043	99	43	112.27±	112.27±	NUM
dpc-2043	99	44	59.25	59.25	NUM
dpc-2043	99	45	0.629	0.629	NUM
dpc-2043	99	46	1.49	1.49	NUM
dpc-2043	99	47	±	±	NUM
dpc-2043	99	48	1.11	1.11	NUM
dpc-2043	99	49	2.54±2.79	2.54±2.79	NOUN
dpc-2043	99	50	0.005	0.005	NUM
dpc-2043	99	51	clinical	clinical	ADJ
dpc-2043	99	52	type	type	NOUN
dpc-2043	99	53	generalized	generalize	VERB
dpc-2043	99	54	(	(	PUNCT
dpc-2043	99	55	82.9	82.9	NUM
dpc-2043	99	56	%	%	NOUN
dpc-2043	99	57	)	)	PUNCT
dpc-2043	99	58	localized	localize	VERB
dpc-2043	99	59	(	(	PUNCT
dpc-2043	99	60	17.09	17.09	NUM
dpc-2043	99	61	%	%	NOUN
dpc-2043	99	62	)	)	PUNCT
dpc-2043	99	63	101.96	101.96	NUM
dpc-2043	99	64	104.72	104.72	NUM
dpc-2043	99	65	111.63±54.18	111.63±54.18	NUM
dpc-2043	99	66	120.74	120.74	NUM
dpc-2043	99	67	±71.64	±71.64	NOUN
dpc-2043	99	68	0.04	0.04	NUM
dpc-2043	99	69	73.01	73.01	NUM
dpc-2043	99	70	110.50	110.50	NUM
dpc-2043	99	71	93.11±59.33	93.11±59.33	NUM
dpc-2043	99	72	98.69±58.63	98.69±58.63	NUM
dpc-2043	99	73	0.006	0.006	NUM
dpc-2043	99	74	1.88±2.02	1.88±2.02	NUM
dpc-2043	99	75	1.40±1.24	1.40±1.24	NUM
dpc-2043	99	76	0.078	0.078	NUM
dpc-2043	99	77	skin	skin	NOUN
dpc-2043	99	78	phototype	phototype	NOUN
dpc-2043	99	79	skin	skin	NOUN
dpc-2043	99	80	type	type	NOUN
dpc-2043	99	81	i	i	PROPN
dpc-2043	99	82	and	and	CCONJ
dpc-2043	99	83	ii	ii	PROPN
dpc-2043	99	84	(	(	PUNCT
dpc-2043	99	85	0	0	NUM
dpc-2043	99	86	%	%	NOUN
dpc-2043	99	87	)	)	PUNCT
dpc-2043	99	88	skin	skin	NOUN
dpc-2043	99	89	type	type	NOUN
dpc-2043	99	90	iii	iii	PROPN
dpc-2043	99	91	(	(	PUNCT
dpc-2043	99	92	69.93	69.93	NUM
dpc-2043	99	93	%	%	NOUN
dpc-2043	99	94	)	)	PUNCT
dpc-2043	99	95	skin	skin	NOUN
dpc-2043	99	96	type	type	NOUN
dpc-2043	99	97	iv	iv	NUM
dpc-2043	99	98	(	(	PUNCT
dpc-2043	99	99	29.97	29.97	NUM
dpc-2043	99	100	%	%	NOUN
dpc-2043	99	101	)	)	PUNCT
dpc-2043	100	1	103.41	103.41	NUM
dpc-2043	100	2	103.61	103.61	NUM
dpc-2043	100	3	112.67±59.66	112.67±59.66	NUM
dpc-2043	100	4	117.04±	117.04±	NUM
dpc-2043	100	5	59.95	59.95	NUM
dpc-2043	100	6	0.113	0.113	NUM
dpc-2043	100	7	84.68	84.68	NUM
dpc-2043	100	8	67.32	67.32	NUM
dpc-2043	100	9	99.24±	99.24±	NUM
dpc-2043	100	10	59.91	59.91	NUM
dpc-2043	100	11	86	86	NUM
dpc-2043	100	12	.	.	PUNCT
dpc-2043	101	1	16±60.62	16±60.62	NUM
dpc-2043	101	2	0.015	0.015	NUM
dpc-2043	101	3	1.48±	1.48±	NUM
dpc-2043	101	4	1.16	1.16	NUM
dpc-2043	101	5	2.45±2.75	2.45±2.75	NUM
dpc-2043	101	6	0.00	0.00	NUM
dpc-2043	101	7	history	history	NOUN
dpc-2043	101	8	of	of	ADP
dpc-2043	101	9	other	other	ADJ
dpc-2043	101	10	auto	auto	NOUN
dpc-2043	101	11	immune	immune	ADJ
dpc-2043	101	12	disease	disease	NOUN
dpc-2043	101	13	yes	yes	INTJ
dpc-2043	101	14	(	(	PUNCT
dpc-2043	101	15	6.84	6.84	NUM
dpc-2043	101	16	%	%	NOUN
dpc-2043	101	17	)	)	PUNCT
dpc-2043	102	1	no	no	INTJ
dpc-2043	102	2	(	(	PUNCT
dpc-2043	102	3	93.16	93.16	NUM
dpc-2043	102	4	%	%	NOUN
dpc-2043	102	5	)	)	PUNCT
dpc-2043	103	1	136.36	136.36	NUM
dpc-2043	103	2	98.15	98.15	NUM
dpc-2043	103	3	143.99±62.61	143.99±62.61	NUM
dpc-2043	103	4	111.34±58.89	111.34±58.89	NUM
dpc-2043	103	5	0.001	0.001	NUM
dpc-2043	103	6	74.48	74.48	NUM
dpc-2043	103	7	77.08	77.08	NUM
dpc-2043	103	8	98.29±68.92	98.29±68.92	NOUN
dpc-2043	103	9	94.71±	94.71±	NUM
dpc-2043	103	10	58.59	58.59	NUM
dpc-2043	103	11	0.008	0.008	NUM
dpc-2043	103	12	2.08±1.33	2.08±1.33	NUM
dpc-2043	103	13	1.79±	1.79±	NOUN
dpc-2043	103	14	1.96	1.96	NUM
dpc-2043	103	15	0.00	0.00	NUM
dpc-2043	103	16	smoking	smoking	NOUN
dpc-2043	103	17	status	status	NOUN
dpc-2043	103	18	smokers	smoker	NOUN
dpc-2043	103	19	(	(	PUNCT
dpc-2043	103	20	16.23	16.23	NUM
dpc-2043	103	21	%	%	NOUN
dpc-2043	103	22	)	)	PUNCT
dpc-2043	103	23	non	non	NOUN
dpc-2043	103	24	-	-	NOUN
dpc-2043	103	25	smokers	smoker	NOUN
dpc-2043	103	26	(	(	PUNCT
dpc-2043	103	27	83.76	83.76	NUM
dpc-2043	103	28	%	%	NOUN
dpc-2043	103	29	)	)	PUNCT
dpc-2043	103	30	99.86	99.86	NUM
dpc-2043	103	31	103.51	103.51	NUM
dpc-2043	103	32	106.93	106.93	NUM
dpc-2043	103	33	±	±	NUM
dpc-2043	103	34	57.08	57.08	NUM
dpc-2043	103	35	115.45	115.45	NUM
dpc-2043	103	36	±	±	NOUN
dpc-2043	103	37	60.20	60.20	NUM
dpc-2043	103	38	0.023	0.023	NUM
dpc-2043	103	39	74.03	74.03	NUM
dpc-2043	103	40	76.25	76.25	NUM
dpc-2043	103	41	99.67	99.67	NUM
dpc-2043	103	42	±	±	NOUN
dpc-2043	103	43	59.49	59.49	NUM
dpc-2043	103	44	94.34±	94.34±	PROPN
dpc-2043	103	45	59.50	59.50	NUM
dpc-2043	103	46	0.05	0.05	NUM
dpc-2043	103	47	1.71±	1.71±	NUM
dpc-2043	103	48	1.63	1.63	NUM
dpc-2043	103	49	1.83±1.95	1.83±1.95	NOUN
dpc-2043	103	50	0.273	0.273	NUM
dpc-2043	103	51	cu	cu	NOUN
dpc-2043	103	52	=	=	PROPN
dpc-2043	103	53	copper	copper	NOUN
dpc-2043	103	54	;	;	PUNCT
dpc-2043	103	55	sd	sd	NOUN
dpc-2043	103	56	=	=	SYM
dpc-2043	103	57	standard	standard	ADJ
dpc-2043	103	58	deviation	deviation	NOUN
dpc-2043	103	59	;	;	PUNCT
dpc-2043	103	60	y	y	PROPN
dpc-2043	103	61	=	=	SYM
dpc-2043	103	62	years	year	NOUN
dpc-2043	103	63	;	;	PUNCT
dpc-2043	103	64	zn	zn	PROPN
dpc-2043	103	65	=	=	SYM
dpc-2043	103	66	zinc	zinc	PROPN
dpc-2043	103	67	.	.	PUNCT
dpc-2043	104	1	pa	pa	PROPN
dpc-2043	104	2	,	,	PUNCT
dpc-2043	104	3	case	case	NOUN
dpc-2043	104	4	–	–	PUNCT
dpc-2043	104	5	case	case	NOUN
dpc-2043	104	6	comparison	comparison	NOUN
dpc-2043	104	7	.	.	PUNCT
dpc-2043	105	1	original	original	ADJ
dpc-2043	105	2	article	article	NOUN
dpc-2043	105	3	|	|	ADV
dpc-2043	105	4	dermatol	dermatol	ADJ
dpc-2043	105	5	pract	pract	NOUN
dpc-2043	105	6	concept	concept	NOUN
dpc-2043	105	7	.	.	PUNCT
dpc-2043	106	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	106	2	5	5	NUM
dpc-2043	106	3	cofactors	cofactor	NOUN
dpc-2043	106	4	for	for	ADP
dpc-2043	106	5	as	as	ADV
dpc-2043	106	6	many	many	ADJ
dpc-2043	106	7	as	as	ADP
dpc-2043	106	8	forty	forty	NUM
dpc-2043	106	9	metallo	metallo	NOUN
dpc-2043	106	10	-	-	PUNCT
dpc-2043	106	11	enzymes	enzyme	NOUN
dpc-2043	106	12	involved	involve	VERB
dpc-2043	106	13	in	in	ADP
dpc-2043	106	14	the	the	DET
dpc-2043	106	15	skin	skin	NOUN
dpc-2043	106	16	pigmentation	pigmentation	NOUN
dpc-2043	106	17	process	process	NOUN
dpc-2043	106	18	.	.	PUNCT
dpc-2043	107	1	these	these	DET
dpc-2043	107	2	two	two	NUM
dpc-2043	107	3	trace	trace	NOUN
dpc-2043	107	4	elements	element	NOUN
dpc-2043	107	5	are	be	AUX
dpc-2043	107	6	essential	essential	ADJ
dpc-2043	107	7	cofactors	cofactor	NOUN
dpc-2043	107	8	of	of	ADP
dpc-2043	107	9	tyrosinase	tyrosinase	NOUN
dpc-2043	107	10	and	and	CCONJ
dpc-2043	107	11	superoxide	superoxide	NOUN
dpc-2043	107	12	dismutase	dismutase	NOUN
dpc-2043	107	13	,	,	PUNCT
dpc-2043	107	14	two	two	NUM
dpc-2043	107	15	enzymes	enzyme	NOUN
dpc-2043	107	16	that	that	PRON
dpc-2043	107	17	are	be	AUX
dpc-2043	107	18	widespread	widespread	ADJ
dpc-2043	107	19	in	in	ADP
dpc-2043	107	20	the	the	DET
dpc-2043	107	21	human	human	ADJ
dpc-2043	107	22	skin	skin	NOUN
dpc-2043	107	23	and	and	CCONJ
dpc-2043	107	24	are	be	AUX
dpc-2043	107	25	specifically	specifically	ADV
dpc-2043	107	26	involved	involve	VERB
dpc-2043	107	27	in	in	ADP
dpc-2043	107	28	skin	skin	NOUN
dpc-2043	107	29	pigmentation	pigmentation	NOUN
dpc-2043	107	30	and	and	CCONJ
dpc-2043	107	31	melanocytes	melanocyte	VERB
dpc-2043	107	32	protection	protection	NOUN
dpc-2043	107	33	against	against	ADP
dpc-2043	107	34	free	free	ADJ
dpc-2043	107	35	radicals	radical	NOUN
dpc-2043	107	36	,	,	PUNCT
dpc-2043	107	37	respectively	respectively	ADV
dpc-2043	107	38	[	[	X
dpc-2043	107	39	13,15,27	13,15,27	NUM
dpc-2043	107	40	]	]	PUNCT
dpc-2043	107	41	.	.	PUNCT
dpc-2043	108	1	there	there	PRON
dpc-2043	108	2	are	be	VERB
dpc-2043	108	3	conflicting	conflicting	ADJ
dpc-2043	108	4	reports	report	NOUN
dpc-2043	108	5	on	on	ADP
dpc-2043	108	6	the	the	DET
dpc-2043	108	7	relationship	relationship	NOUN
dpc-2043	108	8	between	between	ADP
dpc-2043	108	9	serum	serum	PROPN
dpc-2043	108	10	cu	cu	PROPN
dpc-2043	108	11	and	and	CCONJ
dpc-2043	108	12	zn	zn	PROPN
dpc-2043	108	13	concentrations	concentration	NOUN
dpc-2043	108	14	and	and	CCONJ
dpc-2043	108	15	vitiligo	vitiligo	VERB
dpc-2043	108	16	.	.	PUNCT
dpc-2043	109	1	some	some	DET
dpc-2043	109	2	authors	author	NOUN
dpc-2043	109	3	have	have	AUX
dpc-2043	109	4	reported	report	VERB
dpc-2043	109	5	that	that	SCONJ
dpc-2043	109	6	compared	compare	VERB
dpc-2043	109	7	with	with	ADP
dpc-2043	109	8	healthy	healthy	ADJ
dpc-2043	109	9	controls	control	NOUN
dpc-2043	109	10	,	,	PUNCT
dpc-2043	109	11	the	the	DET
dpc-2043	109	12	serum	serum	NOUN
dpc-2043	109	13	zn	zn	PROPN
dpc-2043	109	14	,	,	PUNCT
dpc-2043	109	15	but	but	CCONJ
dpc-2043	109	16	not	not	PART
dpc-2043	109	17	cu	cu	NOUN
dpc-2043	109	18	levels	level	NOUN
dpc-2043	109	19	in	in	ADP
dpc-2043	109	20	vitiligo	vitiligo	NOUN
dpc-2043	109	21	patients	patient	NOUN
dpc-2043	109	22	have	have	AUX
dpc-2043	109	23	undergone	undergo	VERB
dpc-2043	109	24	significant	significant	ADJ
dpc-2043	109	25	changes	change	NOUN
dpc-2043	109	26	[	[	X
dpc-2043	109	27	7,28,31	7,28,31	NUM
dpc-2043	109	28	]	]	PUNCT
dpc-2043	109	29	.	.	PUNCT
dpc-2043	110	1	a	a	DET
dpc-2043	110	2	recent	recent	ADJ
dpc-2043	110	3	case	case	NOUN
dpc-2043	110	4	-	-	PUNCT
dpc-2043	110	5	control	control	NOUN
dpc-2043	110	6	study	study	NOUN
dpc-2043	110	7	of	of	ADP
dpc-2043	110	8	100	100	NUM
dpc-2043	110	9	vitiligo	vitiligo	NOUN
dpc-2043	110	10	patients	patient	NOUN
dpc-2043	110	11	from	from	ADP
dpc-2043	110	12	india	india	PROPN
dpc-2043	110	13	reported	report	VERB
dpc-2043	110	14	decreased	decrease	VERB
dpc-2043	110	15	serum	serum	PROPN
dpc-2043	110	16	zn	zn	PROPN
dpc-2043	110	17	,	,	PUNCT
dpc-2043	110	18	but	but	CCONJ
dpc-2043	110	19	increased	increase	VERB
dpc-2043	110	20	cu	cu	PROPN
dpc-2043	110	21	levels	level	NOUN
dpc-2043	110	22	as	as	SCONJ
dpc-2043	110	23	compared	compare	VERB
dpc-2043	110	24	with	with	ADP
dpc-2043	110	25	healthy	healthy	ADJ
dpc-2043	110	26	individuals	individual	NOUN
dpc-2043	110	27	[	[	X
dpc-2043	110	28	32	32	NUM
dpc-2043	110	29	]	]	PUNCT
dpc-2043	110	30	.	.	PUNCT
dpc-2043	111	1	arora	arora	PROPN
dpc-2043	111	2	et	et	PROPN
dpc-2043	111	3	al	al	PROPN
dpc-2043	111	4	found	find	VERB
dpc-2043	111	5	no	no	DET
dpc-2043	111	6	significant	significant	ADJ
dpc-2043	111	7	difference	difference	NOUN
dpc-2043	111	8	between	between	ADP
dpc-2043	111	9	serum	serum	NOUN
dpc-2043	111	10	zn	zn	PROPN
dpc-2043	111	11	levels	level	NOUN
dpc-2043	111	12	of	of	ADP
dpc-2043	111	13	vitiligo	vitiligo	ADJ
dpc-2043	111	14	patients	patient	NOUN
dpc-2043	111	15	and	and	CCONJ
dpc-2043	111	16	the	the	DET
dpc-2043	111	17	healthy	healthy	ADJ
dpc-2043	111	18	control	control	NOUN
dpc-2043	111	19	group	group	NOUN
dpc-2043	111	20	[	[	X
dpc-2043	111	21	22	22	NUM
dpc-2043	111	22	]	]	PUNCT
dpc-2043	111	23	.	.	PUNCT
dpc-2043	112	1	a	a	DET
dpc-2043	112	2	meta	meta	ADJ
dpc-2043	112	3	-	-	PUNCT
dpc-2043	112	4	analysis	analysis	NOUN
dpc-2043	112	5	of	of	ADP
dpc-2043	112	6	16	16	NUM
dpc-2043	112	7	studies	study	NOUN
dpc-2043	112	8	conducted	conduct	VERB
dpc-2043	112	9	to	to	PART
dpc-2043	112	10	compare	compare	VERB
dpc-2043	112	11	the	the	DET
dpc-2043	112	12	serum	serum	NOUN
dpc-2043	112	13	cu	cu	PROPN
dpc-2043	112	14	and	and	CCONJ
dpc-2043	112	15	zn	zn	PROPN
dpc-2043	112	16	concentrations	concentration	NOUN
dpc-2043	112	17	among	among	ADP
dpc-2043	112	18	891	891	NUM
dpc-2043	112	19	vitiligo	vitiligo	NOUN
dpc-2043	112	20	patients	patient	NOUN
dpc-2043	112	21	and	and	CCONJ
dpc-2043	112	22	1682	1682	NUM
dpc-2043	112	23	healthy	healthy	ADJ
dpc-2043	112	24	controls	control	NOUN
dpc-2043	112	25	,	,	PUNCT
dpc-2043	112	26	demonstrated	demonstrate	VERB
dpc-2043	112	27	that	that	SCONJ
dpc-2043	112	28	the	the	DET
dpc-2043	112	29	serum	serum	PROPN
dpc-2043	112	30	cu	cu	PROPN
dpc-2043	112	31	and	and	CCONJ
dpc-2043	112	32	zn	zn	PROPN
dpc-2043	112	33	concentrations	concentration	NOUN
dpc-2043	112	34	were	be	AUX
dpc-2043	112	35	significantly	significantly	ADV
dpc-2043	112	36	lower	low	ADJ
dpc-2043	112	37	in	in	ADP
dpc-2043	112	38	the	the	DET
dpc-2043	112	39	cases	case	NOUN
dpc-2043	112	40	than	than	ADP
dpc-2043	112	41	controls	control	NOUN
dpc-2043	112	42	(	(	PUNCT
dpc-2043	112	43	p	p	X
dpc-2043	112	44	<	<	X
dpc-2043	112	45	0.0001	0.0001	NUM
dpc-2043	112	46	)	)	PUNCT
dpc-2043	113	1	[	[	X
dpc-2043	113	2	27	27	NUM
dpc-2043	113	3	]	]	PUNCT
dpc-2043	113	4	.	.	PUNCT
dpc-2043	114	1	the	the	DET
dpc-2043	114	2	controversy	controversy	NOUN
dpc-2043	114	3	about	about	ADP
dpc-2043	114	4	the	the	DET
dpc-2043	114	5	changes	change	NOUN
dpc-2043	114	6	of	of	ADP
dpc-2043	114	7	serum	serum	NOUN
dpc-2043	114	8	cu	cu	PROPN
dpc-2043	114	9	and	and	CCONJ
dpc-2043	114	10	zn	zn	PROPN
dpc-2043	114	11	levels	level	NOUN
dpc-2043	114	12	in	in	ADP
dpc-2043	114	13	patients	patient	NOUN
dpc-2043	114	14	with	with	ADP
dpc-2043	114	15	vitiligo	vitiligo	PROPN
dpc-2043	114	16	prompted	prompt	VERB
dpc-2043	114	17	us	we	PRON
dpc-2043	114	18	to	to	PART
dpc-2043	114	19	carry	carry	VERB
dpc-2043	114	20	out	out	ADP
dpc-2043	114	21	this	this	DET
dpc-2043	114	22	study	study	NOUN
dpc-2043	114	23	to	to	PART
dpc-2043	114	24	investigate	investigate	VERB
dpc-2043	114	25	the	the	DET
dpc-2043	114	26	relationship	relationship	NOUN
dpc-2043	114	27	between	between	ADP
dpc-2043	114	28	the	the	DET
dpc-2043	114	29	serum	serum	NOUN
dpc-2043	114	30	levels	level	NOUN
dpc-2043	114	31	of	of	ADP
dpc-2043	114	32	of	of	ADP
dpc-2043	114	33	female	female	ADJ
dpc-2043	114	34	patients	patient	NOUN
dpc-2043	114	35	was	be	AUX
dpc-2043	114	36	higher	high	ADJ
dpc-2043	114	37	than	than	ADP
dpc-2043	114	38	those	those	PRON
dpc-2043	114	39	in	in	ADP
dpc-2043	114	40	male	male	ADJ
dpc-2043	114	41	patients	patient	NOUN
dpc-2043	114	42	(	(	PUNCT
dpc-2043	114	43	p	p	X
dpc-2043	114	44	<	<	X
dpc-2043	114	45	0.02	0.02	NUM
dpc-2043	114	46	)	)	PUNCT
dpc-2043	114	47	.	.	PUNCT
dpc-2043	115	1	in	in	ADP
dpc-2043	115	2	these	these	DET
dpc-2043	115	3	cases	case	NOUN
dpc-2043	115	4	,	,	PUNCT
dpc-2043	115	5	the	the	DET
dpc-2043	115	6	serum	serum	NOUN
dpc-2043	115	7	levels	level	NOUN
dpc-2043	115	8	of	of	ADP
dpc-2043	115	9	cu	cu	PROPN
dpc-2043	115	10	were	be	AUX
dpc-2043	115	11	significantly	significantly	ADV
dpc-2043	115	12	lower	low	ADJ
dpc-2043	115	13	(	(	PUNCT
dpc-2043	115	14	p	p	X
dpc-2043	115	15	=	=	NOUN
dpc-2043	115	16	0.023	0.023	NUM
dpc-2043	115	17	)	)	PUNCT
dpc-2043	115	18	,	,	PUNCT
dpc-2043	115	19	but	but	CCONJ
dpc-2043	115	20	zn	zn	NUM
dpc-2043	115	21	levels	level	NOUN
dpc-2043	115	22	were	be	AUX
dpc-2043	115	23	higher	high	ADJ
dpc-2043	115	24	in	in	ADP
dpc-2043	115	25	smokers	smoker	NOUN
dpc-2043	115	26	than	than	ADP
dpc-2043	115	27	those	those	PRON
dpc-2043	115	28	in	in	ADP
dpc-2043	115	29	non	non	ADJ
dpc-2043	115	30	-	-	ADJ
dpc-2043	115	31	smoker	smoker	ADJ
dpc-2043	115	32	patients	patient	NOUN
dpc-2043	115	33	(	(	PUNCT
dpc-2043	115	34	p	p	X
dpc-2043	115	35	=	=	NOUN
dpc-2043	115	36	0.05	0.05	NUM
dpc-2043	115	37	)	)	PUNCT
dpc-2043	115	38	(	(	PUNCT
dpc-2043	115	39	table	table	NOUN
dpc-2043	115	40	2	2	NUM
dpc-2043	115	41	)	)	PUNCT
dpc-2043	115	42	.	.	PUNCT
dpc-2043	116	1	we	we	PRON
dpc-2043	116	2	also	also	ADV
dpc-2043	116	3	evaluated	evaluate	VERB
dpc-2043	116	4	the	the	DET
dpc-2043	116	5	association	association	NOUN
dpc-2043	116	6	between	between	ADP
dpc-2043	116	7	serum	serum	PROPN
dpc-2043	116	8	cu	cu	PROPN
dpc-2043	116	9	and	and	CCONJ
dpc-2043	116	10	zn	zn	PROPN
dpc-2043	116	11	levels	level	NOUN
dpc-2043	116	12	and	and	CCONJ
dpc-2043	116	13	the	the	DET
dpc-2043	116	14	patients	patient	NOUN
dpc-2043	116	15	’	'	PUNCT
dpc-2043	116	16	clinical	clinical	ADJ
dpc-2043	116	17	data	datum	NOUN
dpc-2043	116	18	.	.	PUNCT
dpc-2043	117	1	the	the	DET
dpc-2043	117	2	serum	serum	PROPN
dpc-2043	117	3	cu	cu	PROPN
dpc-2043	117	4	levels	level	NOUN
dpc-2043	117	5	showed	show	VERB
dpc-2043	117	6	a	a	DET
dpc-2043	117	7	positive	positive	ADJ
dpc-2043	117	8	correlation	correlation	NOUN
dpc-2043	117	9	with	with	ADP
dpc-2043	117	10	the	the	DET
dpc-2043	117	11	early	early	ADJ
dpc-2043	117	12	age	age	NOUN
dpc-2043	117	13	of	of	ADP
dpc-2043	117	14	the	the	DET
dpc-2043	117	15	disease	disease	NOUN
dpc-2043	117	16	onset	onset	NOUN
dpc-2043	117	17	(	(	PUNCT
dpc-2043	117	18	r	r	NOUN
dpc-2043	117	19	=	=	NOUN
dpc-2043	117	20	0.251	0.251	NUM
dpc-2043	117	21	,	,	PUNCT
dpc-2043	117	22	p	p	X
dpc-2043	117	23	=	=	NOUN
dpc-2043	117	24	0.039	0.039	NUM
dpc-2043	117	25	)	)	PUNCT
dpc-2043	117	26	.	.	PUNCT
dpc-2043	118	1	we	we	PRON
dpc-2043	118	2	found	find	VERB
dpc-2043	118	3	a	a	DET
dpc-2043	118	4	significant	significant	ADJ
dpc-2043	118	5	positive	positive	ADJ
dpc-2043	118	6	correlation	correlation	NOUN
dpc-2043	118	7	between	between	ADP
dpc-2043	118	8	serum	serum	NOUN
dpc-2043	118	9	cu	cu	PROPN
dpc-2043	118	10	concentration	concentration	NOUN
dpc-2043	118	11	and	and	CCONJ
dpc-2043	118	12	duration	duration	NOUN
dpc-2043	118	13	of	of	ADP
dpc-2043	118	14	disease	disease	NOUN
dpc-2043	118	15	(	(	PUNCT
dpc-2043	118	16	spearman	spearman	NOUN
dpc-2043	118	17	correlation	correlation	NOUN
dpc-2043	118	18	test	test	NOUN
dpc-2043	118	19	,	,	PUNCT
dpc-2043	118	20	r	r	NOUN
dpc-2043	118	21	=	=	SYM
dpc-2043	118	22	0.256	0.256	NUM
dpc-2043	118	23	,	,	PUNCT
dpc-2043	118	24	p	p	NOUN
dpc-2043	118	25	=	=	NOUN
dpc-2043	118	26	 	 	SPACE
dpc-2043	118	27	0.01	0.01	NUM
dpc-2043	118	28	)	)	PUNCT
dpc-2043	118	29	.	.	PUNCT
dpc-2043	119	1	however	however	ADV
dpc-2043	119	2	,	,	PUNCT
dpc-2043	119	3	the	the	DET
dpc-2043	119	4	correlation	correlation	NOUN
dpc-2043	119	5	coefficient	coefficient	NOUN
dpc-2043	119	6	only	only	ADV
dpc-2043	119	7	reached	reach	VERB
dpc-2043	119	8	statistical	statistical	ADJ
dpc-2043	119	9	significance	significance	NOUN
dpc-2043	119	10	in	in	ADP
dpc-2043	119	11	females	female	NOUN
dpc-2043	119	12	(	(	PUNCT
dpc-2043	119	13	r	r	NOUN
dpc-2043	119	14	=	=	SYM
dpc-2043	119	15	0.225	0.225	NUM
dpc-2043	119	16	,	,	PUNCT
dpc-2043	119	17	p	p	X
dpc-2043	119	18	=	=	NOUN
dpc-2043	119	19	0.034	0.034	NUM
dpc-2043	119	20	)	)	PUNCT
dpc-2043	119	21	,	,	PUNCT
dpc-2043	119	22	but	but	CCONJ
dpc-2043	119	23	not	not	PART
dpc-2043	119	24	in	in	ADP
dpc-2043	119	25	male	male	ADJ
dpc-2043	119	26	patients	patient	NOUN
dpc-2043	119	27	(	(	PUNCT
dpc-2043	119	28	table	table	NOUN
dpc-2043	119	29	3	3	NUM
dpc-2043	119	30	)	)	PUNCT
dpc-2043	119	31	.	.	PUNCT
dpc-2043	120	1	we	we	PRON
dpc-2043	120	2	also	also	ADV
dpc-2043	120	3	observed	observe	VERB
dpc-2043	120	4	a	a	DET
dpc-2043	120	5	positive	positive	ADJ
dpc-2043	120	6	correlation	correlation	NOUN
dpc-2043	120	7	between	between	ADP
dpc-2043	120	8	serum	serum	PROPN
dpc-2043	120	9	cu	cu	PROPN
dpc-2043	120	10	and	and	CCONJ
dpc-2043	120	11	zn	zn	PROPN
dpc-2043	120	12	levels	level	NOUN
dpc-2043	120	13	and	and	CCONJ
dpc-2043	120	14	segmental	segmental	ADJ
dpc-2043	120	15	vitiligo	vitiligo	NOUN
dpc-2043	120	16	(	(	PUNCT
dpc-2043	120	17	r	r	NOUN
dpc-2043	120	18	 	 	SPACE
dpc-2043	120	19	=	=	NOUN
dpc-2043	120	20	 	 	SPACE
dpc-2043	120	21	0.20	0.20	NUM
dpc-2043	120	22	,	,	PUNCT
dpc-2043	120	23	p	p	X
dpc-2043	120	24	=	=	NOUN
dpc-2043	120	25	0.045	0.045	NUM
dpc-2043	120	26	)	)	PUNCT
dpc-2043	120	27	.	.	PUNCT
dpc-2043	121	1	there	there	PRON
dpc-2043	121	2	was	be	VERB
dpc-2043	121	3	no	no	DET
dpc-2043	121	4	correlation	correlation	NOUN
dpc-2043	121	5	between	between	ADP
dpc-2043	121	6	the	the	DET
dpc-2043	121	7	levels	level	NOUN
dpc-2043	121	8	of	of	ADP
dpc-2043	121	9	two	two	NUM
dpc-2043	121	10	serum	serum	NOUN
dpc-2043	121	11	trace	trace	NOUN
dpc-2043	121	12	elements	element	NOUN
dpc-2043	121	13	and	and	CCONJ
dpc-2043	121	14	other	other	ADJ
dpc-2043	121	15	parameters	parameter	NOUN
dpc-2043	121	16	including	include	VERB
dpc-2043	121	17	skin	skin	NOUN
dpc-2043	121	18	and	and	CCONJ
dpc-2043	121	19	clinical	clinical	ADJ
dpc-2043	121	20	types	type	NOUN
dpc-2043	121	21	of	of	ADP
dpc-2043	121	22	the	the	DET
dpc-2043	121	23	disease	disease	NOUN
dpc-2043	121	24	(	(	PUNCT
dpc-2043	121	25	table	table	NOUN
dpc-2043	121	26	3	3	NUM
dpc-2043	121	27	)	)	PUNCT
dpc-2043	121	28	.	.	PUNCT
dpc-2043	122	1	conclusions	conclusion	NOUN
dpc-2043	122	2	numerous	numerous	ADJ
dpc-2043	122	3	studies	study	NOUN
dpc-2043	122	4	have	have	AUX
dpc-2043	122	5	shown	show	VERB
dpc-2043	122	6	a	a	DET
dpc-2043	122	7	role	role	NOUN
dpc-2043	122	8	for	for	ADP
dpc-2043	122	9	the	the	DET
dpc-2043	122	10	oxidant	oxidant	ADJ
dpc-2043	122	11	–	–	PUNCT
dpc-2043	122	12	antioxidant	antioxidant	ADJ
dpc-2043	122	13	imbalance	imbalance	NOUN
dpc-2043	122	14	and	and	CCONJ
dpc-2043	122	15	accumulation	accumulation	NOUN
dpc-2043	122	16	of	of	ADP
dpc-2043	122	17	ros	ros	PROPN
dpc-2043	122	18	in	in	ADP
dpc-2043	122	19	the	the	DET
dpc-2043	122	20	skin	skin	NOUN
dpc-2043	122	21	lesion	lesion	NOUN
dpc-2043	122	22	of	of	ADP
dpc-2043	122	23	vitiligo	vitiligo	ADJ
dpc-2043	122	24	patients	patient	NOUN
dpc-2043	123	1	[	[	X
dpc-2043	123	2	7,10,20	7,10,20	NUM
dpc-2043	123	3	]	]	PUNCT
dpc-2043	123	4	.	.	PUNCT
dpc-2043	124	1	cu	cu	PROPN
dpc-2043	124	2	and	and	CCONJ
dpc-2043	124	3	zn	zn	PROPN
dpc-2043	124	4	are	be	AUX
dpc-2043	124	5	necessary	necessary	ADJ
dpc-2043	124	6	table	table	NOUN
dpc-2043	124	7	3	3	NUM
dpc-2043	124	8	.	.	PUNCT
dpc-2043	124	9	spearman	spearman	NOUN
dpc-2043	124	10	correlation	correlation	NOUN
dpc-2043	124	11	coefficient	coefficient	NOUN
dpc-2043	124	12	(	(	PUNCT
dpc-2043	124	13	r	r	NOUN
dpc-2043	124	14	)	)	PUNCT
dpc-2043	124	15	and	and	CCONJ
dpc-2043	124	16	p	p	NOUN
dpc-2043	124	17	value	value	NOUN
dpc-2043	124	18	between	between	ADP
dpc-2043	124	19	serum	serum	PROPN
dpc-2043	124	20	cu	cu	PROPN
dpc-2043	124	21	,	,	PUNCT
dpc-2043	124	22	zn	zn	PROPN
dpc-2043	124	23	,	,	PUNCT
dpc-2043	124	24	age	age	NOUN
dpc-2043	124	25	of	of	ADP
dpc-2043	124	26	onset	onset	NOUN
dpc-2043	124	27	and	and	CCONJ
dpc-2043	124	28	gender	gender	NOUN
dpc-2043	124	29	in	in	ADP
dpc-2043	124	30	patients	patient	NOUN
dpc-2043	124	31	correlation	correlation	NOUN
dpc-2043	124	32	between	between	ADP
dpc-2043	124	33	r	r	NOUN
dpc-2043	124	34	(	(	PUNCT
dpc-2043	124	35	p	p	NOUN
dpc-2043	124	36	value	value	NOUN
dpc-2043	124	37	)	)	PUNCT
dpc-2043	124	38	serum	serum	NOUN
dpc-2043	124	39	cu	cu	PROPN
dpc-2043	124	40	and	and	CCONJ
dpc-2043	124	41	serum	serum	VERB
dpc-2043	124	42	zn	zn	PROPN
dpc-2043	124	43	0.144	0.144	NUM
dpc-2043	124	44	(	(	PUNCT
dpc-2043	124	45	0.252	0.252	NUM
dpc-2043	124	46	)	)	PUNCT
dpc-2043	124	47	serum	serum	PROPN
dpc-2043	124	48	cu	cu	PROPN
dpc-2043	124	49	and	and	CCONJ
dpc-2043	124	50	age	age	NOUN
dpc-2043	124	51	of	of	ADP
dpc-2043	124	52	onset	onset	NOUN
dpc-2043	124	53	early	early	ADV
dpc-2043	124	54	onset	onset	NOUN
dpc-2043	124	55	0.251	0.251	NUM
dpc-2043	124	56	(	(	PUNCT
dpc-2043	124	57	0.039	0.039	NUM
dpc-2043	124	58	)	)	PUNCT
dpc-2043	124	59	late	late	ADJ
dpc-2043	124	60	onset	onset	VERB
dpc-2043	124	61	0.042	0.042	NUM
dpc-2043	124	62	(	(	PUNCT
dpc-2043	124	63	0.774	0.774	NUM
dpc-2043	124	64	)	)	PUNCT
dpc-2043	124	65	serum	serum	PROPN
dpc-2043	124	66	zn	zn	PROPN
dpc-2043	124	67	and	and	CCONJ
dpc-2043	124	68	age	age	NOUN
dpc-2043	124	69	of	of	ADP
dpc-2043	124	70	onset	onset	NOUN
dpc-2043	124	71	early	early	ADV
dpc-2043	124	72	onset	onset	NOUN
dpc-2043	124	73	0.157	0.157	NUM
dpc-2043	124	74	(	(	PUNCT
dpc-2043	124	75	0.362	0.362	NUM
dpc-2043	124	76	)	)	PUNCT
dpc-2043	124	77	late	late	ADJ
dpc-2043	124	78	onset	onset	VERB
dpc-2043	124	79	0.189	0.189	NUM
dpc-2043	124	80	(	(	PUNCT
dpc-2043	124	81	0.175	0.175	NUM
dpc-2043	124	82	)	)	PUNCT
dpc-2043	124	83	serum	serum	PROPN
dpc-2043	124	84	cu	cu	PROPN
dpc-2043	124	85	or	or	CCONJ
dpc-2043	124	86	zn	zn	PROPN
dpc-2043	124	87	and	and	CCONJ
dpc-2043	124	88	skin	skin	NOUN
dpc-2043	124	89	type	type	NOUN
dpc-2043	124	90	type	type	NOUN
dpc-2043	124	91	iii	iii	NOUN
dpc-2043	124	92	type	type	NOUN
dpc-2043	124	93	iv	iv	NUM
dpc-2043	124	94	0.207	0.207	NUM
dpc-2043	124	95	(	(	PUNCT
dpc-2043	124	96	0.097	0.097	NUM
dpc-2043	124	97	)	)	PUNCT
dpc-2043	124	98	0.071(0.688	0.071(0.688	NUM
dpc-2043	124	99	)	)	PUNCT
dpc-2043	124	100	serum	serum	NOUN
dpc-2043	124	101	cu	cu	PROPN
dpc-2043	124	102	or	or	CCONJ
dpc-2043	124	103	zn	zn	PROPN
dpc-2043	124	104	and	and	CCONJ
dpc-2043	124	105	clinical	clinical	ADJ
dpc-2043	124	106	type	type	NOUN
dpc-2043	124	107	of	of	ADP
dpc-2043	124	108	vitiligo	vitiligo	NOUN
dpc-2043	124	109	generalized	generalize	VERB
dpc-2043	124	110	localized	localize	VERB
dpc-2043	124	111	0.022	0.022	NUM
dpc-2043	124	112	(	(	PUNCT
dpc-2043	124	113	0.844	0.844	NUM
dpc-2043	124	114	)	)	PUNCT
dpc-2043	124	115	0.453	0.453	NUM
dpc-2043	124	116	(	(	PUNCT
dpc-2043	124	117	0.105	0.105	NUM
dpc-2043	124	118	)	)	PUNCT
dpc-2043	124	119	serum	serum	NOUN
dpc-2043	124	120	cu	cu	PROPN
dpc-2043	124	121	or	or	CCONJ
dpc-2043	124	122	zn	zn	PROPN
dpc-2043	124	123	and	and	CCONJ
dpc-2043	124	124	clinical	clinical	ADJ
dpc-2043	124	125	type	type	NOUN
dpc-2043	124	126	of	of	ADP
dpc-2043	124	127	vitiligo	vitiligo	ADJ
dpc-2043	124	128	segmental	segmental	ADJ
dpc-2043	124	129	non	non	ADJ
dpc-2043	124	130	-	-	ADJ
dpc-2043	124	131	segmental	segmental	ADJ
dpc-2043	124	132	0.20	0.20	NUM
dpc-2043	124	133	(	(	PUNCT
dpc-2043	124	134	0.045	0.045	NUM
dpc-2043	124	135	)	)	PUNCT
dpc-2043	124	136	0.062	0.062	NUM
dpc-2043	124	137	(	(	PUNCT
dpc-2043	124	138	0.666	0.666	NUM
dpc-2043	124	139	)	)	PUNCT
dpc-2043	124	140	serum	serum	NOUN
dpc-2043	124	141	zn	zn	PROPN
dpc-2043	124	142	and	and	CCONJ
dpc-2043	124	143	the	the	DET
dpc-2043	124	144	duration	duration	NOUN
dpc-2043	124	145	of	of	ADP
dpc-2043	124	146	disease	disease	NOUN
dpc-2043	124	147	-0.018	-0.018	PUNCT
dpc-2043	124	148	(	(	PUNCT
dpc-2043	124	149	0.862	0.862	NUM
dpc-2043	124	150	)	)	PUNCT
dpc-2043	124	151	serum	serum	NOUN
dpc-2043	124	152	cu	cu	PROPN
dpc-2043	124	153	and	and	CCONJ
dpc-2043	124	154	the	the	DET
dpc-2043	124	155	duration	duration	NOUN
dpc-2043	124	156	of	of	ADP
dpc-2043	124	157	disease	disease	NOUN
dpc-2043	124	158	0.256	0.256	NUM
dpc-2043	124	159	(	(	PUNCT
dpc-2043	124	160	0.010	0.010	NUM
dpc-2043	124	161	)	)	PUNCT
dpc-2043	124	162	serum	serum	NOUN
dpc-2043	124	163	zn	zn	PROPN
dpc-2043	124	164	in	in	ADP
dpc-2043	124	165	male	male	NOUN
dpc-2043	124	166	and	and	CCONJ
dpc-2043	124	167	the	the	DET
dpc-2043	124	168	duration	duration	NOUN
dpc-2043	124	169	of	of	ADP
dpc-2043	124	170	disease	disease	NOUN
dpc-2043	124	171	-0.186	-0.186	X
dpc-2043	124	172	(	(	PUNCT
dpc-2043	124	173	0.252	0.252	NUM
dpc-2043	124	174	)	)	PUNCT
dpc-2043	124	175	serum	serum	PROPN
dpc-2043	124	176	zn	zn	PROPN
dpc-2043	124	177	in	in	ADP
dpc-2043	124	178	female	female	ADJ
dpc-2043	124	179	and	and	CCONJ
dpc-2043	124	180	the	the	DET
dpc-2043	124	181	duration	duration	NOUN
dpc-2043	124	182	of	of	ADP
dpc-2043	124	183	disease	disease	NOUN
dpc-2043	124	184	0.058	0.058	NUM
dpc-2043	124	185	(	(	PUNCT
dpc-2043	124	186	0.662	0.662	NUM
dpc-2043	124	187	)	)	PUNCT
dpc-2043	124	188	serum	serum	NOUN
dpc-2043	124	189	cu	cu	PROPN
dpc-2043	124	190	in	in	ADP
dpc-2043	124	191	male	male	NOUN
dpc-2043	124	192	and	and	CCONJ
dpc-2043	124	193	the	the	DET
dpc-2043	124	194	duration	duration	NOUN
dpc-2043	124	195	of	of	ADP
dpc-2043	124	196	disease	disease	NOUN
dpc-2043	124	197	0.112	0.112	NUM
dpc-2043	124	198	(	(	PUNCT
dpc-2043	124	199	0.448	0.448	NUM
dpc-2043	124	200	)	)	PUNCT
dpc-2043	124	201	serum	serum	NOUN
dpc-2043	124	202	cu	cu	PROPN
dpc-2043	124	203	in	in	ADP
dpc-2043	124	204	female	female	ADJ
dpc-2043	124	205	and	and	CCONJ
dpc-2043	124	206	the	the	DET
dpc-2043	124	207	duration	duration	NOUN
dpc-2043	124	208	of	of	ADP
dpc-2043	124	209	disease	disease	NOUN
dpc-2043	124	210	0.225	0.225	NUM
dpc-2043	124	211	(	(	PUNCT
dpc-2043	124	212	0.034	0.034	NUM
dpc-2043	124	213	)	)	PUNCT
dpc-2043	124	214	cu	cu	NOUN
dpc-2043	124	215	=	=	PROPN
dpc-2043	124	216	copper	copper	NOUN
dpc-2043	124	217	;	;	PUNCT
dpc-2043	124	218	zn	zn	PROPN
dpc-2043	124	219	=	=	SYM
dpc-2043	124	220	zinc	zinc	PROPN
dpc-2043	124	221	.	.	NOUN
dpc-2043	124	222	6	6	NUM
dpc-2043	124	223	original	original	ADJ
dpc-2043	124	224	article	article	NOUN
dpc-2043	124	225	|	|	ADV
dpc-2043	124	226	dermatol	dermatol	ADJ
dpc-2043	124	227	pract	pract	NOUN
dpc-2043	124	228	concept	concept	NOUN
dpc-2043	124	229	.	.	PUNCT
dpc-2043	125	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	125	2	serum	serum	PROPN
dpc-2043	125	3	cu	cu	PROPN
dpc-2043	125	4	and	and	CCONJ
dpc-2043	125	5	zn	zn	PROPN
dpc-2043	125	6	levels	level	NOUN
dpc-2043	125	7	and	and	CCONJ
dpc-2043	125	8	other	other	ADJ
dpc-2043	125	9	parameters	parameter	NOUN
dpc-2043	125	10	in	in	ADP
dpc-2043	125	11	either	either	DET
dpc-2043	125	12	patients	patient	NOUN
dpc-2043	125	13	or	or	CCONJ
dpc-2043	125	14	the	the	DET
dpc-2043	125	15	control	control	NOUN
dpc-2043	125	16	group	group	NOUN
dpc-2043	125	17	.	.	PUNCT
dpc-2043	126	1	some	some	DET
dpc-2043	126	2	previous	previous	ADJ
dpc-2043	126	3	studies	study	NOUN
dpc-2043	126	4	detected	detect	VERB
dpc-2043	126	5	no	no	DET
dpc-2043	126	6	correlation	correlation	NOUN
dpc-2043	126	7	between	between	ADP
dpc-2043	126	8	serum	serum	PROPN
dpc-2043	126	9	cu	cu	PROPN
dpc-2043	126	10	and	and	CCONJ
dpc-2043	126	11	zn	zn	PROPN
dpc-2043	126	12	levels	level	NOUN
dpc-2043	126	13	and	and	CCONJ
dpc-2043	126	14	the	the	DET
dpc-2043	126	15	disease	disease	NOUN
dpc-2043	126	16	subgroups	subgroup	NOUN
dpc-2043	126	17	[	[	X
dpc-2043	126	18	37,38	37,38	NOUN
dpc-2043	126	19	]	]	PUNCT
dpc-2043	126	20	.	.	PUNCT
dpc-2043	127	1	but	but	CCONJ
dpc-2043	127	2	,	,	PUNCT
dpc-2043	127	3	others	other	NOUN
dpc-2043	127	4	reported	report	VERB
dpc-2043	127	5	a	a	DET
dpc-2043	127	6	negative	negative	ADJ
dpc-2043	127	7	correlation	correlation	NOUN
dpc-2043	127	8	between	between	ADP
dpc-2043	127	9	serum	serum	NOUN
dpc-2043	127	10	levels	level	NOUN
dpc-2043	127	11	of	of	ADP
dpc-2043	127	12	zn	zn	PROPN
dpc-2043	127	13	and	and	CCONJ
dpc-2043	127	14	the	the	DET
dpc-2043	127	15	generalized	generalized	ADJ
dpc-2043	127	16	vitiligo	vitiligo	NOUN
dpc-2043	127	17	,	,	PUNCT
dpc-2043	127	18	age	age	NOUN
dpc-2043	127	19	,	,	PUNCT
dpc-2043	127	20	and	and	CCONJ
dpc-2043	127	21	duration	duration	NOUN
dpc-2043	127	22	of	of	ADP
dpc-2043	127	23	disease	disease	NOUN
dpc-2043	127	24	[	[	X
dpc-2043	127	25	28,31	28,31	NUM
dpc-2043	127	26	]	]	PUNCT
dpc-2043	127	27	.	.	PUNCT
dpc-2043	128	1	in	in	ADP
dpc-2043	128	2	a	a	DET
dpc-2043	128	3	study	study	NOUN
dpc-2043	128	4	of	of	ADP
dpc-2043	128	5	tissue	tissue	NOUN
dpc-2043	128	6	copper	copper	NOUN
dpc-2043	128	7	in	in	ADP
dpc-2043	128	8	vitiligo	vitiligo	NOUN
dpc-2043	128	9	patients	patient	NOUN
dpc-2043	128	10	,	,	PUNCT
dpc-2043	128	11	the	the	DET
dpc-2043	128	12	mean	mean	ADJ
dpc-2043	128	13	lesion	lesion	NOUN
dpc-2043	128	14	(	(	PUNCT
dpc-2043	128	15	1.3	1.3	NUM
dpc-2043	128	16	μg	μg	NOUN
dpc-2043	128	17	/	/	SYM
dpc-2043	128	18	g	g	NOUN
dpc-2043	128	19	)	)	PUNCT
dpc-2043	128	20	and	and	CCONJ
dpc-2043	128	21	non	non	ADJ
dpc-2043	128	22	-	-	NOUN
dpc-2043	128	23	lesion	lesion	NOUN
dpc-2043	128	24	(	(	PUNCT
dpc-2043	128	25	1.4	1.4	NUM
dpc-2043	128	26	μg	μg	PROPN
dpc-2043	128	27	/	/	SYM
dpc-2043	128	28	g	g	NOUN
dpc-2043	128	29	)	)	PUNCT
dpc-2043	128	30	cu	cu	PROPN
dpc-2043	128	31	levels	level	NOUN
dpc-2043	128	32	were	be	AUX
dpc-2043	128	33	non	non	ADJ
dpc-2043	128	34	-	-	ADJ
dpc-2043	128	35	significantly	significantly	ADV
dpc-2043	128	36	lower	low	ADJ
dpc-2043	128	37	than	than	ADP
dpc-2043	128	38	tissue	tissue	NOUN
dpc-2043	128	39	cu	cu	NOUN
dpc-2043	128	40	levels	level	NOUN
dpc-2043	128	41	of	of	ADP
dpc-2043	128	42	the	the	DET
dpc-2043	128	43	control	control	NOUN
dpc-2043	128	44	group	group	NOUN
dpc-2043	128	45	(	(	PUNCT
dpc-2043	128	46	1.9	1.9	NUM
dpc-2043	128	47	μg	μg	PROPN
dpc-2043	128	48	/	/	SYM
dpc-2043	128	49	g	g	NOUN
dpc-2043	128	50	)	)	PUNCT
dpc-2043	129	1	[	[	X
dpc-2043	129	2	39	39	NUM
dpc-2043	129	3	]	]	PUNCT
dpc-2043	129	4	.	.	PUNCT
dpc-2043	130	1	melanin	melanin	PROPN
dpc-2043	130	2	has	have	VERB
dpc-2043	130	3	a	a	DET
dpc-2043	130	4	high	high	ADJ
dpc-2043	130	5	affinity	affinity	NOUN
dpc-2043	130	6	for	for	ADP
dpc-2043	130	7	the	the	DET
dpc-2043	130	8	sequestration	sequestration	NOUN
dpc-2043	130	9	of	of	ADP
dpc-2043	130	10	metal	metal	NOUN
dpc-2043	130	11	ions	ion	NOUN
dpc-2043	130	12	,	,	PUNCT
dpc-2043	130	13	and	and	CCONJ
dpc-2043	130	14	pigmented	pigmented	ADJ
dpc-2043	130	15	tissues	tissue	NOUN
dpc-2043	130	16	contain	contain	VERB
dpc-2043	130	17	a	a	DET
dpc-2043	130	18	significant	significant	ADJ
dpc-2043	130	19	amount	amount	NOUN
dpc-2043	130	20	of	of	ADP
dpc-2043	130	21	metal	metal	NOUN
dpc-2043	130	22	cations	cation	NOUN
dpc-2043	130	23	including	include	VERB
dpc-2043	130	24	cu	cu	PROPN
dpc-2043	130	25	and	and	CCONJ
dpc-2043	130	26	zn	zn	NUM
dpc-2043	130	27	  	  	SPACE
dpc-2043	131	1	[	[	X
dpc-2043	131	2	12	12	NUM
dpc-2043	131	3	]	]	PUNCT
dpc-2043	131	4	.	.	PUNCT
dpc-2043	132	1	by	by	ADP
dpc-2043	132	2	binding	bind	VERB
dpc-2043	132	3	and	and	CCONJ
dpc-2043	132	4	sequestering	sequester	VERB
dpc-2043	132	5	metal	metal	NOUN
dpc-2043	132	6	ions	ion	NOUN
dpc-2043	132	7	,	,	PUNCT
dpc-2043	132	8	melanosomes	melanosome	NOUN
dpc-2043	132	9	are	be	AUX
dpc-2043	132	10	protected	protect	VERB
dpc-2043	132	11	from	from	ADP
dpc-2043	132	12	oxidative	oxidative	ADJ
dpc-2043	132	13	damage	damage	NOUN
dpc-2043	132	14	.	.	PUNCT
dpc-2043	133	1	the	the	DET
dpc-2043	133	2	serum	serum	NOUN
dpc-2043	133	3	concentrations	concentration	NOUN
dpc-2043	133	4	of	of	ADP
dpc-2043	133	5	zn	zn	PROPN
dpc-2043	133	6	and	and	CCONJ
dpc-2043	133	7	cu	cu	PROPN
dpc-2043	133	8	have	have	AUX
dpc-2043	133	9	been	be	AUX
dpc-2043	133	10	reported	report	VERB
dpc-2043	133	11	to	to	PART
dpc-2043	133	12	increase	increase	VERB
dpc-2043	133	13	with	with	ADP
dpc-2043	133	14	age	age	NOUN
dpc-2043	133	15	[	[	X
dpc-2043	133	16	30,40,41	30,40,41	NUM
dpc-2043	133	17	]	]	PUNCT
dpc-2043	133	18	.	.	PUNCT
dpc-2043	134	1	in	in	ADP
dpc-2043	134	2	our	our	PRON
dpc-2043	134	3	study	study	NOUN
dpc-2043	134	4	,	,	PUNCT
dpc-2043	134	5	the	the	DET
dpc-2043	134	6	elderly	elderly	ADJ
dpc-2043	134	7	patients	patient	NOUN
dpc-2043	134	8	(	(	PUNCT
dpc-2043	134	9	≥	≥	NOUN
dpc-2043	134	10	50	50	NUM
dpc-2043	134	11	years	year	NOUN
dpc-2043	134	12	)	)	PUNCT
dpc-2043	134	13	had	have	VERB
dpc-2043	134	14	significantly	significantly	ADV
dpc-2043	134	15	higher	high	ADJ
dpc-2043	134	16	serum	serum	PROPN
dpc-2043	134	17	cu	cu	PROPN
dpc-2043	134	18	and	and	CCONJ
dpc-2043	134	19	zn	zn	PROPN
dpc-2043	134	20	concentrations	concentration	NOUN
dpc-2043	134	21	than	than	ADP
dpc-2043	134	22	young	young	ADJ
dpc-2043	134	23	(	(	PUNCT
dpc-2043	134	24	<	<	X
dpc-2043	134	25	50	50	NUM
dpc-2043	134	26	years	year	NOUN
dpc-2043	134	27	)	)	PUNCT
dpc-2043	134	28	patients	patient	NOUN
dpc-2043	134	29	(	(	PUNCT
dpc-2043	134	30	p	p	X
dpc-2043	134	31	=	=	NOUN
dpc-2043	134	32	0.00	0.00	NUM
dpc-2043	134	33	)	)	PUNCT
dpc-2043	134	34	(	(	PUNCT
dpc-2043	134	35	table	table	NOUN
dpc-2043	134	36	1	1	NUM
dpc-2043	134	37	)	)	PUNCT
dpc-2043	134	38	.	.	PUNCT
dpc-2043	135	1	in	in	ADP
dpc-2043	135	2	the	the	DET
dpc-2043	135	3	case	case	NOUN
dpc-2043	135	4	-	-	PUNCT
dpc-2043	135	5	control	control	NOUN
dpc-2043	135	6	comparison	comparison	NOUN
dpc-2043	135	7	,	,	PUNCT
dpc-2043	135	8	both	both	CCONJ
dpc-2043	135	9	the	the	DET
dpc-2043	135	10	elderly	elderly	ADJ
dpc-2043	135	11	and	and	CCONJ
dpc-2043	135	12	young	young	ADJ
dpc-2043	135	13	patients	patient	NOUN
dpc-2043	135	14	had	have	VERB
dpc-2043	135	15	lower	low	ADJ
dpc-2043	135	16	serum	serum	NOUN
dpc-2043	135	17	cu	cu	PROPN
dpc-2043	135	18	levels	level	NOUN
dpc-2043	135	19	than	than	ADP
dpc-2043	135	20	their	their	PRON
dpc-2043	135	21	respective	respective	ADJ
dpc-2043	135	22	healthy	healthy	ADJ
dpc-2043	135	23	controls	control	NOUN
dpc-2043	135	24	(	(	PUNCT
dpc-2043	135	25	p	p	NOUN
dpc-2043	135	26	≤	≤	NUM
dpc-2043	135	27	0.05	0.05	NUM
dpc-2043	135	28	)	)	PUNCT
dpc-2043	135	29	.	.	PUNCT
dpc-2043	136	1	the	the	DET
dpc-2043	136	2	young	young	ADJ
dpc-2043	136	3	patients	patient	NOUN
dpc-2043	136	4	also	also	ADV
dpc-2043	136	5	had	have	VERB
dpc-2043	136	6	significantly	significantly	ADV
dpc-2043	136	7	lower	low	ADJ
dpc-2043	136	8	serum	serum	PROPN
dpc-2043	136	9	zn	zn	PROPN
dpc-2043	136	10	levels	level	NOUN
dpc-2043	136	11	than	than	ADP
dpc-2043	136	12	the	the	DET
dpc-2043	136	13	respective	respective	ADJ
dpc-2043	136	14	control	control	NOUN
dpc-2043	136	15	group	group	NOUN
dpc-2043	136	16	,	,	PUNCT
dpc-2043	136	17	but	but	CCONJ
dpc-2043	136	18	no	no	DET
dpc-2043	136	19	significant	significant	ADJ
dpc-2043	136	20	difference	difference	NOUN
dpc-2043	136	21	was	be	AUX
dpc-2043	136	22	found	find	VERB
dpc-2043	136	23	in	in	ADP
dpc-2043	136	24	terms	term	NOUN
dpc-2043	136	25	of	of	ADP
dpc-2043	136	26	serum	serum	NOUN
dpc-2043	136	27	zn	zn	PROPN
dpc-2043	136	28	concentration	concentration	NOUN
dpc-2043	136	29	between	between	ADP
dpc-2043	136	30	elderly	elderly	ADJ
dpc-2043	136	31	patients	patient	NOUN
dpc-2043	136	32	and	and	CCONJ
dpc-2043	136	33	their	their	PRON
dpc-2043	136	34	respective	respective	ADJ
dpc-2043	136	35	elderly	elderly	ADJ
dpc-2043	136	36	control	control	NOUN
dpc-2043	136	37	group	group	NOUN
dpc-2043	136	38	(	(	PUNCT
dpc-2043	136	39	p	p	X
dpc-2043	136	40	>	>	X
dpc-2043	136	41	0.05	0.05	NUM
dpc-2043	136	42	)	)	PUNCT
dpc-2043	136	43	.	.	PUNCT
dpc-2043	137	1	a	a	DET
dpc-2043	137	2	relationship	relationship	NOUN
dpc-2043	137	3	between	between	ADP
dpc-2043	137	4	vitiligo	vitiligo	NOUN
dpc-2043	137	5	and	and	CCONJ
dpc-2043	137	6	the	the	DET
dpc-2043	137	7	incidence	incidence	NOUN
dpc-2043	137	8	of	of	ADP
dpc-2043	137	9	other	other	ADJ
dpc-2043	137	10	autoimmune	autoimmune	ADJ
dpc-2043	137	11	disorders	disorder	NOUN
dpc-2043	137	12	has	have	AUX
dpc-2043	137	13	been	be	AUX
dpc-2043	137	14	suggested	suggest	VERB
dpc-2043	137	15	[	[	X
dpc-2043	137	16	42,43	42,43	NOUN
dpc-2043	137	17	]	]	PUNCT
dpc-2043	137	18	.	.	PUNCT
dpc-2043	138	1	in	in	ADP
dpc-2043	138	2	our	our	PRON
dpc-2043	138	3	study	study	NOUN
dpc-2043	138	4	,	,	PUNCT
dpc-2043	138	5	6.8	6.8	NUM
dpc-2043	138	6	%	%	NOUN
dpc-2043	138	7	of	of	ADP
dpc-2043	138	8	vitiligo	vitiligo	NOUN
dpc-2043	138	9	patients	patient	NOUN
dpc-2043	138	10	had	have	VERB
dpc-2043	138	11	a	a	DET
dpc-2043	138	12	history	history	NOUN
dpc-2043	138	13	of	of	ADP
dpc-2043	138	14	other	other	ADJ
dpc-2043	138	15	autoimmune	autoimmune	ADJ
dpc-2043	138	16	diseases	disease	NOUN
dpc-2043	138	17	including	include	VERB
dpc-2043	138	18	rheumatoid	rheumatoid	NOUN
dpc-2043	138	19	arthritis	arthritis	NOUN
dpc-2043	138	20	,	,	PUNCT
dpc-2043	138	21	type	type	NOUN
dpc-2043	138	22	1	1	NUM
dpc-2043	138	23	diabetes	diabetes	NOUN
dpc-2043	138	24	mellitus	mellitus	NOUN
dpc-2043	138	25	,	,	PUNCT
dpc-2043	138	26	and	and	CCONJ
dpc-2043	138	27	hypothyroidism	hypothyroidism	NOUN
dpc-2043	138	28	.	.	PUNCT
dpc-2043	139	1	several	several	ADJ
dpc-2043	139	2	previous	previous	ADJ
dpc-2043	139	3	studies	study	NOUN
dpc-2043	139	4	have	have	AUX
dpc-2043	139	5	suggested	suggest	VERB
dpc-2043	139	6	an	an	DET
dpc-2043	139	7	association	association	NOUN
dpc-2043	139	8	between	between	ADP
dpc-2043	139	9	zn	zn	PROPN
dpc-2043	139	10	and	and	CCONJ
dpc-2043	139	11	cu	cu	PROPN
dpc-2043	139	12	deficiency	deficiency	NOUN
dpc-2043	139	13	and	and	CCONJ
dpc-2043	139	14	hypopigmentation	hypopigmentation	NOUN
dpc-2043	139	15	of	of	ADP
dpc-2043	139	16	the	the	DET
dpc-2043	139	17	skin	skin	NOUN
dpc-2043	139	18	and	and	CCONJ
dpc-2043	139	19	hair	hair	NOUN
dpc-2043	139	20	,	,	PUNCT
dpc-2043	139	21	immune	immune	ADJ
dpc-2043	139	22	defects	defect	NOUN
dpc-2043	139	23	,	,	PUNCT
dpc-2043	139	24	and	and	CCONJ
dpc-2043	139	25	autoimmune	autoimmune	ADJ
dpc-2043	139	26	diseases	disease	NOUN
dpc-2043	139	27	like	like	ADP
dpc-2043	139	28	type	type	NOUN
dpc-2043	139	29	1	1	NUM
dpc-2043	139	30	diabetes	diabetes	NOUN
dpc-2043	139	31	,	,	PUNCT
dpc-2043	139	32	rheumatoid	rheumatoid	NOUN
dpc-2043	139	33	arthritis	arthritis	NOUN
dpc-2043	139	34	,	,	PUNCT
dpc-2043	139	35	multiple	multiple	ADJ
dpc-2043	139	36	sclerosis	sclerosis	NOUN
dpc-2043	139	37	,	,	PUNCT
dpc-2043	139	38	systemic	systemic	ADJ
dpc-2043	139	39	lupus	lupus	PROPN
dpc-2043	139	40	erythematosus	erythematosus	PROPN
dpc-2043	139	41	,	,	PUNCT
dpc-2043	139	42	celiac	celiac	ADJ
dpc-2043	139	43	disease	disease	NOUN
dpc-2043	139	44	,	,	PUNCT
dpc-2043	139	45	hashimoto	hashimoto	NOUN
dpc-2043	139	46	thyroiditis	thyroiditis	NOUN
dpc-2043	139	47	,	,	PUNCT
dpc-2043	139	48	and	and	CCONJ
dpc-2043	139	49	juvenile	juvenile	ADJ
dpc-2043	139	50	idiopathic	idiopathic	ADJ
dpc-2043	139	51	arthritis	arthritis	NOUN
dpc-2043	139	52	[	[	X
dpc-2043	139	53	44,45	44,45	NOUN
dpc-2043	139	54	]	]	PUNCT
dpc-2043	139	55	.	.	PUNCT
dpc-2043	140	1	in	in	ADP
dpc-2043	140	2	the	the	DET
dpc-2043	140	3	current	current	ADJ
dpc-2043	140	4	study	study	NOUN
dpc-2043	140	5	,	,	PUNCT
dpc-2043	140	6	the	the	DET
dpc-2043	140	7	median	median	NOUN
dpc-2043	140	8	and	and	CCONJ
dpc-2043	140	9	mean	mean	VERB
dpc-2043	140	10	serum	serum	PROPN
dpc-2043	140	11	cu	cu	PROPN
dpc-2043	140	12	and	and	CCONJ
dpc-2043	140	13	zn	zn	PROPN
dpc-2043	140	14	concentrations	concentration	NOUN
dpc-2043	140	15	in	in	ADP
dpc-2043	140	16	the	the	DET
dpc-2043	140	17	generalized	generalized	ADJ
dpc-2043	140	18	form	form	NOUN
dpc-2043	140	19	of	of	ADP
dpc-2043	140	20	vitiligo	vitiligo	NOUN
dpc-2043	140	21	were	be	AUX
dpc-2043	140	22	less	less	ADJ
dpc-2043	140	23	than	than	ADP
dpc-2043	140	24	those	those	PRON
dpc-2043	140	25	in	in	ADP
dpc-2043	140	26	the	the	DET
dpc-2043	140	27	localized	localized	ADJ
dpc-2043	140	28	form	form	NOUN
dpc-2043	140	29	(	(	PUNCT
dpc-2043	140	30	p	p	NOUN
dpc-2043	140	31	≤	≤	NUM
dpc-2043	140	32	0.05	0.05	NUM
dpc-2043	140	33	)	)	PUNCT
dpc-2043	140	34	.	.	PUNCT
dpc-2043	141	1	mirnezami	mirnezami	AUX
dpc-2043	141	2	 	 	SPACE
dpc-2043	141	3	et	et	NOUN
dpc-2043	141	4	 	 	SPACE
dpc-2043	141	5	al	al	PROPN
dpc-2043	141	6	also	also	ADV
dpc-2043	141	7	reported	report	VERB
dpc-2043	141	8	significantly	significantly	ADV
dpc-2043	141	9	lower	low	ADJ
dpc-2043	141	10	zinc	zinc	NOUN
dpc-2043	141	11	levels	level	NOUN
dpc-2043	141	12	in	in	ADP
dpc-2043	141	13	the	the	DET
dpc-2043	141	14	generalized	generalized	ADJ
dpc-2043	141	15	vitiligo	vitiligo	NOUN
dpc-2043	141	16	than	than	ADP
dpc-2043	141	17	the	the	DET
dpc-2043	141	18	localized	localize	VERB
dpc-2043	141	19	form	form	NOUN
dpc-2043	141	20	[	[	X
dpc-2043	141	21	28	28	NUM
dpc-2043	141	22	]	]	PUNCT
dpc-2043	141	23	.	.	PUNCT
dpc-2043	142	1	in	in	ADP
dpc-2043	142	2	conclusion	conclusion	NOUN
dpc-2043	142	3	,	,	PUNCT
dpc-2043	142	4	our	our	PRON
dpc-2043	142	5	results	result	NOUN
dpc-2043	142	6	are	be	AUX
dpc-2043	142	7	consistent	consistent	ADJ
dpc-2043	142	8	with	with	ADP
dpc-2043	142	9	prior	prior	ADJ
dpc-2043	142	10	study	study	NOUN
dpc-2043	142	11	findings	finding	NOUN
dpc-2043	142	12	of	of	ADP
dpc-2043	142	13	decreased	decrease	VERB
dpc-2043	142	14	and	and	CCONJ
dpc-2043	142	15	imbalanced	imbalanced	ADJ
dpc-2043	142	16	levels	level	NOUN
dpc-2043	142	17	of	of	ADP
dpc-2043	142	18	serum	serum	PROPN
dpc-2043	142	19	cu	cu	PROPN
dpc-2043	142	20	and	and	CCONJ
dpc-2043	142	21	zn	zn	PROPN
dpc-2043	142	22	in	in	ADP
dpc-2043	142	23	vitiligo	vitiligo	NOUN
dpc-2043	142	24	patients	patient	NOUN
dpc-2043	142	25	.	.	PUNCT
dpc-2043	143	1	the	the	DET
dpc-2043	143	2	main	main	ADJ
dpc-2043	143	3	drawback	drawback	NOUN
dpc-2043	143	4	of	of	ADP
dpc-2043	143	5	this	this	DET
dpc-2043	143	6	study	study	NOUN
dpc-2043	143	7	was	be	AUX
dpc-2043	143	8	the	the	DET
dpc-2043	143	9	relatively	relatively	ADV
dpc-2043	143	10	small	small	ADJ
dpc-2043	143	11	sample	sample	NOUN
dpc-2043	143	12	size	size	NOUN
dpc-2043	143	13	that	that	PRON
dpc-2043	143	14	limited	limit	VERB
dpc-2043	143	15	the	the	DET
dpc-2043	143	16	statistical	statistical	ADJ
dpc-2043	143	17	power	power	NOUN
dpc-2043	143	18	to	to	PART
dpc-2043	143	19	perform	perform	VERB
dpc-2043	143	20	analyses	analysis	NOUN
dpc-2043	143	21	across	across	ADP
dpc-2043	143	22	all	all	DET
dpc-2043	143	23	subgroups	subgroup	NOUN
dpc-2043	143	24	of	of	ADP
dpc-2043	143	25	patients	patient	NOUN
dpc-2043	143	26	.	.	PUNCT
dpc-2043	144	1	future	future	ADJ
dpc-2043	144	2	studies	study	NOUN
dpc-2043	144	3	with	with	ADP
dpc-2043	144	4	a	a	DET
dpc-2043	144	5	larger	large	ADJ
dpc-2043	144	6	sample	sample	NOUN
dpc-2043	144	7	size	size	NOUN
dpc-2043	144	8	should	should	AUX
dpc-2043	144	9	be	be	AUX
dpc-2043	144	10	conducted	conduct	VERB
dpc-2043	144	11	to	to	PART
dpc-2043	144	12	understand	understand	VERB
dpc-2043	144	13	the	the	DET
dpc-2043	144	14	etiopathogenic	etiopathogenic	ADJ
dpc-2043	144	15	roles	role	NOUN
dpc-2043	144	16	and	and	CCONJ
dpc-2043	144	17	the	the	DET
dpc-2043	144	18	potential	potential	ADJ
dpc-2043	144	19	therapeutic	therapeutic	ADJ
dpc-2043	144	20	benefits	benefit	NOUN
dpc-2043	144	21	of	of	ADP
dpc-2043	144	22	cu	cu	PROPN
dpc-2043	144	23	and	and	CCONJ
dpc-2043	144	24	zn	zn	PROPN
dpc-2043	144	25	supplementation	supplementation	NOUN
dpc-2043	144	26	for	for	ADP
dpc-2043	144	27	vitiligo	vitiligo	NOUN
dpc-2043	144	28	patients	patient	NOUN
dpc-2043	144	29	.	.	PUNCT
dpc-2043	145	1	these	these	DET
dpc-2043	145	2	trace	trace	NOUN
dpc-2043	145	3	elements	element	NOUN
dpc-2043	145	4	and	and	CCONJ
dpc-2043	145	5	the	the	DET
dpc-2043	145	6	pathogenesis	pathogenesis	NOUN
dpc-2043	145	7	of	of	ADP
dpc-2043	145	8	vitiligo	vitiligo	NOUN
dpc-2043	145	9	among	among	ADP
dpc-2043	145	10	a	a	DET
dpc-2043	145	11	group	group	NOUN
dpc-2043	145	12	of	of	ADP
dpc-2043	145	13	iranian	iranian	ADJ
dpc-2043	145	14	patients	patient	NOUN
dpc-2043	145	15	.	.	PUNCT
dpc-2043	146	1	in	in	ADP
dpc-2043	146	2	our	our	PRON
dpc-2043	146	3	study	study	NOUN
dpc-2043	146	4	,	,	PUNCT
dpc-2043	146	5	the	the	DET
dpc-2043	146	6	median	median	PROPN
dpc-2043	146	7	serum	serum	PROPN
dpc-2043	146	8	cu	cu	PROPN
dpc-2043	146	9	and	and	CCONJ
dpc-2043	146	10	zn	zn	PROPN
dpc-2043	146	11	levels	level	NOUN
dpc-2043	146	12	in	in	ADP
dpc-2043	146	13	both	both	CCONJ
dpc-2043	146	14	the	the	DET
dpc-2043	146	15	localized	localize	VERB
dpc-2043	146	16	(	(	PUNCT
dpc-2043	146	17	104.72	104.72	NUM
dpc-2043	146	18	and	and	CCONJ
dpc-2043	146	19	110.50	110.50	NUM
dpc-2043	146	20	µg	µg	NOUN
dpc-2043	146	21	/	/	SYM
dpc-2043	146	22	dl	dl	NOUN
dpc-2043	146	23	,	,	PUNCT
dpc-2043	146	24	respectively	respectively	ADV
dpc-2043	146	25	)	)	PUNCT
dpc-2043	146	26	and	and	CCONJ
dpc-2043	146	27	generalized	generalize	VERB
dpc-2043	146	28	vitiligo	vitiligo	NOUN
dpc-2043	146	29	patients	patient	NOUN
dpc-2043	146	30	(	(	PUNCT
dpc-2043	146	31	101.96	101.96	NUM
dpc-2043	146	32	and	and	CCONJ
dpc-2043	146	33	73.01	73.01	NUM
dpc-2043	146	34	µg	µg	NOUN
dpc-2043	146	35	/	/	SYM
dpc-2043	146	36	dl	dl	NOUN
dpc-2043	146	37	,	,	PUNCT
dpc-2043	146	38	respectively	respectively	ADV
dpc-2043	146	39	)	)	PUNCT
dpc-2043	146	40	were	be	AUX
dpc-2043	146	41	significantly	significantly	ADV
dpc-2043	146	42	less	less	ADJ
dpc-2043	146	43	than	than	ADP
dpc-2043	146	44	those	those	PRON
dpc-2043	146	45	in	in	ADP
dpc-2043	146	46	the	the	DET
dpc-2043	146	47	control	control	NOUN
dpc-2043	146	48	group	group	NOUN
dpc-2043	146	49	(	(	PUNCT
dpc-2043	146	50	138.58	138.58	NUM
dpc-2043	146	51	and	and	CCONJ
dpc-2043	146	52	118.42	118.42	NUM
dpc-2043	146	53	µg	µg	NOUN
dpc-2043	146	54	/	/	SYM
dpc-2043	146	55	dl	dl	NOUN
dpc-2043	146	56	,	,	PUNCT
dpc-2043	146	57	respectively	respectively	ADV
dpc-2043	146	58	)	)	PUNCT
dpc-2043	146	59	.	.	PUNCT
dpc-2043	147	1	compared	compare	VERB
dpc-2043	147	2	with	with	ADP
dpc-2043	147	3	the	the	DET
dpc-2043	147	4	control	control	NOUN
dpc-2043	147	5	group	group	NOUN
dpc-2043	147	6	,	,	PUNCT
dpc-2043	147	7	the	the	DET
dpc-2043	147	8	mean	mean	ADJ
dpc-2043	147	9	serum	serum	NOUN
dpc-2043	147	10	levels	level	NOUN
dpc-2043	147	11	of	of	ADP
dpc-2043	147	12	cu	cu	PROPN
dpc-2043	147	13	and	and	CCONJ
dpc-2043	147	14	zn	zn	PROPN
dpc-2043	147	15	in	in	ADP
dpc-2043	147	16	the	the	DET
dpc-2043	147	17	patients	patient	NOUN
dpc-2043	147	18	group	group	NOUN
dpc-2043	147	19	were	be	AUX
dpc-2043	147	20	also	also	ADV
dpc-2043	147	21	significantly	significantly	ADV
dpc-2043	147	22	decreased	decrease	VERB
dpc-2043	147	23	(	(	PUNCT
dpc-2043	147	24	p	p	X
dpc-2043	147	25	 	 	SPACE
dpc-2043	147	26	=	=	PUNCT
dpc-2043	147	27	0.00	0.00	NUM
dpc-2043	147	28	)	)	PUNCT
dpc-2043	147	29	(	(	PUNCT
dpc-2043	147	30	table	table	NOUN
dpc-2043	147	31	1	1	NUM
dpc-2043	147	32	)	)	PUNCT
dpc-2043	147	33	.	.	PUNCT
dpc-2043	148	1	the	the	DET
dpc-2043	148	2	mean	mean	ADJ
dpc-2043	148	3	serum	serum	NOUN
dpc-2043	148	4	concentrations	concentration	NOUN
dpc-2043	148	5	of	of	ADP
dpc-2043	148	6	both	both	DET
dpc-2043	148	7	trace	trace	NOUN
dpc-2043	148	8	elements	element	NOUN
dpc-2043	148	9	were	be	AUX
dpc-2043	148	10	significantly	significantly	ADV
dpc-2043	148	11	lower	low	ADJ
dpc-2043	148	12	in	in	ADP
dpc-2043	148	13	male	male	ADJ
dpc-2043	148	14	and	and	CCONJ
dpc-2043	148	15	female	female	ADJ
dpc-2043	148	16	vitiligo	vitiligo	NOUN
dpc-2043	148	17	patients	patient	NOUN
dpc-2043	148	18	,	,	PUNCT
dpc-2043	148	19	as	as	SCONJ
dpc-2043	148	20	compared	compare	VERB
dpc-2043	148	21	to	to	ADP
dpc-2043	148	22	their	their	PRON
dpc-2043	148	23	healthy	healthy	ADJ
dpc-2043	148	24	counterparts	counterpart	NOUN
dpc-2043	148	25	(	(	PUNCT
dpc-2043	148	26	table	table	NOUN
dpc-2043	148	27	  	  	SPACE
dpc-2043	148	28	1	1	NUM
dpc-2043	148	29	)	)	PUNCT
dpc-2043	148	30	.	.	PUNCT
dpc-2043	149	1	our	our	PRON
dpc-2043	149	2	results	result	NOUN
dpc-2043	149	3	are	be	AUX
dpc-2043	149	4	consistent	consistent	ADJ
dpc-2043	149	5	with	with	ADP
dpc-2043	149	6	the	the	DET
dpc-2043	149	7	findings	finding	NOUN
dpc-2043	149	8	of	of	ADP
dpc-2043	149	9	zeng	zeng	PROPN
dpc-2043	149	10	et	et	PROPN
dpc-2043	149	11	al	al	PROPN
dpc-2043	149	12	.	.	PROPN
dpc-2043	149	13	who	who	PRON
dpc-2043	149	14	reported	report	VERB
dpc-2043	149	15	a	a	DET
dpc-2043	149	16	significant	significant	ADJ
dpc-2043	149	17	reduction	reduction	NOUN
dpc-2043	149	18	in	in	ADP
dpc-2043	149	19	serum	serum	NOUN
dpc-2043	149	20	concentrations	concentration	NOUN
dpc-2043	149	21	of	of	ADP
dpc-2043	149	22	both	both	CCONJ
dpc-2043	149	23	cu	cu	PROPN
dpc-2043	149	24	and	and	CCONJ
dpc-2043	149	25	zn	zn	PROPN
dpc-2043	149	26	in	in	ADP
dpc-2043	149	27	chinese	chinese	ADJ
dpc-2043	149	28	vitiligo	vitiligo	NOUN
dpc-2043	149	29	patients	patient	NOUN
dpc-2043	149	30	[	[	X
dpc-2043	149	31	27	27	NUM
dpc-2043	149	32	]	]	PUNCT
dpc-2043	149	33	.	.	PUNCT
dpc-2043	150	1	since	since	SCONJ
dpc-2043	150	2	both	both	CCONJ
dpc-2043	150	3	the	the	DET
dpc-2043	150	4	increased	increase	VERB
dpc-2043	150	5	and	and	CCONJ
dpc-2043	150	6	decreased	decrease	VERB
dpc-2043	150	7	levels	level	NOUN
dpc-2043	150	8	of	of	ADP
dpc-2043	150	9	trace	trace	NOUN
dpc-2043	150	10	elements	element	NOUN
dpc-2043	150	11	can	can	AUX
dpc-2043	150	12	affect	affect	VERB
dpc-2043	150	13	the	the	DET
dpc-2043	150	14	activity	activity	NOUN
dpc-2043	150	15	of	of	ADP
dpc-2043	150	16	antioxidant	antioxidant	ADJ
dpc-2043	150	17	enzymes	enzyme	NOUN
dpc-2043	150	18	and	and	CCONJ
dpc-2043	150	19	oxidative	oxidative	ADJ
dpc-2043	150	20	stress	stress	NOUN
dpc-2043	150	21	,	,	PUNCT
dpc-2043	150	22	a	a	DET
dpc-2043	150	23	u	u	ADJ
dpc-2043	150	24	-	-	ADJ
dpc-2043	150	25	shaped	shape	VERB
dpc-2043	150	26	relation	relation	NOUN
dpc-2043	150	27	between	between	ADP
dpc-2043	150	28	zinc	zinc	NOUN
dpc-2043	150	29	and	and	CCONJ
dpc-2043	150	30	copper	copper	NOUN
dpc-2043	150	31	status	status	NOUN
dpc-2043	150	32	and	and	CCONJ
dpc-2043	150	33	optimal	optimal	ADJ
dpc-2043	150	34	health	health	NOUN
dpc-2043	150	35	condition	condition	NOUN
dpc-2043	150	36	has	have	AUX
dpc-2043	150	37	been	be	AUX
dpc-2043	150	38	proposed	propose	VERB
dpc-2043	150	39	[	[	X
dpc-2043	150	40	33	33	NUM
dpc-2043	150	41	]	]	PUNCT
dpc-2043	150	42	.	.	PUNCT
dpc-2043	151	1	thus	thus	ADV
dpc-2043	151	2	,	,	PUNCT
dpc-2043	151	3	the	the	DET
dpc-2043	151	4	conflicting	conflicting	ADJ
dpc-2043	151	5	reports	report	NOUN
dpc-2043	151	6	regarding	regard	VERB
dpc-2043	151	7	the	the	DET
dpc-2043	151	8	changes	change	NOUN
dpc-2043	151	9	in	in	ADP
dpc-2043	151	10	the	the	DET
dpc-2043	151	11	level	level	NOUN
dpc-2043	151	12	of	of	ADP
dpc-2043	151	13	these	these	DET
dpc-2043	151	14	trace	trace	NOUN
dpc-2043	151	15	elements	element	NOUN
dpc-2043	151	16	in	in	ADP
dpc-2043	151	17	vitiligo	vitiligo	NOUN
dpc-2043	151	18	might	might	AUX
dpc-2043	151	19	be	be	AUX
dpc-2043	151	20	true	true	ADJ
dpc-2043	151	21	findings	finding	NOUN
dpc-2043	151	22	.	.	PUNCT
dpc-2043	152	1	otherwise	otherwise	ADV
dpc-2043	152	2	,	,	PUNCT
dpc-2043	152	3	the	the	DET
dpc-2043	152	4	discordance	discordance	NOUN
dpc-2043	152	5	could	could	AUX
dpc-2043	152	6	be	be	AUX
dpc-2043	152	7	linked	link	VERB
dpc-2043	152	8	to	to	ADP
dpc-2043	152	9	the	the	DET
dpc-2043	152	10	sample	sample	NOUN
dpc-2043	152	11	size	size	NOUN
dpc-2043	152	12	,	,	PUNCT
dpc-2043	152	13	racial	racial	ADJ
dpc-2043	152	14	,	,	PUNCT
dpc-2043	152	15	or	or	CCONJ
dpc-2043	152	16	environmental	environmental	ADJ
dpc-2043	152	17	factors	factor	NOUN
dpc-2043	152	18	such	such	ADJ
dpc-2043	152	19	as	as	ADP
dpc-2043	152	20	diet	diet	PROPN
dpc-2043	152	21	variety	variety	NOUN
dpc-2043	152	22	.	.	PUNCT
dpc-2043	153	1	in	in	ADP
dpc-2043	153	2	our	our	PRON
dpc-2043	153	3	study	study	NOUN
dpc-2043	153	4	,	,	PUNCT
dpc-2043	153	5	the	the	DET
dpc-2043	153	6	mean	mean	ADJ
dpc-2043	153	7	concentration	concentration	NOUN
dpc-2043	153	8	of	of	ADP
dpc-2043	153	9	serum	serum	NOUN
dpc-2043	153	10	cu	cu	PROPN
dpc-2043	153	11	in	in	ADP
dpc-2043	153	12	smoker	smoker	ADJ
dpc-2043	153	13	patients	patient	NOUN
dpc-2043	153	14	(	(	PUNCT
dpc-2043	153	15	106.93	106.93	NUM
dpc-2043	153	16	±	±	NUM
dpc-2043	153	17	57.08	57.08	NUM
dpc-2043	153	18	µg	µg	PROPN
dpc-2043	153	19	/	/	SYM
dpc-2043	153	20	dl	dl	NOUN
dpc-2043	153	21	)	)	PUNCT
dpc-2043	153	22	was	be	AUX
dpc-2043	153	23	lower	low	ADJ
dpc-2043	153	24	,	,	PUNCT
dpc-2043	153	25	but	but	CCONJ
dpc-2043	153	26	the	the	DET
dpc-2043	153	27	mean	mean	ADJ
dpc-2043	153	28	zn	zn	PROPN
dpc-2043	153	29	levels	level	NOUN
dpc-2043	153	30	(	(	PUNCT
dpc-2043	153	31	99.67	99.67	NUM
dpc-2043	153	32	±	±	NUM
dpc-2043	153	33	59.49	59.49	NUM
dpc-2043	153	34	µg	µg	NOUN
dpc-2043	153	35	/	/	SYM
dpc-2043	153	36	dl	dl	NOUN
dpc-2043	153	37	)	)	PUNCT
dpc-2043	153	38	was	be	AUX
dpc-2043	153	39	higher	high	ADJ
dpc-2043	153	40	than	than	ADP
dpc-2043	153	41	those	those	PRON
dpc-2043	153	42	in	in	ADP
dpc-2043	153	43	non	non	ADJ
dpc-2043	153	44	-	-	ADJ
dpc-2043	153	45	smoker	smoker	ADJ
dpc-2043	153	46	patients	patient	NOUN
dpc-2043	153	47	(	(	PUNCT
dpc-2043	153	48	115.45	115.45	NUM
dpc-2043	153	49	±	±	NOUN
dpc-2043	153	50	60.20	60.20	NUM
dpc-2043	153	51	µg	µg	NOUN
dpc-2043	153	52	/	/	SYM
dpc-2043	153	53	dl	dl	PROPN
dpc-2043	153	54	and	and	CCONJ
dpc-2043	153	55	94.34±	94.34±	NUM
dpc-2043	153	56	59.50	59.50	NUM
dpc-2043	153	57	µg	µg	NOUN
dpc-2043	153	58	/	/	SYM
dpc-2043	153	59	dl	dl	NOUN
dpc-2043	153	60	,	,	PUNCT
dpc-2043	153	61	respectively	respectively	ADV
dpc-2043	153	62	)	)	PUNCT
dpc-2043	154	1	(	(	PUNCT
dpc-2043	154	2	p	p	NOUN
dpc-2043	154	3	≤	≤	NOUN
dpc-2043	154	4	0.05	0.05	NUM
dpc-2043	154	5	)	)	PUNCT
dpc-2043	154	6	.	.	PUNCT
dpc-2043	155	1	it	it	PRON
dpc-2043	155	2	has	have	AUX
dpc-2043	155	3	been	be	AUX
dpc-2043	155	4	suggested	suggest	VERB
dpc-2043	155	5	that	that	SCONJ
dpc-2043	155	6	there	there	PRON
dpc-2043	155	7	is	be	VERB
dpc-2043	155	8	a	a	DET
dpc-2043	155	9	close	close	ADJ
dpc-2043	155	10	relation	relation	NOUN
dpc-2043	155	11	between	between	ADP
dpc-2043	155	12	cu	cu	PROPN
dpc-2043	155	13	/	/	SYM
dpc-2043	155	14	zn	zn	PROPN
dpc-2043	155	15	ratio	ratio	NOUN
dpc-2043	155	16	and	and	CCONJ
dpc-2043	155	17	systemic	systemic	ADJ
dpc-2043	155	18	oxidative	oxidative	ADJ
dpc-2043	155	19	state	state	NOUN
dpc-2043	155	20	and	and	CCONJ
dpc-2043	155	21	the	the	DET
dpc-2043	155	22	balance	balance	NOUN
dpc-2043	155	23	between	between	ADP
dpc-2043	155	24	serum	serum	PROPN
dpc-2043	155	25	cu	cu	PROPN
dpc-2043	155	26	and	and	CCONJ
dpc-2043	155	27	zn	zn	PROPN
dpc-2043	155	28	is	be	AUX
dpc-2043	155	29	clinically	clinically	ADV
dpc-2043	155	30	more	more	ADV
dpc-2043	155	31	important	important	ADJ
dpc-2043	155	32	than	than	ADP
dpc-2043	155	33	their	their	PRON
dpc-2043	155	34	concentrations	concentration	NOUN
dpc-2043	155	35	in	in	ADP
dpc-2043	155	36	serum	serum	NOUN
dpc-2043	156	1	[	[	X
dpc-2043	156	2	17,34	17,34	NUM
dpc-2043	156	3	]	]	PUNCT
dpc-2043	156	4	.	.	PUNCT
dpc-2043	157	1	wacewicz	wacewicz	AUX
dpc-2043	157	2	et	et	PROPN
dpc-2043	157	3	al	al	PROPN
dpc-2043	157	4	found	find	VERB
dpc-2043	157	5	a	a	DET
dpc-2043	157	6	significantly	significantly	ADV
dpc-2043	157	7	higher	high	ADJ
dpc-2043	157	8	cu	cu	PROPN
dpc-2043	157	9	/	/	SYM
dpc-2043	157	10	zn	zn	PROPN
dpc-2043	157	11	ratio	ratio	NOUN
dpc-2043	157	12	in	in	ADP
dpc-2043	157	13	the	the	DET
dpc-2043	157	14	serum	serum	NOUN
dpc-2043	157	15	of	of	ADP
dpc-2043	157	16	vitiligo	vitiligo	ADJ
dpc-2043	157	17	patients	patient	NOUN
dpc-2043	157	18	as	as	SCONJ
dpc-2043	157	19	compared	compare	VERB
dpc-2043	157	20	to	to	ADP
dpc-2043	157	21	healthy	healthy	ADJ
dpc-2043	157	22	controls	control	NOUN
dpc-2043	157	23	[	[	X
dpc-2043	157	24	35	35	NUM
dpc-2043	157	25	]	]	PUNCT
dpc-2043	157	26	.	.	PUNCT
dpc-2043	158	1	a	a	DET
dpc-2043	158	2	previous	previous	ADJ
dpc-2043	158	3	study	study	NOUN
dpc-2043	158	4	on	on	ADP
dpc-2043	158	5	151	151	NUM
dpc-2043	158	6	cases	case	NOUN
dpc-2043	158	7	of	of	ADP
dpc-2043	158	8	three	three	NUM
dpc-2043	158	9	groups	group	NOUN
dpc-2043	158	10	of	of	ADP
dpc-2043	158	11	skin	skin	NOUN
dpc-2043	158	12	diseases	disease	NOUN
dpc-2043	158	13	including	include	VERB
dpc-2043	158	14	skin	skin	NOUN
dpc-2043	158	15	cancer	cancer	NOUN
dpc-2043	158	16	,	,	PUNCT
dpc-2043	158	17	inflammatory	inflammatory	ADJ
dpc-2043	158	18	,	,	PUNCT
dpc-2043	158	19	and	and	CCONJ
dpc-2043	158	20	non	non	ADJ
dpc-2043	158	21	-	-	ADJ
dpc-2043	158	22	inflammatory	inflammatory	ADJ
dpc-2043	158	23	diseases	disease	NOUN
dpc-2043	158	24	reported	report	VERB
dpc-2043	158	25	that	that	SCONJ
dpc-2043	158	26	the	the	DET
dpc-2043	158	27	serum	serum	NOUN
dpc-2043	158	28	cu/	cu/	VERB
dpc-2043	158	29	zn	zn	PROPN
dpc-2043	158	30	ratio	ratio	NOUN
dpc-2043	158	31	among	among	ADP
dpc-2043	158	32	examined	examined	ADJ
dpc-2043	158	33	patients	patient	NOUN
dpc-2043	158	34	was	be	AUX
dpc-2043	158	35	higher	high	ADJ
dpc-2043	158	36	than	than	ADP
dpc-2043	158	37	the	the	DET
dpc-2043	158	38	control	control	NOUN
dpc-2043	158	39	group	group	NOUN
dpc-2043	158	40	and	and	CCONJ
dpc-2043	158	41	reflected	reflect	VERB
dpc-2043	158	42	the	the	DET
dpc-2043	158	43	clinical	clinical	ADJ
dpc-2043	158	44	severity	severity	NOUN
dpc-2043	158	45	in	in	ADP
dpc-2043	158	46	each	each	DET
dpc-2043	158	47	disease	disease	NOUN
dpc-2043	158	48	group	group	NOUN
dpc-2043	158	49	[	[	X
dpc-2043	158	50	36	36	NUM
dpc-2043	158	51	]	]	PUNCT
dpc-2043	158	52	.	.	PUNCT
dpc-2043	159	1	we	we	PRON
dpc-2043	159	2	also	also	ADV
dpc-2043	159	3	found	find	VERB
dpc-2043	159	4	a	a	DET
dpc-2043	159	5	higher	high	ADJ
dpc-2043	159	6	cu	cu	PROPN
dpc-2043	159	7	/	/	SYM
dpc-2043	159	8	zn	zn	PROPN
dpc-2043	159	9	ratio	ratio	NOUN
dpc-2043	159	10	among	among	ADP
dpc-2043	159	11	vitiligo	vitiligo	NOUN
dpc-2043	159	12	patients	patient	NOUN
dpc-2043	159	13	(	(	PUNCT
dpc-2043	159	14	1.81	1.81	NUM
dpc-2043	159	15	±	±	NUM
dpc-2043	159	16	1.90	1.90	NUM
dpc-2043	159	17	)	)	PUNCT
dpc-2043	159	18	than	than	ADP
dpc-2043	159	19	healthy	healthy	ADJ
dpc-2043	159	20	controls	control	NOUN
dpc-2043	159	21	(	(	PUNCT
dpc-2043	159	22	1.28	1.28	NUM
dpc-2043	159	23	±	±	NUM
dpc-2043	159	24	0.573	0.573	NUM
dpc-2043	159	25	)	)	PUNCT
dpc-2043	159	26	,	,	PUNCT
dpc-2043	159	27	but	but	CCONJ
dpc-2043	159	28	the	the	DET
dpc-2043	159	29	difference	difference	NOUN
dpc-2043	159	30	was	be	AUX
dpc-2043	159	31	not	not	PART
dpc-2043	159	32	statically	statically	ADV
dpc-2043	159	33	significant	significant	ADJ
dpc-2043	159	34	(	(	PUNCT
dpc-2043	159	35	p	p	X
dpc-2043	159	36	=	=	NOUN
dpc-2043	159	37	0.49	0.49	NUM
dpc-2043	159	38	,	,	PUNCT
dpc-2043	159	39	table	table	NOUN
dpc-2043	159	40	1	1	NUM
dpc-2043	159	41	)	)	PUNCT
dpc-2043	159	42	.	.	PUNCT
dpc-2043	160	1	we	we	PRON
dpc-2043	160	2	observed	observe	VERB
dpc-2043	160	3	a	a	DET
dpc-2043	160	4	higher	high	ADJ
dpc-2043	160	5	serum	serum	NOUN
dpc-2043	160	6	cu	cu	PROPN
dpc-2043	160	7	/	/	SYM
dpc-2043	160	8	zn	zn	PROPN
dpc-2043	160	9	ratio	ratio	NOUN
dpc-2043	160	10	in	in	ADP
dpc-2043	160	11	young	young	ADJ
dpc-2043	160	12	(	(	PUNCT
dpc-2043	160	13	1.96	1.96	NUM
dpc-2043	160	14	±	±	NUM
dpc-2043	160	15	2.09	2.09	NUM
dpc-2043	160	16	)	)	PUNCT
dpc-2043	160	17	and	and	CCONJ
dpc-2043	160	18	male	male	ADJ
dpc-2043	160	19	cases	case	NOUN
dpc-2043	160	20	(	(	PUNCT
dpc-2043	160	21	1.67	1.67	NUM
dpc-2043	160	22	±	±	NUM
dpc-2043	160	23	1.48	1.48	NUM
dpc-2043	160	24	)	)	PUNCT
dpc-2043	160	25	,	,	PUNCT
dpc-2043	160	26	as	as	SCONJ
dpc-2043	160	27	compared	compare	VERB
dpc-2043	160	28	to	to	ADP
dpc-2043	160	29	their	their	PRON
dpc-2043	160	30	healthy	healthy	ADJ
dpc-2043	160	31	counterparts	counterpart	NOUN
dpc-2043	160	32	(	(	PUNCT
dpc-2043	160	33	1.24	1.24	NUM
dpc-2043	160	34	±	±	NUM
dpc-2043	160	35	0.438	0.438	NUM
dpc-2043	160	36	and	and	CCONJ
dpc-2043	160	37	1.11	1.11	NUM
dpc-2043	160	38	±	±	NUM
dpc-2043	160	39	0.358	0.358	NOUN
dpc-2043	160	40	,	,	PUNCT
dpc-2043	160	41	respectively	respectively	ADV
dpc-2043	160	42	)	)	PUNCT
dpc-2043	160	43	(	(	PUNCT
dpc-2043	160	44	p	p	X
dpc-2043	160	45	=	=	NOUN
dpc-2043	160	46	0.01	0.01	NUM
dpc-2043	160	47	)	)	PUNCT
dpc-2043	160	48	.	.	PUNCT
dpc-2043	161	1	a	a	DET
dpc-2043	161	2	linear	linear	ADJ
dpc-2043	161	3	regression	regression	NOUN
dpc-2043	161	4	analysis	analysis	NOUN
dpc-2043	161	5	showed	show	VERB
dpc-2043	161	6	positive	positive	ADJ
dpc-2043	161	7	correlations	correlation	NOUN
dpc-2043	161	8	between	between	ADP
dpc-2043	161	9	serum	serum	PROPN
dpc-2043	161	10	cu	cu	PROPN
dpc-2043	161	11	and	and	CCONJ
dpc-2043	161	12	the	the	DET
dpc-2043	161	13	early	early	ADJ
dpc-2043	161	14	age	age	NOUN
dpc-2043	161	15	of	of	ADP
dpc-2043	161	16	onset	onset	NOUN
dpc-2043	161	17	(	(	PUNCT
dpc-2043	161	18	r	r	NOUN
dpc-2043	161	19	=	=	NOUN
dpc-2043	161	20	0.251	0.251	NUM
dpc-2043	161	21	,	,	PUNCT
dpc-2043	161	22	p	p	X
dpc-2043	161	23	  	  	SPACE
dpc-2043	161	24	=	=	NOUN
dpc-2043	161	25	  	  	SPACE
dpc-2043	161	26	0.039	0.039	NUM
dpc-2043	161	27	)	)	PUNCT
dpc-2043	161	28	and	and	CCONJ
dpc-2043	161	29	the	the	DET
dpc-2043	161	30	segmental	segmental	ADJ
dpc-2043	161	31	type	type	NOUN
dpc-2043	161	32	of	of	ADP
dpc-2043	161	33	the	the	DET
dpc-2043	161	34	disease	disease	NOUN
dpc-2043	161	35	(	(	PUNCT
dpc-2043	161	36	r	r	NOUN
dpc-2043	161	37	=	=	NOUN
dpc-2043	161	38	0.2	0.2	NUM
dpc-2043	161	39	,	,	PUNCT
dpc-2043	161	40	p	p	NOUN
dpc-2043	161	41	=	=	NOUN
dpc-2043	161	42	 	 	SPACE
dpc-2043	161	43	0.045	0.045	NUM
dpc-2043	161	44	)	)	PUNCT
dpc-2043	161	45	(	(	PUNCT
dpc-2043	161	46	table	table	NOUN
dpc-2043	161	47	3	3	NUM
dpc-2043	161	48	)	)	PUNCT
dpc-2043	161	49	.	.	PUNCT
dpc-2043	162	1	a	a	DET
dpc-2043	162	2	significant	significant	ADJ
dpc-2043	162	3	positive	positive	ADJ
dpc-2043	162	4	correlation	correlation	NOUN
dpc-2043	162	5	was	be	AUX
dpc-2043	162	6	also	also	ADV
dpc-2043	162	7	observed	observe	VERB
dpc-2043	162	8	between	between	ADP
dpc-2043	162	9	serum	serum	PROPN
dpc-2043	162	10	cu	cu	PROPN
dpc-2043	162	11	concentrations	concentration	NOUN
dpc-2043	162	12	and	and	CCONJ
dpc-2043	162	13	the	the	DET
dpc-2043	162	14	duration	duration	NOUN
dpc-2043	162	15	of	of	ADP
dpc-2043	162	16	disease	disease	NOUN
dpc-2043	162	17	,	,	PUNCT
dpc-2043	162	18	especially	especially	ADV
dpc-2043	162	19	in	in	ADP
dpc-2043	162	20	the	the	DET
dpc-2043	162	21	female	female	ADJ
dpc-2043	162	22	patients	patient	NOUN
dpc-2043	162	23	(	(	PUNCT
dpc-2043	162	24	r=0.225	r=0.225	X
dpc-2043	162	25	,	,	PUNCT
dpc-2043	162	26	p	p	X
dpc-2043	162	27	=	=	NOUN
dpc-2043	162	28	0.034	0.034	NUM
dpc-2043	162	29	)	)	PUNCT
dpc-2043	162	30	.	.	PUNCT
dpc-2043	163	1	no	no	DET
dpc-2043	163	2	significant	significant	ADJ
dpc-2043	163	3	correlation	correlation	NOUN
dpc-2043	163	4	was	be	AUX
dpc-2043	163	5	observed	observe	VERB
dpc-2043	163	6	between	between	ADP
dpc-2043	163	7	original	original	ADJ
dpc-2043	163	8	article	article	NOUN
dpc-2043	163	9	|	|	ADV
dpc-2043	163	10	dermatol	dermatol	ADJ
dpc-2043	163	11	pract	pract	NOUN
dpc-2043	163	12	concept	concept	NOUN
dpc-2043	163	13	.	.	PUNCT
dpc-2043	164	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	164	2	7	7	NUM
dpc-2043	164	3	med	med	PROPN
dpc-2043	164	4	(	(	PUNCT
dpc-2043	164	5	lausanne	lausanne	PROPN
dpc-2043	164	6	)	)	PUNCT
dpc-2043	164	7	.	.	PUNCT
dpc-2043	165	1	2020;7:183	2020;7:183	NUM
dpc-2043	165	2	.	.	PUNCT
dpc-2043	165	3	doi:10.3389	doi:10.3389	PROPN
dpc-2043	165	4	/	/	SYM
dpc-2043	165	5	fmed.2020.00183	fmed.2020.00183	PROPN
dpc-2043	165	6	.	.	PUNCT
dpc-2043	166	1	pmid	pmid	NOUN
dpc-2043	166	2	:	:	PUNCT
dpc-2043	166	3	32478084	32478084	NUM
dpc-2043	166	4	.	.	PUNCT
dpc-2043	167	1	pmcid	pmcid	NOUN
dpc-2043	167	2	:	:	PUNCT
dpc-2043	167	3	pmc7235401	pmc7235401	NOUN
dpc-2043	167	4	.	.	PUNCT
dpc-2043	168	1	16	16	NUM
dpc-2043	168	2	.	.	PUNCT
dpc-2043	169	1	khoshdel	khoshdel	PROPN
dpc-2043	169	2	z	z	PROPN
dpc-2043	169	3	,	,	PUNCT
dpc-2043	169	4	naghibalhossaini	naghibalhossaini	PROPN
dpc-2043	169	5	f	f	PROPN
dpc-2043	169	6	,	,	PUNCT
dpc-2043	169	7	abdollahi	abdollahi	PROPN
dpc-2043	169	8	k	k	NOUN
dpc-2043	169	9	,	,	PUNCT
dpc-2043	169	10	shojaei	shojaei	NOUN
dpc-2043	169	11	s	s	NOUN
dpc-2043	169	12	,	,	PUNCT
dpc-2043	169	13	moradi	moradi	NOUN
dpc-2043	169	14	m	m	PROPN
dpc-2043	169	15	,	,	PUNCT
dpc-2043	169	16	malekzadeh	malekzadeh	PROPN
dpc-2043	169	17	m.	m.	NOUN
dpc-2043	169	18	serum	serum	PROPN
dpc-2043	169	19	copper	copper	PROPN
dpc-2043	169	20	and	and	CCONJ
dpc-2043	169	21	zinc	zinc	NOUN
dpc-2043	169	22	levels	level	NOUN
dpc-2043	169	23	among	among	ADP
dpc-2043	169	24	iranian	iranian	ADJ
dpc-2043	169	25	colorectal	colorectal	ADJ
dpc-2043	169	26	cancer	cancer	NOUN
dpc-2043	169	27	patients	patient	NOUN
dpc-2043	169	28	.	.	PUNCT
dpc-2043	170	1	biol	biol	PROPN
dpc-2043	170	2	trace	trace	NOUN
dpc-2043	170	3	elem	elem	NOUN
dpc-2043	170	4	res	re	NOUN
dpc-2043	170	5	.	.	PUNCT
dpc-2043	171	1	2016;170(2):294	2016;170(2):294	NUM
dpc-2043	171	2	-	-	SYM
dpc-2043	171	3	299	299	NUM
dpc-2043	171	4	.	.	PUNCT
dpc-2043	172	1	doi	doi	NOUN
dpc-2043	172	2	:	:	PUNCT
dpc-2043	172	3	10.1007	10.1007	NUM
dpc-2043	172	4	/	/	SYM
dpc-2043	172	5	s12011	s12011	NOUN
dpc-2043	172	6	-	-	PUNCT
dpc-2043	172	7	015	015	NUM
dpc-2043	172	8	-	-	NOUN
dpc-2043	172	9	0483	0483	NUM
dpc-2043	172	10	-	-	PUNCT
dpc-2043	172	11	4	4	NUM
dpc-2043	172	12	.	.	PUNCT
dpc-2043	173	1	pmid	pmid	NOUN
dpc-2043	173	2	:	:	PUNCT
dpc-2043	173	3	26329996.17	26329996.17	NUM
dpc-2043	173	4	.	.	PUNCT
dpc-2043	173	5	osredkar	osredkar	PROPN
dpc-2043	173	6	j	j	PROPN
dpc-2043	173	7	,	,	PUNCT
dpc-2043	173	8	sustar	sustar	PROPN
dpc-2043	173	9	n.	n.	PROPN
dpc-2043	173	10	copper	copper	PROPN
dpc-2043	173	11	and	and	CCONJ
dpc-2043	173	12	zinc	zinc	NOUN
dpc-2043	173	13	,	,	PUNCT
dpc-2043	173	14	biological	biological	ADJ
dpc-2043	173	15	role	role	NOUN
dpc-2043	173	16	and	and	CCONJ
dpc-2043	173	17	significance	significance	NOUN
dpc-2043	173	18	of	of	ADP
dpc-2043	173	19	copper	copper	NOUN
dpc-2043	173	20	/	/	SYM
dpc-2043	173	21	zinc	zinc	NOUN
dpc-2043	173	22	imbalance	imbalance	NOUN
dpc-2043	173	23	.	.	PUNCT
dpc-2043	174	1	j	j	PROPN
dpc-2043	174	2	clinic	clinic	PROPN
dpc-2043	174	3	toxicol	toxicol	PROPN
dpc-2043	174	4	.	.	PUNCT
dpc-2043	175	1	2011;s3:001	2011;s3:001	NUM
dpc-2043	175	2	.	.	PUNCT
dpc-2043	176	1	doi:10.4172/2161	doi:10.4172/2161	VERB
dpc-2043	176	2	-	-	PUNCT
dpc-2043	176	3	0495.s3	0495.s3	NOUN
dpc-2043	176	4	-	-	PUNCT
dpc-2043	176	5	001	001	NUM
dpc-2043	176	6	17	17	NUM
dpc-2043	176	7	.	.	PUNCT
dpc-2043	177	1	hassan	hassan	PROPN
dpc-2043	177	2	mi	mi	PROPN
dpc-2043	177	3	,	,	PUNCT
dpc-2043	177	4	waheed	waheed	PROPN
dpc-2043	177	5	a	a	PROPN
dpc-2043	177	6	,	,	PUNCT
dpc-2043	177	7	yadav	yadav	PROPN
dpc-2043	177	8	s	s	PROPN
dpc-2043	177	9	,	,	PUNCT
dpc-2043	177	10	singh	singh	PROPN
dpc-2043	177	11	tp	tp	PROPN
dpc-2043	177	12	,	,	PUNCT
dpc-2043	177	13	ahmad	ahmad	PROPN
dpc-2043	177	14	f.	f.	PROPN
dpc-2043	177	15	zinc	zinc	PROPN
dpc-2043	177	16	alpha	alpha	NOUN
dpc-2043	177	17	2	2	NUM
dpc-2043	177	18	-	-	PUNCT
dpc-2043	177	19	glycoprotein	glycoprotein	NOUN
dpc-2043	177	20	:	:	PUNCT
dpc-2043	177	21	a	a	DET
dpc-2043	177	22	multidisciplinary	multidisciplinary	ADJ
dpc-2043	177	23	protein	protein	NOUN
dpc-2043	177	24	.	.	PUNCT
dpc-2043	178	1	mol	mol	ADP
dpc-2043	178	2	cancer	cancer	NOUN
dpc-2043	178	3	res	re	NOUN
dpc-2043	178	4	.	.	PUNCT
dpc-2043	178	5	2008	2008	NUM
dpc-2043	178	6	;	;	PUNCT
dpc-2043	179	1	6(6):892	6(6):892	NUM
dpc-2043	179	2	-	-	SYM
dpc-2043	179	3	906	906	NUM
dpc-2043	179	4	.	.	PUNCT
dpc-2043	180	1	doi	doi	NOUN
dpc-2043	180	2	:	:	PUNCT
dpc-2043	180	3	10.1158/1541	10.1158/1541	NUM
dpc-2043	180	4	-	-	PUNCT
dpc-2043	180	5	7786.mcr-07	7786.mcr-07	NUM
dpc-2043	180	6	-	-	PUNCT
dpc-2043	180	7	2195	2195	NUM
dpc-2043	180	8	.	.	PUNCT
dpc-2043	181	1	pmid	pmid	NOUN
dpc-2043	181	2	:	:	PUNCT
dpc-2043	181	3	18567794	18567794	NUM
dpc-2043	181	4	.	.	PUNCT
dpc-2043	182	1	18	18	NUM
dpc-2043	182	2	.	.	X
dpc-2043	182	3	tsiskarishvili	tsiskarishvili	NOUN
dpc-2043	182	4	n.	n.	NOUN
dpc-2043	182	5	cuprum	cuprum	PROPN
dpc-2043	182	6	sulfate	sulfate	NOUN
dpc-2043	182	7	and	and	CCONJ
dpc-2043	182	8	vitix	vitix	NOUN
dpc-2043	182	9	in	in	ADP
dpc-2043	182	10	the	the	DET
dpc-2043	182	11	treatment	treatment	NOUN
dpc-2043	182	12	of	of	ADP
dpc-2043	182	13	vitiligo	vitiligo	NOUN
dpc-2043	182	14	in	in	ADP
dpc-2043	182	15	children	child	NOUN
dpc-2043	182	16	.	.	PUNCT
dpc-2043	183	1	georgian	georgian	PROPN
dpc-2043	183	2	med	med	PROPN
dpc-2043	183	3	news	news	PROPN
dpc-2043	183	4	.	.	PUNCT
dpc-2043	184	1	2005;121:48	2005;121:48	NUM
dpc-2043	184	2	-	-	SYM
dpc-2043	184	3	51	51	NUM
dpc-2043	184	4	.	.	PUNCT
dpc-2043	185	1	pmid	pmid	NOUN
dpc-2043	185	2	:	:	PUNCT
dpc-2043	185	3	15908724	15908724	NUM
dpc-2043	185	4	.	.	PUNCT
dpc-2043	186	1	19	19	NUM
dpc-2043	186	2	.	.	X
dpc-2043	186	3	jalel	jalel	VERB
dpc-2043	186	4	a	a	PRON
dpc-2043	186	5	,	,	PUNCT
dpc-2043	186	6	soumaya	soumaya	PROPN
dpc-2043	186	7	gs	gs	PROPN
dpc-2043	186	8	,	,	PUNCT
dpc-2043	186	9	hamdaoui	hamdaoui	PROPN
dpc-2043	186	10	mh	mh	PROPN
dpc-2043	186	11	.	.	PUNCT
dpc-2043	187	1	vitiligo	vitiligo	PROPN
dpc-2043	187	2	treatment	treatment	NOUN
dpc-2043	187	3	with	with	ADP
dpc-2043	187	4	vitamins	vitamin	NOUN
dpc-2043	187	5	,	,	PUNCT
dpc-2043	187	6	minerals	mineral	NOUN
dpc-2043	187	7	and	and	CCONJ
dpc-2043	187	8	polyphenol	polyphenol	NOUN
dpc-2043	187	9	supplementation	supplementation	NOUN
dpc-2043	187	10	.	.	PUNCT
dpc-2043	188	1	indian	indian	PROPN
dpc-2043	188	2	j	j	PROPN
dpc-2043	188	3	dermatol	dermatol	NOUN
dpc-2043	188	4	.	.	PUNCT
dpc-2043	189	1	2009	2009	NUM
dpc-2043	189	2	;	;	PUNCT
dpc-2043	189	3	54(4):357	54(4):357	NUM
dpc-2043	189	4	-	-	PUNCT
dpc-2043	189	5	360	360	NUM
dpc-2043	189	6	.	.	PUNCT
dpc-2043	190	1	doi	doi	NOUN
dpc-2043	190	2	:	:	PUNCT
dpc-2043	190	3	10.4103/0019	10.4103/0019	NUM
dpc-2043	190	4	-	-	SYM
dpc-2043	190	5	5154.57613	5154.57613	NUM
dpc-2043	190	6	.	.	PUNCT
dpc-2043	191	1	pmid	pmid	NOUN
dpc-2043	191	2	:	:	PUNCT
dpc-2043	191	3	20101338	20101338	NUM
dpc-2043	191	4	.	.	PUNCT
dpc-2043	192	1	pmcid	pmcid	NOUN
dpc-2043	192	2	:	:	PUNCT
dpc-2043	192	3	pmc2807713	pmc2807713	NOUN
dpc-2043	192	4	.	.	PUNCT
dpc-2043	193	1	20	20	NUM
dpc-2043	193	2	.	.	PUNCT
dpc-2043	194	1	shameer	shameer	PROPN
dpc-2043	194	2	p	p	PROPN
dpc-2043	194	3	,	,	PUNCT
dpc-2043	194	4	prasad	prasad	PROPN
dpc-2043	194	5	pv	pv	NOUN
dpc-2043	194	6	,	,	PUNCT
dpc-2043	194	7	kaviarasan	kaviarasan	PROPN
dpc-2043	194	8	pk	pk	PROPN
dpc-2043	194	9	.	.	PROPN
dpc-2043	194	10	serum	serum	PROPN
dpc-2043	194	11	zinc	zinc	NOUN
dpc-2043	194	12	level	level	NOUN
dpc-2043	194	13	in	in	ADP
dpc-2043	194	14	vitiligo	vitiligo	NOUN
dpc-2043	194	15	:	:	PUNCT
dpc-2043	194	16	a	a	DET
dpc-2043	194	17	case	case	NOUN
dpc-2043	194	18	control	control	NOUN
dpc-2043	194	19	study	study	NOUN
dpc-2043	194	20	.	.	PUNCT
dpc-2043	195	1	indian	indian	PROPN
dpc-2043	195	2	j	j	PROPN
dpc-2043	195	3	dermatol	dermatol	PROPN
dpc-2043	195	4	venereol	venereol	ADJ
dpc-2043	195	5	leprol	leprol	NOUN
dpc-2043	195	6	.	.	PUNCT
dpc-2043	196	1	2005;71(3):206	2005;71(3):206	NOUN
dpc-2043	196	2	-	-	PUNCT
dpc-2043	196	3	207	207	NUM
dpc-2043	196	4	.	.	PUNCT
dpc-2043	197	1	doi	doi	NOUN
dpc-2043	197	2	:	:	PUNCT
dpc-2043	197	3	10.4103/0378	10.4103/0378	NUM
dpc-2043	197	4	-	-	PUNCT
dpc-2043	197	5	6323.16243	6323.16243	NUM
dpc-2043	197	6	.	.	PUNCT
dpc-2043	198	1	pmid	pmid	NOUN
dpc-2043	198	2	:	:	PUNCT
dpc-2043	198	3	16394417	16394417	NUM
dpc-2043	198	4	.	.	PUNCT
dpc-2043	199	1	21	21	NUM
dpc-2043	199	2	.	.	PUNCT
dpc-2043	200	1	arora	arora	PROPN
dpc-2043	200	2	pn	pn	PROPN
dpc-2043	200	3	,	,	PUNCT
dpc-2043	200	4	dhillon	dhillon	PROPN
dpc-2043	200	5	ks	ks	PROPN
dpc-2043	200	6	,	,	PUNCT
dpc-2043	200	7	rajan	rajan	PROPN
dpc-2043	200	8	sr	sr	PROPN
dpc-2043	200	9	,	,	PUNCT
dpc-2043	200	10	sayal	sayal	PROPN
dpc-2043	200	11	sk	sk	PROPN
dpc-2043	200	12	,	,	PUNCT
dpc-2043	200	13	das	das	PROPN
dpc-2043	200	14	al	al	PROPN
dpc-2043	200	15	.	.	PROPN
dpc-2043	200	16	serum	serum	PROPN
dpc-2043	200	17	zinc	zinc	NOUN
dpc-2043	200	18	levels	level	NOUN
dpc-2043	200	19	in	in	ADP
dpc-2043	200	20	cutaneous	cutaneous	ADJ
dpc-2043	200	21	disorders	disorder	NOUN
dpc-2043	200	22	.	.	PUNCT
dpc-2043	201	1	med	med	PROPN
dpc-2043	201	2	j	j	PROPN
dpc-2043	201	3	armed	armed	PROPN
dpc-2043	201	4	forces	forces	PROPN
dpc-2043	201	5	india	india	PROPN
dpc-2043	201	6	.	.	PUNCT
dpc-2043	201	7	2002	2002	NUM
dpc-2043	201	8	;	;	PUNCT
dpc-2043	201	9	58(4):304	58(4):304	NUM
dpc-2043	201	10	-	-	SYM
dpc-2043	201	11	306	306	NUM
dpc-2043	201	12	.	.	PUNCT
dpc-2043	202	1	doi	doi	NOUN
dpc-2043	202	2	:	:	PUNCT
dpc-2043	202	3	10.1016	10.1016	NUM
dpc-2043	202	4	/	/	SYM
dpc-2043	202	5	s0377	s0377	NOUN
dpc-2043	202	6	-	-	PUNCT
dpc-2043	202	7	1237(02)80083	1237(02)80083	NUM
dpc-2043	202	8	-	-	PUNCT
dpc-2043	202	9	1	1	NUM
dpc-2043	202	10	.	.	PUNCT
dpc-2043	203	1	pmid	pmid	NOUN
dpc-2043	203	2	:	:	PUNCT
dpc-2043	203	3	27407419	27407419	NUM
dpc-2043	203	4	.	.	PUNCT
dpc-2043	204	1	pmcid	pmcid	NOUN
dpc-2043	204	2	:	:	PUNCT
dpc-2043	204	3	pmc4925128	pmc4925128	ADV
dpc-2043	204	4	.	.	PUNCT
dpc-2043	205	1	22	22	NUM
dpc-2043	205	2	.	.	PUNCT
dpc-2043	206	1	haider	haider	PROPN
dpc-2043	206	2	n	n	CCONJ
dpc-2043	206	3	,	,	PUNCT
dpc-2043	206	4	islam	islam	PROPN
dpc-2043	206	5	ms	ms	PROPN
dpc-2043	206	6	,	,	PUNCT
dpc-2043	206	7	maruf	maruf	ADJ
dpc-2043	206	8	aa	aa	PROPN
dpc-2043	206	9	,	,	PUNCT
dpc-2043	206	10	et	et	PROPN
dpc-2043	206	11	al	al	PROPN
dpc-2043	206	12	.	.	PROPN
dpc-2043	206	13	oxidative	oxidative	ADJ
dpc-2043	206	14	stress	stress	NOUN
dpc-2043	206	15	and	and	CCONJ
dpc-2043	206	16	antioxidant	antioxidant	ADJ
dpc-2043	206	17	status	status	NOUN
dpc-2043	206	18	in	in	ADP
dpc-2043	206	19	vitiligo	vitiligo	NOUN
dpc-2043	206	20	patients	patient	NOUN
dpc-2043	206	21	.	.	PUNCT
dpc-2043	207	1	dhaka	dhaka	PROPN
dpc-2043	207	2	univ	univ	PROPN
dpc-2043	207	3	j	j	PROPN
dpc-2043	207	4	pharm	pharm	PROPN
dpc-2043	207	5	sci	sci	PROPN
dpc-2043	207	6	.	.	PUNCT
dpc-2043	208	1	2010;9:103–108	2010;9:103–108	X
dpc-2043	208	2	.	.	PUNCT
dpc-2043	209	1	doi	doi	NOUN
dpc-2043	209	2	:	:	PUNCT
dpc-2043	209	3	10.3329	10.3329	NUM
dpc-2043	209	4	/	/	SYM
dpc-2043	209	5	dujps.v9i2.7894	dujps.v9i2.7894	PROPN
dpc-2043	209	6	.	.	PROPN
dpc-2043	209	7	23	23	NUM
dpc-2043	209	8	.	.	PUNCT
dpc-2043	210	1	muawia	muawia	PROPN
dpc-2043	210	2	m	m	PROPN
dpc-2043	210	3	,	,	PUNCT
dpc-2043	210	4	h	h	PROPN
dpc-2043	210	5	h	h	NOUN
dpc-2043	210	6	s	s	PROPN
dpc-2043	210	7	,	,	PUNCT
dpc-2043	210	8	modawe	modawe	PROPN
dpc-2043	210	9	ga	ga	PROPN
dpc-2043	210	10	.	.	PROPN
dpc-2043	210	11	assessment	assessment	NOUN
dpc-2043	210	12	of	of	ADP
dpc-2043	210	13	serum	serum	NOUN
dpc-2043	210	14	copper	copper	NOUN
dpc-2043	210	15	level	level	NOUN
dpc-2043	210	16	among	among	ADP
dpc-2043	210	17	sudanese	sudanese	ADJ
dpc-2043	210	18	patients	patient	NOUN
dpc-2043	210	19	with	with	ADP
dpc-2043	210	20	vitiligo	vitiligo	PROPN
dpc-2043	210	21	”	"	PUNCT
dpc-2043	210	22	.	.	PUNCT
dpc-2043	211	1	sudan	sudan	PROPN
dpc-2043	211	2	journal	journal	PROPN
dpc-2043	211	3	of	of	ADP
dpc-2043	211	4	medical	medical	ADJ
dpc-2043	211	5	sciences	science	NOUN
dpc-2043	211	6	.	.	PUNCT
dpc-2043	212	1	2020;15:73–84	2020;15:73–84	NUM
dpc-2043	212	2	.	.	PUNCT
dpc-2043	212	3	doi:10.18502	doi:10.18502	VERB
dpc-2043	212	4	/	/	SYM
dpc-2043	212	5	sjms.v15i1.6707	sjms.v15i1.6707	NOUN
dpc-2043	212	6	.	.	PUNCT
dpc-2043	213	1	24	24	NUM
dpc-2043	213	2	.	.	PUNCT
dpc-2043	213	3	bagherani	bagherani	PROPN
dpc-2043	213	4	n	n	CCONJ
dpc-2043	213	5	,	,	PUNCT
dpc-2043	213	6	yaghoobi	yaghoobi	PROPN
dpc-2043	213	7	r	r	PROPN
dpc-2043	213	8	,	,	PUNCT
dpc-2043	213	9	omidian	omidian	ADJ
dpc-2043	213	10	m.	m.	NOUN
dpc-2043	213	11	hypothesis	hypothesis	NOUN
dpc-2043	213	12	:	:	PUNCT
dpc-2043	213	13	zinc	zinc	NOUN
dpc-2043	213	14	can	can	AUX
dpc-2043	213	15	be	be	AUX
dpc-2043	213	16	effective	effective	ADJ
dpc-2043	213	17	in	in	ADP
dpc-2043	213	18	treatment	treatment	NOUN
dpc-2043	213	19	of	of	ADP
dpc-2043	213	20	vitiligo	vitiligo	NOUN
dpc-2043	213	21	.	.	PUNCT
dpc-2043	214	1	indian	indian	PROPN
dpc-2043	214	2	j	j	PROPN
dpc-2043	214	3	dermatol	dermatol	NOUN
dpc-2043	214	4	.	.	PUNCT
dpc-2043	215	1	2011;5695:480	2011;5695:480	VERB
dpc-2043	215	2	-	-	PUNCT
dpc-2043	215	3	484	484	NUM
dpc-2043	215	4	.	.	PUNCT
dpc-2043	216	1	doi	doi	NOUN
dpc-2043	216	2	:	:	PUNCT
dpc-2043	216	3	10.4103/0019	10.4103/0019	NUM
dpc-2043	216	4	-	-	SYM
dpc-2043	216	5	5154.87116	5154.87116	NUM
dpc-2043	216	6	.	.	PUNCT
dpc-2043	217	1	pmid	pmid	NOUN
dpc-2043	217	2	:	:	PUNCT
dpc-2043	217	3	22121258	22121258	NUM
dpc-2043	217	4	.	.	PUNCT
dpc-2043	218	1	pmcid	pmcid	NOUN
dpc-2043	218	2	:	:	PUNCT
dpc-2043	218	3	pmc3221203	pmc3221203	ADJ
dpc-2043	218	4	.	.	PUNCT
dpc-2043	219	1	25	25	NUM
dpc-2043	219	2	.	.	PUNCT
dpc-2043	220	1	smith	smith	PROPN
dpc-2043	220	2	mk	mk	PROPN
dpc-2043	220	3	,	,	PUNCT
dpc-2043	220	4	mohammad	mohammad	PROPN
dpc-2043	220	5	tf	tf	PROPN
dpc-2043	220	6	,	,	PUNCT
dpc-2043	220	7	hamzavi	hamzavi	PROPN
dpc-2043	220	8	ih	ih	PRON
dpc-2043	220	9	.	.	PUNCT
dpc-2043	221	1	assessment	assessment	NOUN
dpc-2043	221	2	of	of	ADP
dpc-2043	221	3	dietary	dietary	ADJ
dpc-2043	221	4	supplementation	supplementation	NOUN
dpc-2043	221	5	in	in	ADP
dpc-2043	221	6	the	the	DET
dpc-2043	221	7	treatment	treatment	NOUN
dpc-2043	221	8	of	of	ADP
dpc-2043	221	9	vitiligo	vitiligo	NOUN
dpc-2043	221	10	.	.	PUNCT
dpc-2043	222	1	the	the	DET
dpc-2043	222	2	open	open	ADJ
dpc-2043	222	3	dermatology	dermatology	NOUN
dpc-2043	222	4	journal	journal	NOUN
dpc-2043	222	5	.	.	PUNCT
dpc-2043	223	1	2017;11:12	2017;11:12	NUM
dpc-2043	223	2	-	-	SYM
dpc-2043	223	3	21	21	NUM
dpc-2043	223	4	.	.	PUNCT
dpc-2043	224	1	doi	doi	NOUN
dpc-2043	224	2	:	:	PUNCT
dpc-2043	224	3	10.2174/18743722017	10.2174/18743722017	NUM
dpc-2043	224	4	11010012	11010012	NUM
dpc-2043	224	5	.	.	PUNCT
dpc-2043	225	1	26	26	NUM
dpc-2043	225	2	.	.	PUNCT
dpc-2043	226	1	zeng	zeng	PROPN
dpc-2043	226	2	q	q	PROPN
dpc-2043	226	3	,	,	PUNCT
dpc-2043	226	4	yin	yin	PROPN
dpc-2043	226	5	j	j	PROPN
dpc-2043	226	6	,	,	PUNCT
dpc-2043	226	7	fan	fan	PROPN
dpc-2043	226	8	f	f	PROPN
dpc-2043	226	9	,	,	PUNCT
dpc-2043	226	10	et	et	PROPN
dpc-2043	226	11	al	al	PROPN
dpc-2043	226	12	.	.	PROPN
dpc-2043	226	13	decreased	decrease	VERB
dpc-2043	226	14	copper	copper	NOUN
dpc-2043	226	15	and	and	CCONJ
dpc-2043	226	16	zinc	zinc	NOUN
dpc-2043	226	17	in	in	ADP
dpc-2043	226	18	sera	sera	NOUN
dpc-2043	226	19	of	of	ADP
dpc-2043	226	20	chinese	chinese	ADJ
dpc-2043	226	21	vitiligo	vitiligo	NOUN
dpc-2043	226	22	patients	patient	NOUN
dpc-2043	226	23	:	:	PUNCT
dpc-2043	226	24	a	a	DET
dpc-2043	226	25	meta	meta	ADJ
dpc-2043	226	26	-	-	PUNCT
dpc-2043	226	27	analysis	analysis	NOUN
dpc-2043	226	28	.	.	PUNCT
dpc-2043	227	1	j	j	PROPN
dpc-2043	227	2	dermatol	dermatol	NOUN
dpc-2043	227	3	.	.	PUNCT
dpc-2043	228	1	2014	2014	NUM
dpc-2043	228	2	;	;	PUNCT
dpc-2043	229	1	41(3):245	41(3):245	X
dpc-2043	229	2	-	-	PUNCT
dpc-2043	229	3	251	251	NUM
dpc-2043	229	4	.	.	PUNCT
dpc-2043	230	1	doi	doi	NOUN
dpc-2043	230	2	:	:	PUNCT
dpc-2043	230	3	10.1111/1346	10.1111/1346	NUM
dpc-2043	230	4	-	-	SYM
dpc-2043	230	5	8138.12392	8138.12392	NUM
dpc-2043	230	6	.	.	PUNCT
dpc-2043	231	1	pmid	pmid	NOUN
dpc-2043	231	2	:	:	PUNCT
dpc-2043	231	3	24	24	NUM
dpc-2043	231	4	517587	517587	NUM
dpc-2043	231	5	.	.	PUNCT
dpc-2043	232	1	27	27	NUM
dpc-2043	232	2	.	.	PUNCT
dpc-2043	233	1	mirnezami	mirnezami	PROPN
dpc-2043	233	2	m	m	PROPN
dpc-2043	233	3	,	,	PUNCT
dpc-2043	233	4	rahimi	rahimi	PROPN
dpc-2043	233	5	h.	h.	PROPN
dpc-2043	233	6	serum	serum	PROPN
dpc-2043	233	7	zinc	zinc	NOUN
dpc-2043	233	8	level	level	NOUN
dpc-2043	233	9	in	in	ADP
dpc-2043	233	10	vitiligo	vitiligo	NOUN
dpc-2043	233	11	:	:	PUNCT
dpc-2043	233	12	a	a	DET
dpc-2043	233	13	case	case	NOUN
dpc-2043	233	14	-	-	PUNCT
dpc-2043	233	15	control	control	NOUN
dpc-2043	233	16	study	study	NOUN
dpc-2043	233	17	.	.	PUNCT
dpc-2043	234	1	indian	indian	PROPN
dpc-2043	234	2	j	j	PROPN
dpc-2043	234	3	dermatol	dermatol	NOUN
dpc-2043	234	4	.	.	PUNCT
dpc-2043	235	1	2018;63(3):227	2018;63(3):227	NUM
dpc-2043	235	2	-	-	PUNCT
dpc-2043	235	3	230	230	NUM
dpc-2043	235	4	.	.	PUNCT
dpc-2043	235	5	doi:10.4103	doi:10.4103	ADJ
dpc-2043	235	6	/	/	SYM
dpc-2043	235	7	ijd.ijd_457_16	ijd.ijd_457_16	PROPN
dpc-2043	235	8	.	.	PUNCT
dpc-2043	236	1	pmid	pmid	NOUN
dpc-2043	236	2	:	:	PUNCT
dpc-2043	236	3	29937559	29937559	NUM
dpc-2043	236	4	.	.	PUNCT
dpc-2043	237	1	pmcid	pmcid	NOUN
dpc-2043	237	2	:	:	PUNCT
dpc-2043	237	3	pmc5996627	pmc5996627	VERB
dpc-2043	237	4	.	.	PUNCT
dpc-2043	238	1	28	28	NUM
dpc-2043	238	2	.	.	PUNCT
dpc-2043	239	1	mogaddam	mogaddam	PROPN
dpc-2043	239	2	mr	mr	PROPN
dpc-2043	239	3	,	,	PUNCT
dpc-2043	239	4	ardabili	ardabili	PROPN
dpc-2043	239	5	ns	ns	NUM
dpc-2043	239	6	,	,	PUNCT
dpc-2043	239	7	maleki	maleki	NOUN
dpc-2043	239	8	n	n	CCONJ
dpc-2043	239	9	,	,	PUNCT
dpc-2043	239	10	chinifroush	chinifroush	NOUN
dpc-2043	239	11	mm	mm	PROPN
dpc-2043	239	12	,	,	PUNCT
dpc-2043	239	13	fard	fard	NOUN
dpc-2043	239	14	em	em	PRON
dpc-2043	239	15	.	.	PUNCT
dpc-2043	240	1	evaluation	evaluation	NOUN
dpc-2043	240	2	of	of	ADP
dpc-2043	240	3	the	the	DET
dpc-2043	240	4	serum	serum	NOUN
dpc-2043	240	5	zinc	zinc	NOUN
dpc-2043	240	6	level	level	NOUN
dpc-2043	240	7	in	in	ADP
dpc-2043	240	8	patients	patient	NOUN
dpc-2043	240	9	with	with	ADP
dpc-2043	240	10	vitiligo	vitiligo	PROPN
dpc-2043	240	11	.	.	PUNCT
dpc-2043	241	1	postepy	postepy	ADJ
dpc-2043	241	2	dermatol	dermatol	NOUN
dpc-2043	241	3	alergol	alergol	NOUN
dpc-2043	241	4	.	.	PUNCT
dpc-2043	242	1	2017;34(2):116	2017;34(2):116	NUM
dpc-2043	242	2	-	-	SYM
dpc-2043	242	3	119	119	NUM
dpc-2043	242	4	.	.	PUNCT
dpc-2043	243	1	doi:10.5114/	doi:10.5114/	NUM
dpc-2043	243	2	ada.2017.67073	ada.2017.67073	NOUN
dpc-2043	243	3	.	.	PUNCT
dpc-2043	244	1	pmid	pmid	NOUN
dpc-2043	244	2	:	:	PUNCT
dpc-2043	244	3	28507489	28507489	NUM
dpc-2043	244	4	.	.	PUNCT
dpc-2043	245	1	pmcid	pmcid	ADJ
dpc-2043	245	2	:	:	PUNCT
dpc-2043	245	3	pmc5420602	pmc5420602	NOUN
dpc-2043	245	4	.	.	PUNCT
dpc-2043	246	1	29	29	NUM
dpc-2043	246	2	.	.	PUNCT
dpc-2043	247	1	sadeghi	sadeghi	PROPN
dpc-2043	247	2	n	n	CCONJ
dpc-2043	247	3	,	,	PUNCT
dpc-2043	247	4	oveisi	oveisi	ADJ
dpc-2043	247	5	mr	mr	PROPN
dpc-2043	247	6	,	,	PUNCT
dpc-2043	247	7	jannat	jannat	PROPN
dpc-2043	247	8	b	b	PROPN
dpc-2043	247	9	,	,	PUNCT
dpc-2043	247	10	et	et	PROPN
dpc-2043	247	11	al	al	PROPN
dpc-2043	247	12	.	.	PUNCT
dpc-2043	248	1	the	the	DET
dpc-2043	248	2	relationship	relationship	NOUN
dpc-2043	248	3	between	between	ADP
dpc-2043	248	4	bone	bone	NOUN
dpc-2043	248	5	health	health	NOUN
dpc-2043	248	6	and	and	CCONJ
dpc-2043	248	7	plasma	plasma	NOUN
dpc-2043	248	8	zinc	zinc	NOUN
dpc-2043	248	9	,	,	PUNCT
dpc-2043	248	10	copper	copper	NOUN
dpc-2043	248	11	lead	lead	NOUN
dpc-2043	248	12	and	and	CCONJ
dpc-2043	248	13	cadmium	cadmium	NOUN
dpc-2043	248	14	concentration	concentration	NOUN
dpc-2043	248	15	in	in	ADP
dpc-2043	248	16	osteoporotic	osteoporotic	ADJ
dpc-2043	248	17	women	woman	NOUN
dpc-2043	248	18	.	.	PUNCT
dpc-2043	249	1	j	j	PROPN
dpc-2043	249	2	environ	environ	PROPN
dpc-2043	249	3	health	health	PROPN
dpc-2043	249	4	sci	sci	PROPN
dpc-2043	249	5	eng	eng	PROPN
dpc-2043	249	6	.	.	PUNCT
dpc-2043	250	1	2014;12(1):125	2014;12(1):125	NUM
dpc-2043	250	2	.	.	PUNCT
dpc-2043	251	1	doi:10.1186	doi:10.1186	PROPN
dpc-2043	251	2	/	/	SYM
dpc-2043	251	3	s40201	s40201	PROPN
dpc-2043	251	4	-	-	PUNCT
dpc-2043	251	5	014	014	NUM
dpc-2043	251	6	-	-	PUNCT
dpc-2043	251	7	0125	0125	NUM
dpc-2043	251	8	-	-	PUNCT
dpc-2043	251	9	3	3	NUM
dpc-2043	251	10	.	.	PUNCT
dpc-2043	252	1	pmid	pmid	NOUN
dpc-2043	252	2	:	:	PUNCT
dpc-2043	252	3	2546	2546	NUM
dpc-2043	252	4	9307	9307	NUM
dpc-2043	252	5	.	.	PUNCT
dpc-2043	253	1	pmcid	pmcid	NOUN
dpc-2043	253	2	:	:	PUNCT
dpc-2043	253	3	pmc4251679	pmc4251679	NOUN
dpc-2043	253	4	.	.	PUNCT
dpc-2043	254	1	acknowledgements	acknowledgement	NOUN
dpc-2043	254	2	this	this	DET
dpc-2043	254	3	research	research	NOUN
dpc-2043	254	4	was	be	AUX
dpc-2043	254	5	supported	support	VERB
dpc-2043	254	6	by	by	ADP
dpc-2043	254	7	the	the	DET
dpc-2043	254	8	vice	vice	NOUN
dpc-2043	254	9	chancellor	chancellor	NOUN
dpc-2043	254	10	for	for	ADP
dpc-2043	254	11	research	research	NOUN
dpc-2043	254	12	,	,	PUNCT
dpc-2043	254	13	shiraz	shiraz	PROPN
dpc-2043	254	14	university	university	PROPN
dpc-2043	254	15	of	of	ADP
dpc-2043	254	16	medical	medical	ADJ
dpc-2043	254	17	sciences	science	NOUN
dpc-2043	254	18	through	through	ADP
dpc-2043	254	19	grant	grant	NOUN
dpc-2043	254	20	number	number	NOUN
dpc-2043	254	21	98	98	NUM
dpc-2043	254	22	-	-	SYM
dpc-2043	254	23	01	01	NUM
dpc-2043	254	24	-	-	PUNCT
dpc-2043	254	25	17	17	NUM
dpc-2043	254	26	-	-	SYM
dpc-2043	254	27	19678	19678	NUM
dpc-2043	254	28	.	.	PUNCT
dpc-2043	255	1	references	reference	NOUN
dpc-2043	255	2	1	1	NUM
dpc-2043	255	3	.	.	PUNCT
dpc-2043	255	4	malhotra	malhotra	PROPN
dpc-2043	255	5	n	n	CCONJ
dpc-2043	255	6	,	,	PUNCT
dpc-2043	255	7	dytoc	dytoc	NOUN
dpc-2043	255	8	m.	m.	NOUN
dpc-2043	255	9	the	the	DET
dpc-2043	255	10	pathogenesis	pathogenesis	NOUN
dpc-2043	255	11	of	of	ADP
dpc-2043	255	12	vitiligo	vitiligo	NOUN
dpc-2043	255	13	.	.	PUNCT
dpc-2043	256	1	j	j	PROPN
dpc-2043	256	2	cutan	cutan	PROPN
dpc-2043	256	3	med	med	ADJ
dpc-2043	256	4	surg	surg	NOUN
dpc-2043	256	5	.	.	PUNCT
dpc-2043	257	1	2013;17(3):153	2013;17(3):153	NUM
dpc-2043	257	2	-	-	SYM
dpc-2043	257	3	172	172	NUM
dpc-2043	257	4	.	.	PUNCT
dpc-2043	257	5	doi	doi	NOUN
dpc-2043	257	6	:	:	PUNCT
dpc-2043	257	7	10.2310/7750.2012.12005	10.2310/7750.2012.12005	NUM
dpc-2043	257	8	.	.	PUNCT
dpc-2043	258	1	pmid	pmid	NOUN
dpc-2043	258	2	:	:	PUNCT
dpc-2043	258	3	23673299	23673299	NUM
dpc-2043	258	4	.	.	PUNCT
dpc-2043	259	1	2	2	X
dpc-2043	259	2	.	.	X
dpc-2043	259	3	yaghoobi	yaghoobi	PROPN
dpc-2043	259	4	r	r	PROPN
dpc-2043	259	5	,	,	PUNCT
dpc-2043	259	6	omidian	omidian	NOUN
dpc-2043	259	7	m	m	PROPN
dpc-2043	259	8	,	,	PUNCT
dpc-2043	259	9	bagherani	bagherani	ADJ
dpc-2043	259	10	n.	n.	NOUN
dpc-2043	259	11	vitiligo	vitiligo	PROPN
dpc-2043	259	12	:	:	PUNCT
dpc-2043	259	13	a	a	DET
dpc-2043	259	14	review	review	NOUN
dpc-2043	259	15	of	of	ADP
dpc-2043	259	16	the	the	DET
dpc-2043	259	17	published	publish	VERB
dpc-2043	259	18	work	work	NOUN
dpc-2043	259	19	.	.	PUNCT
dpc-2043	260	1	j	j	PROPN
dpc-2043	260	2	dermatol	dermatol	NOUN
dpc-2043	260	3	.	.	PUNCT
dpc-2043	261	1	2011;38(5):419	2011;38(5):419	NUM
dpc-2043	261	2	-	-	PUNCT
dpc-2043	261	3	431	431	NUM
dpc-2043	261	4	.	.	PUNCT
dpc-2043	262	1	doi	doi	NOUN
dpc-2043	262	2	:	:	PUNCT
dpc-2043	262	3	10.1111	10.1111	NUM
dpc-2043	262	4	/	/	SYM
dpc-2043	262	5	j.1346	j.1346	VERB
dpc-2043	262	6	-	-	PUNCT
dpc-2043	262	7	8138.2010.01139.x	8138.2010.01139.x	NUM
dpc-2043	262	8	.	.	PUNCT
dpc-2043	263	1	pmid	pmid	NOUN
dpc-2043	263	2	:	:	PUNCT
dpc-2043	263	3	21667529	21667529	NUM
dpc-2043	263	4	.	.	PUNCT
dpc-2043	264	1	3	3	X
dpc-2043	264	2	.	.	X
dpc-2043	264	3	jain	jain	PROPN
dpc-2043	264	4	d	d	PROPN
dpc-2043	264	5	,	,	PUNCT
dpc-2043	264	6	misra	misra	ADJ
dpc-2043	264	7	r	r	NOUN
dpc-2043	264	8	,	,	PUNCT
dpc-2043	264	9	kumar	kumar	PROPN
dpc-2043	264	10	a	a	PROPN
dpc-2043	264	11	,	,	PUNCT
dpc-2043	264	12	jaiswal	jaiswal	PROPN
dpc-2043	264	13	g.	g.	PROPN
dpc-2043	264	14	levels	level	NOUN
dpc-2043	264	15	of	of	ADP
dpc-2043	264	16	malondialdehyde	malondialdehyde	NOUN
dpc-2043	264	17	and	and	CCONJ
dpc-2043	264	18	antioxidants	antioxidant	NOUN
dpc-2043	264	19	in	in	ADP
dpc-2043	264	20	the	the	DET
dpc-2043	264	21	blood	blood	NOUN
dpc-2043	264	22	of	of	ADP
dpc-2043	264	23	patients	patient	NOUN
dpc-2043	264	24	with	with	ADP
dpc-2043	264	25	vitiligo	vitiligo	NOUN
dpc-2043	264	26	of	of	ADP
dpc-2043	264	27	age	age	NOUN
dpc-2043	264	28	group	group	NOUN
dpc-2043	264	29	11	11	NUM
dpc-2043	264	30	-	-	SYM
dpc-2043	264	31	20	20	NUM
dpc-2043	264	32	years	year	NOUN
dpc-2043	264	33	.	.	PUNCT
dpc-2043	265	1	indian	indian	PROPN
dpc-2043	265	2	j	j	PROPN
dpc-2043	265	3	physiol	physiol	PROPN
dpc-2043	265	4	pharmacol	pharmacol	PROPN
dpc-2043	265	5	.	.	PUNCT
dpc-2043	266	1	2008;52930:297	2008;52930:297	PROPN
dpc-2043	266	2	-	-	SYM
dpc-2043	266	3	301	301	NUM
dpc-2043	266	4	.	.	PUNCT
dpc-2043	267	1	pmid	pmid	NOUN
dpc-2043	267	2	:	:	PUNCT
dpc-2043	267	3	19552063	19552063	NUM
dpc-2043	267	4	.	.	PUNCT
dpc-2043	268	1	4	4	X
dpc-2043	268	2	.	.	X
dpc-2043	268	3	harris	harris	PROPN
dpc-2043	268	4	je	je	AUX
dpc-2043	268	5	.	.	PUNCT
dpc-2043	268	6	optimizing	optimize	VERB
dpc-2043	268	7	vitiligo	vitiligo	NOUN
dpc-2043	268	8	management	management	NOUN
dpc-2043	268	9	:	:	PUNCT
dpc-2043	268	10	past	past	ADJ
dpc-2043	268	11	,	,	PUNCT
dpc-2043	268	12	present	present	ADJ
dpc-2043	268	13	,	,	PUNCT
dpc-2043	268	14	and	and	CCONJ
dpc-2043	268	15	future	future	NOUN
dpc-2043	268	16	.	.	PUNCT
dpc-2043	269	1	dermatol	dermatol	NOUN
dpc-2043	269	2	clin	clin	PROPN
dpc-2043	269	3	.	.	PUNCT
dpc-2043	270	1	2017;35(2):xi	2017;35(2):xi	NUM
dpc-2043	270	2	.	.	PUNCT
dpc-2043	271	1	doi	doi	NOUN
dpc-2043	271	2	:	:	PUNCT
dpc-2043	271	3	10.1016	10.1016	NUM
dpc-2043	271	4	/	/	SYM
dpc-2043	271	5	j.det.2017	j.det.2017	PROPN
dpc-2043	271	6	.	.	PUNCT
dpc-2043	271	7	01.001	01.001	NUM
dpc-2043	271	8	.	.	PUNCT
dpc-2043	272	1	pmid	pmid	NOUN
dpc-2043	272	2	:	:	PUNCT
dpc-2043	272	3	28317535	28317535	NUM
dpc-2043	272	4	.	.	PUNCT
dpc-2043	273	1	5	5	X
dpc-2043	273	2	.	.	X
dpc-2043	273	3	riding	ride	VERB
dpc-2043	273	4	rl	rl	PROPN
dpc-2043	273	5	,	,	PUNCT
dpc-2043	273	6	harris	harris	PROPN
dpc-2043	273	7	je	je	PROPN
dpc-2043	273	8	.	.	PUNCT
dpc-2043	274	1	the	the	DET
dpc-2043	274	2	role	role	NOUN
dpc-2043	274	3	of	of	ADP
dpc-2043	274	4	memory	memory	NOUN
dpc-2043	274	5	cd8	cd8	PROPN
dpc-2043	274	6	+	+	PROPN
dpc-2043	274	7	t	t	PROPN
dpc-2043	274	8	cells	cell	NOUN
dpc-2043	274	9	in	in	ADP
dpc-2043	274	10	vitiligo	vitiligo	NOUN
dpc-2043	274	11	.	.	PUNCT
dpc-2043	275	1	j	j	PROPN
dpc-2043	275	2	immunol	immunol	NOUN
dpc-2043	275	3	.	.	PUNCT
dpc-2043	276	1	2019;203(1):11	2019;203(1):11	NUM
dpc-2043	276	2	-	-	SYM
dpc-2043	276	3	19	19	NUM
dpc-2043	276	4	.	.	PUNCT
dpc-2043	276	5	doi	doi	NOUN
dpc-2043	276	6	:	:	PUNCT
dpc-2043	276	7	10.4049	10.4049	NUM
dpc-2043	276	8	/	/	SYM
dpc-2043	276	9	jimmunol.1900027	jimmunol.1900027	PROPN
dpc-2043	276	10	.	.	PUNCT
dpc-2043	277	1	pmid	pmid	NOUN
dpc-2043	277	2	:	:	PUNCT
dpc-2043	277	3	31209143	31209143	NUM
dpc-2043	277	4	.	.	PUNCT
dpc-2043	278	1	pmcid	pmcid	NOUN
dpc-2043	278	2	:	:	PUNCT
dpc-2043	278	3	pmc6709670	pmc6709670	NOUN
dpc-2043	278	4	.	.	PUNCT
dpc-2043	279	1	6	6	X
dpc-2043	279	2	.	.	X
dpc-2043	279	3	spritz	spritz	PROPN
dpc-2043	279	4	ra	ra	PROPN
dpc-2043	279	5	,	,	PUNCT
dpc-2043	279	6	andersen	andersen	PROPN
dpc-2043	279	7	gh	gh	PROPN
dpc-2043	279	8	.	.	PUNCT
dpc-2043	280	1	genetics	genetic	NOUN
dpc-2043	280	2	of	of	ADP
dpc-2043	280	3	vitiligo	vitiligo	NOUN
dpc-2043	280	4	.	.	PUNCT
dpc-2043	281	1	dermatol	dermatol	NOUN
dpc-2043	281	2	clin	clin	PROPN
dpc-2043	281	3	.	.	PUNCT
dpc-2043	282	1	2017	2017	NUM
dpc-2043	282	2	;	;	PUNCT
dpc-2043	283	1	35(2):245	35(2):245	PROPN
dpc-2043	283	2	-	-	SYM
dpc-2043	283	3	255	255	NUM
dpc-2043	283	4	.	.	PUNCT
dpc-2043	284	1	doi	doi	NOUN
dpc-2043	284	2	:	:	PUNCT
dpc-2043	284	3	10.1016	10.1016	NUM
dpc-2043	284	4	/	/	SYM
dpc-2043	284	5	j.det.2016.11.013	j.det.2016.11.013	PROPN
dpc-2043	284	6	.	.	PUNCT
dpc-2043	285	1	pmid	pmid	NOUN
dpc-2043	285	2	:	:	PUNCT
dpc-2043	285	3	28317533	28317533	NUM
dpc-2043	285	4	.	.	PUNCT
dpc-2043	286	1	pmcid	pmcid	ADJ
dpc-2043	286	2	:	:	PUNCT
dpc-2043	286	3	pmc5362127	pmc5362127	NOUN
dpc-2043	286	4	.	.	PUNCT
dpc-2043	287	1	7	7	X
dpc-2043	287	2	.	.	NUM
dpc-2043	287	3	helmy	helmy	PROPN
dpc-2043	287	4	mi	mi	PROPN
dpc-2043	287	5	,	,	PUNCT
dpc-2043	287	6	gayyar	gayyar	PROPN
dpc-2043	287	7	el	el	PROPN
dpc-2043	287	8	,	,	PUNCT
dpc-2043	287	9	hawas	hawa	VERB
dpc-2043	287	10	s	s	NOUN
dpc-2043	287	11	,	,	PUNCT
dpc-2043	287	12	eissa	eissa	PROPN
dpc-2043	287	13	ae	ae	PROPN
dpc-2043	287	14	.	.	PUNCT
dpc-2043	288	1	role	role	NOUN
dpc-2043	288	2	of	of	ADP
dpc-2043	288	3	oxidative	oxidative	ADJ
dpc-2043	288	4	stress	stress	NOUN
dpc-2043	288	5	in	in	ADP
dpc-2043	288	6	the	the	DET
dpc-2043	288	7	pathogenesis	pathogenesis	NOUN
dpc-2043	288	8	of	of	ADP
dpc-2043	288	9	vitiligo	vitiligo	NOUN
dpc-2043	288	10	.	.	PUNCT
dpc-2043	289	1	j	j	PROPN
dpc-2043	289	2	pan	pan	PROPN
dpc-2043	289	3	-	-	PROPN
dpc-2043	289	4	arab	arab	ADJ
dpc-2043	289	5	league	league	PROPN
dpc-2043	289	6	dermatologist	dermatologist	NOUN
dpc-2043	289	7	.	.	PUNCT
dpc-2043	290	1	2004	2004	NUM
dpc-2043	290	2	;	;	PUNCT
dpc-2043	290	3	15:97–105	15:97–105	NUM
dpc-2043	290	4	.	.	NOUN
dpc-2043	290	5	8	8	NUM
dpc-2043	290	6	.	.	PUNCT
dpc-2043	291	1	ines	ines	PROPN
dpc-2043	291	2	d	d	PROPN
dpc-2043	291	3	,	,	PUNCT
dpc-2043	291	4	sonia	sonia	PROPN
dpc-2043	291	5	b	b	PROPN
dpc-2043	291	6	,	,	PUNCT
dpc-2043	291	7	riadh	riadh	PROPN
dpc-2043	291	8	bm	bm	PROPN
dpc-2043	291	9	,	,	PUNCT
dpc-2043	291	10	et	et	PROPN
dpc-2043	291	11	al	al	PROPN
dpc-2043	291	12	.	.	PUNCT
dpc-2043	292	1	a	a	DET
dpc-2043	292	2	comparative	comparative	ADJ
dpc-2043	292	3	study	study	NOUN
dpc-2043	292	4	of	of	ADP
dpc-2043	292	5	oxidant	oxidant	ADJ
dpc-2043	292	6	-	-	PUNCT
dpc-2043	292	7	antioxidant	antioxidant	NOUN
dpc-2043	292	8	status	status	NOUN
dpc-2043	292	9	in	in	ADP
dpc-2043	292	10	stable	stable	ADJ
dpc-2043	292	11	and	and	CCONJ
dpc-2043	292	12	active	active	ADJ
dpc-2043	292	13	vitiligo	vitiligo	NOUN
dpc-2043	292	14	patients	patient	NOUN
dpc-2043	292	15	.	.	PUNCT
dpc-2043	293	1	arch	arch	ADJ
dpc-2043	293	2	dermatol	dermatol	NOUN
dpc-2043	293	3	res	re	NOUN
dpc-2043	293	4	.	.	PUNCT
dpc-2043	293	5	2006	2006	NUM
dpc-2043	293	6	;	;	PUNCT
dpc-2043	293	7	298(4):147	298(4):147	NUM
dpc-2043	293	8	-	-	SYM
dpc-2043	293	9	152	152	NUM
dpc-2043	293	10	.	.	PUNCT
dpc-2043	294	1	doi	doi	NOUN
dpc-2043	294	2	:	:	PUNCT
dpc-2043	294	3	10.1007	10.1007	NUM
dpc-2043	294	4	/	/	SYM
dpc-2043	294	5	s00	s00	NOUN
dpc-2043	294	6	403	403	NUM
dpc-2043	294	7	-	-	PUNCT
dpc-2043	294	8	006	006	NUM
dpc-2043	294	9	-	-	PUNCT
dpc-2043	294	10	0680	0680	NUM
dpc-2043	294	11	-	-	PUNCT
dpc-2043	294	12	2	2	NUM
dpc-2043	294	13	.	.	PUNCT
dpc-2043	295	1	pmid	pmid	NOUN
dpc-2043	295	2	:	:	PUNCT
dpc-2043	295	3	16897080	16897080	NUM
dpc-2043	295	4	.	.	PUNCT
dpc-2043	296	1	9	9	X
dpc-2043	296	2	.	.	X
dpc-2043	296	3	schallreuter	schallreuter	PROPN
dpc-2043	296	4	ku	ku	PROPN
dpc-2043	296	5	,	,	PUNCT
dpc-2043	296	6	wood	wood	PROPN
dpc-2043	296	7	jm	jm	PROPN
dpc-2043	296	8	,	,	PUNCT
dpc-2043	296	9	berger	berger	PROPN
dpc-2043	296	10	j.	j.	PROPN
dpc-2043	296	11	low	low	PROPN
dpc-2043	296	12	catalase	catalase	PROPN
dpc-2043	296	13	levels	level	NOUN
dpc-2043	296	14	in	in	ADP
dpc-2043	296	15	the	the	DET
dpc-2043	296	16	epidermis	epidermis	NOUN
dpc-2043	296	17	of	of	ADP
dpc-2043	296	18	patients	patient	NOUN
dpc-2043	296	19	with	with	ADP
dpc-2043	296	20	vitiligo	vitiligo	PROPN
dpc-2043	296	21	.	.	PUNCT
dpc-2043	297	1	j	j	PROPN
dpc-2043	297	2	invest	invest	VERB
dpc-2043	297	3	dermatol	dermatol	NOUN
dpc-2043	297	4	.	.	PUNCT
dpc-2043	298	1	1991	1991	NUM
dpc-2043	298	2	;	;	PUNCT
dpc-2043	298	3	97(6):1081	97(6):1081	NUM
dpc-2043	298	4	-	-	SYM
dpc-2043	298	5	1085	1085	NUM
dpc-2043	298	6	.	.	PUNCT
dpc-2043	299	1	doi	doi	NOUN
dpc-2043	299	2	:	:	PUNCT
dpc-2043	299	3	10.1111/1523	10.1111/1523	NUM
dpc-2043	299	4	-	-	NOUN
dpc-2043	299	5	1747.ep12492612	1747.ep12492612	NOUN
dpc-2043	299	6	.	.	PUNCT
dpc-2043	300	1	pmid	pmid	NOUN
dpc-2043	300	2	:	:	PUNCT
dpc-2043	300	3	1748819	1748819	NUM
dpc-2043	300	4	.	.	PUNCT
dpc-2043	301	1	10	10	NUM
dpc-2043	301	2	.	.	X
dpc-2043	302	1	akoglu	akoglu	PROPN
dpc-2043	302	2	g	g	PROPN
dpc-2043	302	3	,	,	PUNCT
dpc-2043	302	4	emre	emre	PROPN
dpc-2043	302	5	s	s	PROPN
dpc-2043	302	6	,	,	PUNCT
dpc-2043	302	7	metin	metin	PROPN
dpc-2043	302	8	a	a	PROPN
dpc-2043	302	9	,	,	PUNCT
dpc-2043	302	10	et	et	PROPN
dpc-2043	302	11	al	al	PROPN
dpc-2043	302	12	.	.	PUNCT
dpc-2043	302	13	evaluation	evaluation	NOUN
dpc-2043	302	14	of	of	ADP
dpc-2043	302	15	total	total	ADJ
dpc-2043	302	16	oxidant	oxidant	NOUN
dpc-2043	302	17	and	and	CCONJ
dpc-2043	302	18	antioxidant	antioxidant	ADJ
dpc-2043	302	19	status	status	NOUN
dpc-2043	302	20	in	in	ADP
dpc-2043	302	21	localized	localized	ADJ
dpc-2043	302	22	and	and	CCONJ
dpc-2043	302	23	generalized	generalized	ADJ
dpc-2043	302	24	vitiligo	vitiligo	NOUN
dpc-2043	302	25	.	.	PUNCT
dpc-2043	303	1	clin	clin	PROPN
dpc-2043	303	2	exp	exp	NOUN
dpc-2043	303	3	dermatol	dermatol	NOUN
dpc-2043	303	4	.	.	PUNCT
dpc-2043	304	1	2013;38(7):701	2013;38(7):701	NUM
dpc-2043	304	2	-	-	PUNCT
dpc-2043	304	3	706	706	NUM
dpc-2043	304	4	.	.	PUNCT
dpc-2043	304	5	doi	doi	NOUN
dpc-2043	304	6	:	:	PUNCT
dpc-2043	304	7	10.1111	10.1111	NUM
dpc-2043	304	8	/	/	SYM
dpc-2043	304	9	ced.12054	ced.12054	NOUN
dpc-2043	304	10	.	.	PUNCT
dpc-2043	305	1	pmid	pmid	NOUN
dpc-2043	305	2	:	:	PUNCT
dpc-2043	305	3	23601201	23601201	NUM
dpc-2043	305	4	.	.	PUNCT
dpc-2043	306	1	11	11	NUM
dpc-2043	306	2	.	.	PUNCT
dpc-2043	306	3	lotti	lotti	PROPN
dpc-2043	306	4	t	t	PROPN
dpc-2043	306	5	,	,	PUNCT
dpc-2043	306	6	gori	gori	PROPN
dpc-2043	306	7	a	a	X
dpc-2043	306	8	,	,	PUNCT
dpc-2043	306	9	zanieri	zanieri	PROPN
dpc-2043	306	10	f	f	PROPN
dpc-2043	306	11	,	,	PUNCT
dpc-2043	306	12	colucci	colucci	PROPN
dpc-2043	306	13	r	r	PROPN
dpc-2043	306	14	,	,	PUNCT
dpc-2043	306	15	moretti	moretti	PROPN
dpc-2043	306	16	s.	s.	PROPN
dpc-2043	306	17	vitiligo	vitiligo	PROPN
dpc-2043	306	18	:	:	PUNCT
dpc-2043	306	19	new	new	ADJ
dpc-2043	306	20	and	and	CCONJ
dpc-2043	306	21	emerging	emerge	VERB
dpc-2043	306	22	treatments	treatment	NOUN
dpc-2043	306	23	.	.	PUNCT
dpc-2043	307	1	dermatol	dermatol	NOUN
dpc-2043	307	2	ther	ther	ADV
dpc-2043	307	3	.	.	PUNCT
dpc-2043	308	1	2008;21(2):110	2008;21(2):110	NOUN
dpc-2043	308	2	-	-	PUNCT
dpc-2043	308	3	117	117	NUM
dpc-2043	308	4	.	.	PUNCT
dpc-2043	308	5	doi	doi	NOUN
dpc-2043	308	6	:	:	PUNCT
dpc-2043	308	7	10.1111	10.1111	NUM
dpc-2043	308	8	/	/	SYM
dpc-2043	308	9	j.1529	j.1529	NOUN
dpc-2043	308	10	-	-	PUNCT
dpc-2043	308	11	8019.2008.00178.x	8019.2008.00178.x	NUM
dpc-2043	308	12	.	.	PUNCT
dpc-2043	309	1	pmid	pmid	NOUN
dpc-2043	309	2	:	:	PUNCT
dpc-2043	309	3	18394085	18394085	NUM
dpc-2043	309	4	.	.	PUNCT
dpc-2043	310	1	12	12	NUM
dpc-2043	310	2	.	.	PUNCT
dpc-2043	311	1	hong	hong	PROPN
dpc-2043	311	2	l	l	PROPN
dpc-2043	311	3	,	,	PUNCT
dpc-2043	311	4	simon	simon	PROPN
dpc-2043	311	5	jd	jd	PROPN
dpc-2043	311	6	.	.	PUNCT
dpc-2043	312	1	current	current	ADJ
dpc-2043	312	2	understanding	understanding	NOUN
dpc-2043	312	3	of	of	ADP
dpc-2043	312	4	the	the	DET
dpc-2043	312	5	binding	bind	VERB
dpc-2043	312	6	sites	site	NOUN
dpc-2043	312	7	,	,	PUNCT
dpc-2043	312	8	capacity	capacity	NOUN
dpc-2043	312	9	,	,	PUNCT
dpc-2043	312	10	affinity	affinity	NOUN
dpc-2043	312	11	,	,	PUNCT
dpc-2043	312	12	and	and	CCONJ
dpc-2043	312	13	biological	biological	ADJ
dpc-2043	312	14	significance	significance	NOUN
dpc-2043	312	15	of	of	ADP
dpc-2043	312	16	metals	metal	NOUN
dpc-2043	312	17	in	in	ADP
dpc-2043	312	18	melanin	melanin	NOUN
dpc-2043	312	19	.	.	PUNCT
dpc-2043	313	1	j	j	PROPN
dpc-2043	313	2	phys	phys	PROPN
dpc-2043	313	3	chem	chem	PROPN
dpc-2043	313	4	b.	b.	PROPN
dpc-2043	313	5	2007;111928):7938	2007;111928):7938	PROPN
dpc-2043	313	6	-	-	PUNCT
dpc-2043	313	7	7947	7947	NUM
dpc-2043	313	8	.	.	PUNCT
dpc-2043	314	1	doi:10.1021	doi:10.1021	PROPN
dpc-2043	314	2	/	/	SYM
dpc-2043	314	3	jp071	jp071	PROPN
dpc-2043	314	4	439h	439h	PROPN
dpc-2043	314	5	.	.	PUNCT
dpc-2043	315	1	pmid	pmid	NOUN
dpc-2043	315	2	:	:	PUNCT
dpc-2043	315	3	17580858	17580858	NUM
dpc-2043	315	4	.	.	PUNCT
dpc-2043	316	1	pmcid	pmcid	ADJ
dpc-2043	316	2	:	:	PUNCT
dpc-2043	316	3	pmc2533804	pmc2533804	NOUN
dpc-2043	316	4	.	.	PUNCT
dpc-2043	317	1	13	13	NUM
dpc-2043	317	2	.	.	X
dpc-2043	318	1	d’alba	d’alba	PROPN
dpc-2043	318	2	l	l	NOUN
dpc-2043	318	3	,	,	PUNCT
dpc-2043	318	4	shawkey	shawkey	PROPN
dpc-2043	318	5	md	md	PROPN
dpc-2043	318	6	.	.	PUNCT
dpc-2043	319	1	melanosomes	melanosome	NOUN
dpc-2043	319	2	:	:	PUNCT
dpc-2043	319	3	biogenesis	biogenesis	NOUN
dpc-2043	319	4	,	,	PUNCT
dpc-2043	319	5	properties	property	NOUN
dpc-2043	319	6	,	,	PUNCT
dpc-2043	319	7	and	and	CCONJ
dpc-2043	319	8	evolution	evolution	NOUN
dpc-2043	319	9	of	of	ADP
dpc-2043	319	10	an	an	DET
dpc-2043	319	11	ancient	ancient	ADJ
dpc-2043	319	12	organelle	organelle	NOUN
dpc-2043	319	13	.	.	PUNCT
dpc-2043	320	1	physiol	physiol	PROPN
dpc-2043	320	2	rev	rev	PROPN
dpc-2043	320	3	.	.	PUNCT
dpc-2043	320	4	2019;99(1):1	2019;99(1):1	NUM
dpc-2043	320	5	-	-	SYM
dpc-2043	320	6	19	19	NUM
dpc-2043	320	7	.	.	PUNCT
dpc-2043	321	1	doi	doi	NOUN
dpc-2043	321	2	:	:	PUNCT
dpc-2043	321	3	10.1152	10.1152	NUM
dpc-2043	321	4	/	/	SYM
dpc-2043	321	5	physrev.00059.2017	physrev.00059.2017	NOUN
dpc-2043	321	6	.	.	PUNCT
dpc-2043	322	1	pmid	pmid	NOUN
dpc-2043	322	2	:	:	PUNCT
dpc-2043	322	3	30255724	30255724	NUM
dpc-2043	322	4	.	.	PUNCT
dpc-2043	323	1	14	14	NUM
dpc-2043	323	2	.	.	PUNCT
dpc-2043	324	1	solano	solano	PROPN
dpc-2043	324	2	f.	f.	PROPN
dpc-2043	324	3	on	on	ADP
dpc-2043	324	4	the	the	DET
dpc-2043	324	5	metal	metal	NOUN
dpc-2043	324	6	cofactor	cofactor	NOUN
dpc-2043	324	7	in	in	ADP
dpc-2043	324	8	the	the	DET
dpc-2043	324	9	tyrosinase	tyrosinase	NOUN
dpc-2043	324	10	family	family	NOUN
dpc-2043	324	11	.	.	PUNCT
dpc-2043	325	1	int	int	PROPN
dpc-2043	325	2	j	j	PROPN
dpc-2043	325	3	mol	mol	ADP
dpc-2043	325	4	sci	sci	PROPN
dpc-2043	325	5	.	.	PROPN
dpc-2043	325	6	2018	2018	NUM
dpc-2043	325	7	;	;	PUNCT
dpc-2043	326	1	19(2):633	19(2):633	NUM
dpc-2043	326	2	.	.	PUNCT
dpc-2043	326	3	doi:10.3390	doi:10.3390	PROPN
dpc-2043	326	4	/	/	SYM
dpc-2043	326	5	ijms19020633	ijms19020633	PROPN
dpc-2043	326	6	.	.	PUNCT
dpc-2043	327	1	pmid	pmid	NOUN
dpc-2043	327	2	:	:	PUNCT
dpc-2043	327	3	29473882	29473882	NUM
dpc-2043	327	4	.	.	PUNCT
dpc-2043	328	1	pmcid	pmcid	NOUN
dpc-2043	328	2	:	:	PUNCT
dpc-2043	328	3	pmc5855855	pmc5855855	NOUN
dpc-2043	328	4	.	.	PUNCT
dpc-2043	329	1	15	15	X
dpc-2043	329	2	.	.	X
dpc-2043	329	3	altobelli	altobelli	PROPN
dpc-2043	329	4	gg	gg	PROPN
dpc-2043	329	5	,	,	PUNCT
dpc-2043	329	6	van	van	PROPN
dpc-2043	329	7	noorden	noorden	PROPN
dpc-2043	329	8	s	s	PROPN
dpc-2043	329	9	,	,	PUNCT
dpc-2043	329	10	balato	balato	NOUN
dpc-2043	329	11	a	a	DET
dpc-2043	329	12	,	,	PUNCT
dpc-2043	329	13	cimini	cimini	PROPN
dpc-2043	329	14	v.	v.	ADP
dpc-2043	329	15	copper	copper	NOUN
dpc-2043	329	16	/	/	SYM
dpc-2043	329	17	zinc	zinc	NOUN
dpc-2043	329	18	superoxide	superoxide	NOUN
dpc-2043	329	19	dismutase	dismutase	NOUN
dpc-2043	329	20	in	in	ADP
dpc-2043	329	21	human	human	ADJ
dpc-2043	329	22	skin	skin	NOUN
dpc-2043	329	23	:	:	PUNCT
dpc-2043	329	24	current	current	ADJ
dpc-2043	329	25	knowledge	knowledge	NOUN
dpc-2043	329	26	.	.	PUNCT
dpc-2043	330	1	front	front	ADJ
dpc-2043	330	2	8	8	NUM
dpc-2043	330	3	original	original	ADJ
dpc-2043	330	4	article	article	NOUN
dpc-2043	330	5	|	|	ADV
dpc-2043	330	6	dermatol	dermatol	ADJ
dpc-2043	330	7	pract	pract	NOUN
dpc-2043	330	8	concept	concept	NOUN
dpc-2043	330	9	.	.	PUNCT
dpc-2043	331	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	331	2	36	36	NUM
dpc-2043	331	3	.	.	PUNCT
dpc-2043	332	1	wang	wang	PROPN
dpc-2043	332	2	yd	yd	PROPN
dpc-2043	332	3	,	,	PUNCT
dpc-2043	332	4	liu	liu	PROPN
dpc-2043	332	5	xh	xh	PROPN
dpc-2043	332	6	,	,	PUNCT
dpc-2043	332	7	lv	lv	PROPN
dpc-2043	332	8	xh	xh	PROPN
dpc-2043	332	9	,	,	PUNCT
dpc-2043	332	10	et	et	PROPN
dpc-2043	332	11	al	al	PROPN
dpc-2043	332	12	.	.	PUNCT
dpc-2043	332	13	analysis	analysis	NOUN
dpc-2043	332	14	of	of	ADP
dpc-2043	332	15	serum	serum	NOUN
dpc-2043	332	16	trace	trace	NOUN
dpc-2043	332	17	elements	element	NOUN
dpc-2043	332	18	of	of	ADP
dpc-2043	332	19	vitiligo	vitiligo	ADJ
dpc-2043	332	20	patients	patient	NOUN
dpc-2043	332	21	in	in	ADP
dpc-2043	332	22	daqing	daqe	VERB
dpc-2043	332	23	district	district	NOUN
dpc-2043	332	24	.	.	PUNCT
dpc-2043	333	1	j	j	PROPN
dpc-2043	333	2	qiqihar	qiqihar	PROPN
dpc-2043	333	3	univ	univ	PROPN
dpc-2043	333	4	med	med	PROPN
dpc-2043	333	5	.	.	PROPN
dpc-2043	334	1	2012;33:39–40	2012;33:39–40	NUM
dpc-2043	334	2	.	.	X
dpc-2043	335	1	37	37	NUM
dpc-2043	335	2	.	.	PUNCT
dpc-2043	336	1	tan	tan	PROPN
dpc-2043	336	2	qm	qm	PROPN
dpc-2043	336	3	,	,	PUNCT
dpc-2043	336	4	wang	wang	PROPN
dpc-2043	336	5	cf	cf	PROPN
dpc-2043	336	6	,	,	PUNCT
dpc-2043	336	7	gan	gan	PROPN
dpc-2043	336	8	zj	zj	PROPN
dpc-2043	336	9	,	,	PUNCT
dpc-2043	336	10	et	et	PROPN
dpc-2043	336	11	al	al	PROPN
dpc-2043	336	12	.	.	PUNCT
dpc-2043	337	1	detecting	detect	VERB
dpc-2043	337	2	of	of	ADP
dpc-2043	337	3	copper	copper	NOUN
dpc-2043	337	4	and	and	CCONJ
dpc-2043	337	5	zinc	zinc	NOUN
dpc-2043	337	6	levels	level	NOUN
dpc-2043	337	7	in	in	ADP
dpc-2043	337	8	serum	serum	NOUN
dpc-2043	337	9	and	and	CCONJ
dpc-2043	337	10	skin	skin	NOUN
dpc-2043	337	11	lesions	lesion	NOUN
dpc-2043	337	12	,	,	PUNCT
dpc-2043	337	13	and	and	CCONJ
dpc-2043	337	14	free	free	ADJ
dpc-2043	337	15	radical	radical	ADJ
dpc-2043	337	16	eliminated	eliminate	VERB
dpc-2043	337	17	system	system	NOUN
dpc-2043	337	18	in	in	ADP
dpc-2043	337	19	serum	serum	NOUN
dpc-2043	337	20	in	in	ADP
dpc-2043	337	21	vitiligo	vitiligo	ADJ
dpc-2043	337	22	patients	patient	NOUN
dpc-2043	337	23	.	.	PUNCT
dpc-2043	338	1	j	j	PROPN
dpc-2043	338	2	clin	clin	PROPN
dpc-2043	338	3	dermat	dermat	PROPN
dpc-2043	338	4	.	.	PUNCT
dpc-2043	339	1	1997;3:171–173	1997;3:171–173	NUM
dpc-2043	339	2	.	.	PUNCT
dpc-2043	340	1	38	38	NUM
dpc-2043	340	2	.	.	PUNCT
dpc-2043	341	1	archana	archana	PROPN
dpc-2043	341	2	s	s	PROPN
dpc-2043	341	3	,	,	PUNCT
dpc-2043	341	4	rangappa	rangappa	VERB
dpc-2043	341	5	v	v	NOUN
dpc-2043	341	6	,	,	PUNCT
dpc-2043	341	7	savitha	savitha	PROPN
dpc-2043	341	8	t	t	PROPN
dpc-2043	341	9	,	,	PUNCT
dpc-2043	341	10	jayadev	jayadev	PROPN
dpc-2043	341	11	b	b	PROPN
dpc-2043	341	12	,	,	PUNCT
dpc-2043	341	13	kushalappa	kushalappa	PROPN
dpc-2043	341	14	pa	pa	PROPN
dpc-2043	341	15	,	,	PUNCT
dpc-2043	341	16	ashwini	ashwini	PROPN
dpc-2043	341	17	pk	pk	NOUN
dpc-2043	341	18	.	.	PROPN
dpc-2043	341	19	does	do	AUX
dpc-2043	341	20	copper	copper	NOUN
dpc-2043	341	21	has	have	VERB
dpc-2043	341	22	a	a	DET
dpc-2043	341	23	role	role	NOUN
dpc-2043	341	24	in	in	ADP
dpc-2043	341	25	vitiligo	vitiligo	NOUN
dpc-2043	341	26	?	?	PUNCT
dpc-2043	342	1	analysis	analysis	NOUN
dpc-2043	342	2	of	of	ADP
dpc-2043	342	3	tissue	tissue	NOUN
dpc-2043	342	4	and	and	CCONJ
dpc-2043	342	5	serum	serum	NOUN
dpc-2043	342	6	copper	copper	NOUN
dpc-2043	342	7	in	in	ADP
dpc-2043	342	8	vitiligo	vitiligo	PROPN
dpc-2043	342	9	.	.	PUNCT
dpc-2043	343	1	pigment	pigment	PROPN
dpc-2043	343	2	int	int	PROPN
dpc-2043	343	3	.	.	PUNCT
dpc-2043	344	1	2021;8:30	2021;8:30	NOUN
dpc-2043	344	2	-	-	PUNCT
dpc-2043	344	3	34	34	NUM
dpc-2043	344	4	.	.	PUNCT
dpc-2043	345	1	doi	doi	PROPN
dpc-2043	345	2	:	:	PUNCT
dpc-2043	345	3	 	 	SPACE
dpc-2043	345	4	10.4103	10.4103	NUM
dpc-2043	345	5	/	/	SYM
dpc-2043	345	6	pigmentinternational.pigmentinternational	pigmentinternational.pigmentinternational	NUM
dpc-2043	345	7	_	_	NOUN
dpc-2043	345	8	39	39	NUM
dpc-2043	345	9	.	.	PUNCT
dpc-2043	346	1	parizadeh	parizadeh	NOUN
dpc-2043	346	2	smr	smr	PROPN
dpc-2043	346	3	,	,	PUNCT
dpc-2043	346	4	kazemi	kazemi	PROPN
dpc-2043	346	5	-	-	PUNCT
dpc-2043	346	6	bajestani	bajestani	NOUN
dpc-2043	346	7	smr	smr	NOUN
dpc-2043	346	8	,	,	PUNCT
dpc-2043	346	9	shapourimoghaddam	shapourimoghaddam	NOUN
dpc-2043	346	10	a	a	X
dpc-2043	346	11	,	,	PUNCT
dpc-2043	346	12	et	et	PROPN
dpc-2043	346	13	al	al	PROPN
dpc-2043	346	14	.	.	PROPN
dpc-2043	346	15	serum	serum	PROPN
dpc-2043	346	16	zinc	zinc	PROPN
dpc-2043	346	17	and	and	CCONJ
dpc-2043	346	18	copper	copper	NOUN
dpc-2043	346	19	concentrations	concentration	NOUN
dpc-2043	346	20	and	and	CCONJ
dpc-2043	346	21	socioeconomic	socioeconomic	ADJ
dpc-2043	346	22	status	status	NOUN
dpc-2043	346	23	in	in	ADP
dpc-2043	346	24	a	a	DET
dpc-2043	346	25	large	large	ADJ
dpc-2043	346	26	persian	persian	ADJ
dpc-2043	346	27	cohort	cohort	NOUN
dpc-2043	346	28	.	.	PUNCT
dpc-2043	347	1	asian	asian	ADJ
dpc-2043	347	2	biomedicine	biomedicine	NOUN
dpc-2043	347	3	.	.	PUNCT
dpc-2043	348	1	2017;5:329	2017;5:329	NUM
dpc-2043	348	2	-	-	PUNCT
dpc-2043	348	3	335	335	NUM
dpc-2043	348	4	.	.	PUNCT
dpc-2043	349	1	doi	doi	NOUN
dpc-2043	349	2	:	:	PUNCT
dpc-2043	349	3	10.5372/1905	10.5372/1905	NUM
dpc-2043	349	4	-	-	SYM
dpc-2043	349	5	7415.0502.028	7415.0502.028	NUM
dpc-2043	349	6	.	.	NOUN
dpc-2043	349	7	40	40	NUM
dpc-2043	349	8	.	.	PUNCT
dpc-2043	350	1	wright	wright	PROPN
dpc-2043	350	2	aj	aj	PROPN
dpc-2043	350	3	,	,	PUNCT
dpc-2043	350	4	southon	southon	PROPN
dpc-2043	350	5	s	s	PROPN
dpc-2043	350	6	,	,	PUNCT
dpc-2043	350	7	bailey	bailey	PROPN
dpc-2043	350	8	al	al	PROPN
dpc-2043	350	9	,	,	PUNCT
dpc-2043	350	10	finglas	finglas	PROPN
dpc-2043	350	11	pm	pm	NOUN
dpc-2043	350	12	,	,	PUNCT
dpc-2043	350	13	maisey	maisey	NOUN
dpc-2043	350	14	s	s	PROPN
dpc-2043	350	15	,	,	PUNCT
dpc-2043	350	16	fulcher	fulcher	ADJ
dpc-2043	350	17	ra	ra	PROPN
dpc-2043	350	18	.	.	PUNCT
dpc-2043	351	1	nutrient	nutrient	PROPN
dpc-2043	351	2	intake	intake	NOUN
dpc-2043	351	3	and	and	CCONJ
dpc-2043	351	4	biochemical	biochemical	ADJ
dpc-2043	351	5	status	status	NOUN
dpc-2043	351	6	of	of	ADP
dpc-2043	351	7	non	non	ADJ
dpc-2043	351	8	-	-	ADJ
dpc-2043	351	9	instutionalized	instutionalized	ADJ
dpc-2043	351	10	elderly	elderly	ADJ
dpc-2043	351	11	subjects	subject	NOUN
dpc-2043	351	12	in	in	ADP
dpc-2043	351	13	norwich	norwich	NOUN
dpc-2043	351	14	:	:	PUNCT
dpc-2043	351	15	comparison	comparison	NOUN
dpc-2043	351	16	with	with	ADP
dpc-2043	351	17	younger	young	ADJ
dpc-2043	351	18	adults	adult	NOUN
dpc-2043	351	19	and	and	CCONJ
dpc-2043	351	20	adolescents	adolescent	NOUN
dpc-2043	351	21	from	from	ADP
dpc-2043	351	22	the	the	DET
dpc-2043	351	23	same	same	ADJ
dpc-2043	351	24	general	general	ADJ
dpc-2043	351	25	community	community	NOUN
dpc-2043	351	26	.	.	PUNCT
dpc-2043	352	1	br	br	PROPN
dpc-2043	352	2	j	j	PROPN
dpc-2043	352	3	nutr	nutr	PROPN
dpc-2043	352	4	.	.	PUNCT
dpc-2043	353	1	1995;74(4):453475	1995;74(4):453475	NUM
dpc-2043	353	2	.	.	PUNCT
dpc-2043	354	1	doi	doi	NOUN
dpc-2043	354	2	:	:	PUNCT
dpc-2043	354	3	10.1079	10.1079	NUM
dpc-2043	354	4	/	/	SYM
dpc-2043	354	5	bjn19950151	bjn19950151	NOUN
dpc-2043	354	6	.	.	PUNCT
dpc-2043	355	1	pmid	pmid	NOUN
dpc-2043	355	2	:	:	PUNCT
dpc-2043	355	3	7577886	7577886	NUM
dpc-2043	355	4	.	.	PUNCT
dpc-2043	356	1	41	41	NUM
dpc-2043	356	2	.	.	PUNCT
dpc-2043	357	1	vrijman	vrijman	PROPN
dpc-2043	357	2	c	c	PROPN
dpc-2043	357	3	,	,	PUNCT
dpc-2043	357	4	kroon	kroon	PROPN
dpc-2043	357	5	mw	mw	PROPN
dpc-2043	357	6	,	,	PUNCT
dpc-2043	357	7	limpens	limpens	PROPN
dpc-2043	357	8	j	j	PROPN
dpc-2043	357	9	,	,	PUNCT
dpc-2043	357	10	et	et	PROPN
dpc-2043	357	11	al	al	PROPN
dpc-2043	357	12	.	.	PUNCT
dpc-2043	358	1	the	the	DET
dpc-2043	358	2	prevalence	prevalence	NOUN
dpc-2043	358	3	of	of	ADP
dpc-2043	358	4	thyroid	thyroid	NOUN
dpc-2043	358	5	disease	disease	NOUN
dpc-2043	358	6	in	in	ADP
dpc-2043	358	7	patients	patient	NOUN
dpc-2043	358	8	with	with	ADP
dpc-2043	358	9	vitiligo	vitiligo	NOUN
dpc-2043	358	10	:	:	PUNCT
dpc-2043	358	11	a	a	DET
dpc-2043	358	12	systematic	systematic	ADJ
dpc-2043	358	13	review	review	NOUN
dpc-2043	358	14	.	.	PUNCT
dpc-2043	359	1	br	br	PROPN
dpc-2043	359	2	j	j	PROPN
dpc-2043	359	3	dermatol	dermatol	NOUN
dpc-2043	359	4	.	.	PUNCT
dpc-2043	360	1	2012;167(6):1224	2012;167(6):1224	NUM
dpc-2043	360	2	-	-	SYM
dpc-2043	360	3	1235	1235	NUM
dpc-2043	360	4	.	.	PUNCT
dpc-2043	361	1	doi	doi	NOUN
dpc-2043	361	2	:	:	PUNCT
dpc-2043	361	3	10.1111	10.1111	NUM
dpc-2043	361	4	/	/	SYM
dpc-2043	361	5	j.1365	j.1365	NOUN
dpc-2043	361	6	-	-	PUNCT
dpc-2043	361	7	2133.2012.111	2133.2012.111	NUM
dpc-2043	361	8	98.x	98.x	NOUN
dpc-2043	361	9	.	.	PUNCT
dpc-2043	362	1	pmid	pmid	NOUN
dpc-2043	362	2	:	:	PUNCT
dpc-2043	362	3	22860695	22860695	NUM
dpc-2043	362	4	.	.	PUNCT
dpc-2043	363	1	30	30	NUM
dpc-2043	363	2	.	.	PUNCT
dpc-2043	364	1	wu	wu	PROPN
dpc-2043	364	2	y	y	PROPN
dpc-2043	364	3	,	,	PUNCT
dpc-2043	364	4	he	he	PRON
dpc-2043	364	5	n	n	CCONJ
dpc-2043	364	6	,	,	PUNCT
dpc-2043	364	7	li	li	PROPN
dpc-2043	364	8	js	js	PROPN
dpc-2043	364	9	,	,	PUNCT
dpc-2043	364	10	et	et	PROPN
dpc-2043	364	11	al	al	PROPN
dpc-2043	364	12	.	.	PUNCT
dpc-2043	365	1	the	the	DET
dpc-2043	365	2	zinc	zinc	NOUN
dpc-2043	365	3	and	and	CCONJ
dpc-2043	365	4	copper	copper	NOUN
dpc-2043	365	5	levels	level	NOUN
dpc-2043	365	6	in	in	ADP
dpc-2043	365	7	serum	serum	NOUN
dpc-2043	365	8	of	of	ADP
dpc-2043	365	9	70	70	NUM
dpc-2043	365	10	vitiligo	vitiligo	NOUN
dpc-2043	365	11	patients	patient	NOUN
dpc-2043	365	12	from	from	ADP
dpc-2043	365	13	guangxi	guangxi	PROPN
dpc-2043	365	14	province	province	PROPN
dpc-2043	365	15	.	.	PUNCT
dpc-2043	366	1	chin	chin	PROPN
dpc-2043	366	2	j	j	PROPN
dpc-2043	366	3	derm	derm	NOUN
dpc-2043	366	4	venereol	venereol	NOUN
dpc-2043	366	5	.	.	PUNCT
dpc-2043	367	1	2010;24	2010;24	NUM
dpc-2043	367	2	:	:	PUNCT
dpc-2043	368	1	722–723	722–723	NUM
dpc-2043	368	2	.	.	NOUN
dpc-2043	368	3	31	31	NUM
dpc-2043	368	4	.	.	PUNCT
dpc-2043	369	1	narang	narang	PROPN
dpc-2043	369	2	i	i	PROPN
dpc-2043	369	3	,	,	PUNCT
dpc-2043	369	4	barman	barman	PROPN
dpc-2043	369	5	kd	kd	PROPN
dpc-2043	369	6	,	,	PUNCT
dpc-2043	369	7	sahoo	sahoo	PROPN
dpc-2043	369	8	b	b	PROPN
dpc-2043	369	9	,	,	PUNCT
dpc-2043	369	10	lali	lali	PROPN
dpc-2043	369	11	p.	p.	PROPN
dpc-2043	369	12	evaluation	evaluation	NOUN
dpc-2043	369	13	of	of	ADP
dpc-2043	369	14	serum	serum	NOUN
dpc-2043	369	15	levels	level	NOUN
dpc-2043	369	16	of	of	ADP
dpc-2043	369	17	zinc	zinc	NOUN
dpc-2043	369	18	and	and	CCONJ
dpc-2043	369	19	copper	copper	NOUN
dpc-2043	369	20	in	in	ADP
dpc-2043	369	21	vitiligo	vitiligo	PROPN
dpc-2043	369	22	.	.	PUNCT
dpc-2043	370	1	pigment	pigment	PROPN
dpc-2043	370	2	int	int	PROPN
dpc-2043	370	3	.	.	PUNCT
dpc-2043	371	1	2021	2021	NUM
dpc-2043	371	2	8:42	8:42	NUM
dpc-2043	371	3	-	-	SYM
dpc-2043	371	4	47	47	NUM
dpc-2043	371	5	.	.	PUNCT
dpc-2043	372	1	doi	doi	NOUN
dpc-2043	372	2	:	:	PUNCT
dpc-2043	372	3	 	 	SPACE
dpc-2043	372	4	10.4103	10.4103	NUM
dpc-2043	372	5	/	/	SYM
dpc-2043	372	6	pigmentinternational.pigmentinternational	pigmentinternational.pigmentinternational	NUM
dpc-2043	372	7	_	_	NOUN
dpc-2043	372	8	32	32	NUM
dpc-2043	372	9	.	.	PUNCT
dpc-2043	373	1	yelinova	yelinova	PROPN
dpc-2043	373	2	v	v	PROPN
dpc-2043	373	3	,	,	PUNCT
dpc-2043	373	4	glazachev	glazachev	VERB
dpc-2043	373	5	y	y	PROPN
dpc-2043	373	6	,	,	PUNCT
dpc-2043	373	7	khramtsov	khramtsov	PROPN
dpc-2043	373	8	v	v	NOUN
dpc-2043	373	9	,	,	PUNCT
dpc-2043	373	10	kudryashova	kudryashova	PROPN
dpc-2043	373	11	l	l	NOUN
dpc-2043	373	12	,	,	PUNCT
dpc-2043	373	13	rykova	rykova	PROPN
dpc-2043	373	14	v	v	NOUN
dpc-2043	373	15	,	,	PUNCT
dpc-2043	373	16	salganik	salganik	PROPN
dpc-2043	373	17	r.	r.	PROPN
dpc-2043	373	18	studies	study	NOUN
dpc-2043	373	19	of	of	ADP
dpc-2043	373	20	human	human	ADJ
dpc-2043	373	21	and	and	CCONJ
dpc-2043	373	22	rat	rat	NOUN
dpc-2043	373	23	blood	blood	NOUN
dpc-2043	373	24	under	under	ADP
dpc-2043	373	25	oxidative	oxidative	ADJ
dpc-2043	373	26	stress	stress	NOUN
dpc-2043	373	27	:	:	PUNCT
dpc-2043	373	28	changes	change	NOUN
dpc-2043	373	29	in	in	ADP
dpc-2043	373	30	plasma	plasma	NOUN
dpc-2043	373	31	thiol	thiol	ADJ
dpc-2043	373	32	level	level	NOUN
dpc-2043	373	33	,	,	PUNCT
dpc-2043	373	34	antioxidant	antioxidant	ADJ
dpc-2043	373	35	enzyme	enzyme	NOUN
dpc-2043	373	36	activity	activity	NOUN
dpc-2043	373	37	,	,	PUNCT
dpc-2043	373	38	protein	protein	NOUN
dpc-2043	373	39	carbonyl	carbonyl	NOUN
dpc-2043	373	40	content	content	NOUN
dpc-2043	373	41	,	,	PUNCT
dpc-2043	373	42	and	and	CCONJ
dpc-2043	373	43	fluidity	fluidity	NOUN
dpc-2043	373	44	of	of	ADP
dpc-2043	373	45	erythrocyte	erythrocyte	ADJ
dpc-2043	373	46	membrane	membrane	NOUN
dpc-2043	373	47	.	.	PUNCT
dpc-2043	374	1	biochem	biochem	PROPN
dpc-2043	374	2	biophys	biophy	VERB
dpc-2043	374	3	res	re	NOUN
dpc-2043	374	4	commun	commun	PROPN
dpc-2043	374	5	.	.	PUNCT
dpc-2043	375	1	1996;221(2):300	1996;221(2):300	NUM
dpc-2043	375	2	-	-	SYM
dpc-2043	375	3	303	303	NUM
dpc-2043	375	4	.	.	PUNCT
dpc-2043	376	1	doi	doi	NOUN
dpc-2043	376	2	:	:	PUNCT
dpc-2043	376	3	10.1006	10.1006	NUM
dpc-2043	376	4	/	/	SYM
dpc-2043	376	5	bbrc.1996.0590	bbrc.1996.0590	NUM
dpc-2043	376	6	.	.	PUNCT
dpc-2043	377	1	pmid	pmid	NOUN
dpc-2043	377	2	:	:	PUNCT
dpc-2043	377	3	8619850	8619850	NUM
dpc-2043	377	4	.	.	PUNCT
dpc-2043	378	1	33	33	NUM
dpc-2043	378	2	.	.	PUNCT
dpc-2043	379	1	mezzetti	mezzetti	PROPN
dpc-2043	379	2	a	a	X
dpc-2043	379	3	,	,	PUNCT
dpc-2043	379	4	pierdomenico	pierdomenico	NOUN
dpc-2043	379	5	sd	sd	NOUN
dpc-2043	379	6	,	,	PUNCT
dpc-2043	379	7	costantini	costantini	PROPN
dpc-2043	379	8	f	f	PROPN
dpc-2043	379	9	,	,	PUNCT
dpc-2043	379	10	et	et	PROPN
dpc-2043	379	11	al	al	PROPN
dpc-2043	379	12	.	.	PUNCT
dpc-2043	379	13	copper	copper	PROPN
dpc-2043	379	14	/	/	SYM
dpc-2043	379	15	zinc	zinc	NOUN
dpc-2043	379	16	ratio	ratio	NOUN
dpc-2043	379	17	and	and	CCONJ
dpc-2043	379	18	systemic	systemic	ADJ
dpc-2043	379	19	oxidant	oxidant	ADJ
dpc-2043	379	20	load	load	NOUN
dpc-2043	379	21	:	:	PUNCT
dpc-2043	379	22	effect	effect	NOUN
dpc-2043	379	23	of	of	ADP
dpc-2043	379	24	aging	age	VERB
dpc-2043	379	25	and	and	CCONJ
dpc-2043	379	26	aging	age	VERB
dpc-2043	379	27	-	-	PUNCT
dpc-2043	379	28	related	relate	VERB
dpc-2043	379	29	degenerative	degenerative	ADJ
dpc-2043	379	30	diseases	disease	NOUN
dpc-2043	379	31	.	.	PUNCT
dpc-2043	380	1	free	free	ADJ
dpc-2043	380	2	radic	radic	ADJ
dpc-2043	380	3	biol	biol	PROPN
dpc-2043	380	4	med	me	VERB
dpc-2043	380	5	.	.	PUNCT
dpc-2043	381	1	1998;25(6):676	1998;25(6):676	PROPN
dpc-2043	381	2	-	-	PUNCT
dpc-2043	381	3	681	681	NUM
dpc-2043	381	4	.	.	PUNCT
dpc-2043	382	1	doi	doi	NOUN
dpc-2043	382	2	:	:	PUNCT
dpc-2043	382	3	10.1016	10.1016	NUM
dpc-2043	382	4	/	/	SYM
dpc-2043	382	5	s0891	s0891	NUM
dpc-2043	382	6	-	-	PUNCT
dpc-2043	382	7	5849(98)00109	5849(98)00109	NUM
dpc-2043	382	8	-	-	PUNCT
dpc-2043	382	9	9	9	NUM
dpc-2043	382	10	.	.	PUNCT
dpc-2043	383	1	pmid	pmid	NOUN
dpc-2043	383	2	:	:	PUNCT
dpc-2043	383	3	9801067	9801067	NUM
dpc-2043	383	4	.	.	PUNCT
dpc-2043	384	1	34	34	NUM
dpc-2043	384	2	.	.	X
dpc-2043	384	3	wacewicz	wacewicz	PROPN
dpc-2043	384	4	m	m	PROPN
dpc-2043	384	5	,	,	PUNCT
dpc-2043	384	6	socha	socha	PROPN
dpc-2043	384	7	k	k	PROPN
dpc-2043	384	8	,	,	PUNCT
dpc-2043	384	9	soroczyńska	soroczyńska	PROPN
dpc-2043	384	10	j	j	PROPN
dpc-2043	384	11	,	,	PUNCT
dpc-2043	384	12	et	et	PROPN
dpc-2043	384	13	al	al	PROPN
dpc-2043	384	14	.	.	PROPN
dpc-2043	384	15	selenium	selenium	NOUN
dpc-2043	384	16	,	,	PUNCT
dpc-2043	384	17	zinc	zinc	NOUN
dpc-2043	384	18	,	,	PUNCT
dpc-2043	384	19	copper	copper	NOUN
dpc-2043	384	20	,	,	PUNCT
dpc-2043	384	21	cu	cu	PROPN
dpc-2043	384	22	/	/	SYM
dpc-2043	384	23	zn	zn	PROPN
dpc-2043	384	24	ratio	ratio	NOUN
dpc-2043	384	25	and	and	CCONJ
dpc-2043	384	26	total	total	ADJ
dpc-2043	384	27	antioxidant	antioxidant	ADJ
dpc-2043	384	28	status	status	NOUN
dpc-2043	384	29	in	in	ADP
dpc-2043	384	30	the	the	DET
dpc-2043	384	31	serum	serum	NOUN
dpc-2043	384	32	of	of	ADP
dpc-2043	384	33	vitiligo	vitiligo	ADJ
dpc-2043	384	34	patients	patient	NOUN
dpc-2043	384	35	treated	treat	VERB
dpc-2043	384	36	by	by	ADP
dpc-2043	384	37	narrow	narrow	ADJ
dpc-2043	384	38	-	-	PUNCT
dpc-2043	384	39	band	band	NOUN
dpc-2043	384	40	ultraviolet	ultraviolet	NOUN
dpc-2043	384	41	-	-	PUNCT
dpc-2043	384	42	b	b	NOUN
dpc-2043	384	43	phototherapy	phototherapy	NOUN
dpc-2043	384	44	.	.	PUNCT
dpc-2043	385	1	j	j	PROPN
dpc-2043	385	2	dermatolog	dermatolog	PROPN
dpc-2043	385	3	treat	treat	NOUN
dpc-2043	385	4	.	.	PUNCT
dpc-2043	386	1	2018;29(2):190	2018;29(2):190	PROPN
dpc-2043	386	2	-	-	PUNCT
dpc-2043	386	3	195	195	NUM
dpc-2043	386	4	.	.	PUNCT
dpc-2043	386	5	doi	doi	NOUN
dpc-2043	386	6	:	:	PUNCT
dpc-2043	386	7	10.1080/09546634.2017.1357797	10.1080/09546634.2017.1357797	NUM
dpc-2043	386	8	.	.	PUNCT
dpc-2043	387	1	pmid	pmid	NOUN
dpc-2043	387	2	:	:	PUNCT
dpc-2043	387	3	28718676	28718676	NUM
dpc-2043	387	4	.	.	PUNCT
dpc-2043	388	1	35	35	NUM
dpc-2043	388	2	.	.	PUNCT
dpc-2043	389	1	tasaki	tasaki	PROPN
dpc-2043	389	2	m	m	PROPN
dpc-2043	389	3	,	,	PUNCT
dpc-2043	389	4	hanada	hanada	PROPN
dpc-2043	389	5	k	k	NOUN
dpc-2043	389	6	,	,	PUNCT
dpc-2043	389	7	hashimoto	hashimoto	NOUN
dpc-2043	389	8	i.	i.	NOUN
dpc-2043	389	9	analyses	analysis	NOUN
dpc-2043	389	10	of	of	ADP
dpc-2043	389	11	serum	serum	NOUN
dpc-2043	389	12	copper	copper	NOUN
dpc-2043	389	13	and	and	CCONJ
dpc-2043	389	14	zinc	zinc	NOUN
dpc-2043	389	15	levels	level	NOUN
dpc-2043	389	16	and	and	CCONJ
dpc-2043	389	17	copper	copper	NOUN
dpc-2043	389	18	/	/	SYM
dpc-2043	389	19	zinc	zinc	NOUN
dpc-2043	389	20	ratios	ratio	NOUN
dpc-2043	389	21	in	in	ADP
dpc-2043	389	22	skin	skin	NOUN
dpc-2043	389	23	diseases	disease	NOUN
dpc-2043	389	24	.	.	PUNCT
dpc-2043	390	1	j	j	NOUN
dpc-2043	390	2	  	  	SPACE
dpc-2043	390	3	dermatol	dermatol	NOUN
dpc-2043	390	4	.	.	PUNCT
dpc-2043	391	1	1993;20(1	1993;20(1	NUM
dpc-2043	391	2	):	):	PUNCT
dpc-2043	391	3	21	21	NUM
dpc-2043	391	4	-	-	SYM
dpc-2043	391	5	24	24	NUM
dpc-2043	391	6	.	.	PUNCT
dpc-2043	391	7	doi	doi	NOUN
dpc-2043	391	8	:	:	PUNCT
dpc-2043	391	9	10.1111	10.1111	NUM
dpc-2043	391	10	/	/	SYM
dpc-2043	391	11	j.1346	j.1346	VERB
dpc-2043	391	12	-	-	PUNCT
dpc-2043	391	13	8138.1993.tb03823.x	8138.1993.tb03823.x	NOUN
dpc-2043	391	14	.	.	PUNCT
dpc-2043	392	1	pmid	pmid	NOUN
dpc-2043	392	2	:	:	PUNCT
dpc-2043	392	3	8482748	8482748	NUM
dpc-2043	392	4	.	.	PUNCT
dpc-2043	393	1	original	original	ADJ
dpc-2043	393	2	article	article	NOUN
dpc-2043	393	3	|	|	ADV
dpc-2043	393	4	dermatol	dermatol	ADJ
dpc-2043	393	5	pract	pract	NOUN
dpc-2043	393	6	concept	concept	NOUN
dpc-2043	393	7	.	.	PUNCT
dpc-2043	394	1	2022;12(4):e2022140	2022;12(4):e2022140	NUM
dpc-2043	394	2	9	9	NUM
dpc-2043	394	3	42	42	NUM
dpc-2043	394	4	.	.	PUNCT
dpc-2043	395	1	terpiłowska	terpiłowska	PROPN
dpc-2043	395	2	s	s	PROPN
dpc-2043	395	3	,	,	PUNCT
dpc-2043	395	4	siwicki	siwicki	PROPN
dpc-2043	395	5	ak	ak	PROPN
dpc-2043	395	6	.	.	PUNCT
dpc-2043	396	1	the	the	DET
dpc-2043	396	2	role	role	NOUN
dpc-2043	396	3	of	of	ADP
dpc-2043	396	4	selected	select	VERB
dpc-2043	396	5	microelements	microelement	NOUN
dpc-2043	396	6	:	:	PUNCT
dpc-2043	396	7	selenium	selenium	NOUN
dpc-2043	396	8	,	,	PUNCT
dpc-2043	396	9	zinc	zinc	NOUN
dpc-2043	396	10	,	,	PUNCT
dpc-2043	396	11	chromium	chromium	NOUN
dpc-2043	396	12	and	and	CCONJ
dpc-2043	396	13	iron	iron	NOUN
dpc-2043	396	14	in	in	ADP
dpc-2043	396	15	immune	immune	ADJ
dpc-2043	396	16	system	system	NOUN
dpc-2043	396	17	.	.	PUNCT
dpc-2043	397	1	centr	centr	VERB
dpc-2043	397	2	eur	eur	PROPN
dpc-2043	397	3	j	j	PROPN
dpc-2043	397	4	immunol	immunol	NOUN
dpc-2043	397	5	.	.	PUNCT
dpc-2043	398	1	2011;36:303–307	2011;36:303–307	NUM
dpc-2043	398	2	.	.	PUNCT
dpc-2043	399	1	43	43	NUM
dpc-2043	399	2	.	.	PUNCT
dpc-2043	400	1	cannas	canna	NOUN
dpc-2043	400	2	d	d	PROPN
dpc-2043	400	3	,	,	PUNCT
dpc-2043	400	4	loi	loi	PROPN
dpc-2043	400	5	e	e	PROPN
dpc-2043	400	6	,	,	PUNCT
dpc-2043	400	7	serra	serra	PROPN
dpc-2043	400	8	m	m	PROPN
dpc-2043	400	9	,	,	PUNCT
dpc-2043	400	10	firinu	firinu	PROPN
dpc-2043	400	11	d	d	PROPN
dpc-2043	400	12	,	,	PUNCT
dpc-2043	400	13	valera	valera	PROPN
dpc-2043	400	14	p	p	PROPN
dpc-2043	400	15	,	,	PUNCT
dpc-2043	400	16	zavattari	zavattari	PROPN
dpc-2043	400	17	p.	p.	NOUN
dpc-2043	400	18	relevance	relevance	NOUN
dpc-2043	400	19	of	of	ADP
dpc-2043	400	20	essential	essential	ADJ
dpc-2043	400	21	trace	trace	NOUN
dpc-2043	400	22	elements	element	NOUN
dpc-2043	400	23	in	in	ADP
dpc-2043	400	24	nutrition	nutrition	NOUN
dpc-2043	400	25	and	and	CCONJ
dpc-2043	400	26	drinking	drink	VERB
dpc-2043	400	27	water	water	NOUN
dpc-2043	400	28	for	for	ADP
dpc-2043	400	29	human	human	ADJ
dpc-2043	400	30	health	health	PROPN
dpc-2043	400	31	and	and	CCONJ
dpc-2043	400	32	autoimmune	autoimmune	ADJ
dpc-2043	400	33	disease	disease	NOUN
dpc-2043	400	34	risk	risk	NOUN
dpc-2043	400	35	.	.	PUNCT
dpc-2043	401	1	nutrients	nutrient	NOUN
dpc-2043	401	2	.	.	PUNCT
dpc-2043	402	1	2020;12(7):2074	2020;12(7):2074	PROPN
dpc-2043	402	2	.	.	PUNCT
dpc-2043	403	1	doi:10.3390	doi:10.3390	PROPN
dpc-2043	403	2	/	/	SYM
dpc-2043	403	3	nu12072074	nu12072074	PROPN
dpc-2043	403	4	.	.	PUNCT
dpc-2043	404	1	pmid	pmid	NOUN
dpc-2043	404	2	:	:	PUNCT
dpc-2043	404	3	32668647	32668647	NUM
dpc-2043	404	4	.	.	PUNCT
dpc-2043	405	1	pmcid	pmcid	ADJ
dpc-2043	405	2	:	:	PUNCT
dpc-2043	405	3	pmc7400883	pmc7400883	NOUN
dpc-2043	405	4	.	.	PUNCT
dpc-2043	406	1	44	44	NUM
dpc-2043	406	2	.	.	PUNCT
dpc-2043	407	1	sanna	sanna	PROPN
dpc-2043	407	2	a	a	PRON
dpc-2043	407	3	,	,	PUNCT
dpc-2043	407	4	firinu	firinu	NOUN
dpc-2043	407	5	d	d	PROPN
dpc-2043	407	6	,	,	PUNCT
dpc-2043	407	7	zavattari	zavattari	PROPN
dpc-2043	407	8	p	p	X
dpc-2043	407	9	,	,	PUNCT
dpc-2043	407	10	valera	valera	PROPN
dpc-2043	407	11	p.	p.	PROPN
dpc-2043	407	12	zinc	zinc	NOUN
dpc-2043	407	13	status	status	NOUN
dpc-2043	407	14	and	and	CCONJ
dpc-2043	407	15	autoimmunity	autoimmunity	NOUN
dpc-2043	407	16	:	:	PUNCT
dpc-2043	407	17	a	a	DET
dpc-2043	407	18	systematic	systematic	ADJ
dpc-2043	407	19	review	review	NOUN
dpc-2043	407	20	and	and	CCONJ
dpc-2043	407	21	meta	meta	ADJ
dpc-2043	407	22	-	-	PUNCT
dpc-2043	407	23	analysis	analysis	NOUN
dpc-2043	407	24	.	.	PUNCT
dpc-2043	408	1	nutrients	nutrient	NOUN
dpc-2043	408	2	.	.	PUNCT
dpc-2043	409	1	2018;10:68	2018;10:68	X
dpc-2043	409	2	.	.	PUNCT
dpc-2043	410	1	doi	doi	NOUN
dpc-2043	410	2	:	:	PUNCT
dpc-2043	410	3	10.3390	10.3390	NUM
dpc-2043	410	4	/	/	SYM
dpc-2043	410	5	nu10010068	nu10010068	ADJ
dpc-2043	410	6	.	.	PUNCT
dpc-2043	411	1	pmid	pmid	NOUN
dpc-2043	411	2	:	:	PUNCT
dpc-2043	411	3	29324654	29324654	NUM
dpc-2043	411	4	.	.	PUNCT
dpc-2043	412	1	pmcid	pmcid	NOUN
dpc-2043	412	2	:	:	PUNCT
dpc-2043	412	3	pmc	pmc	PROPN
dpc-2043	412	4	5793296	5793296	NUM
dpc-2043	412	5	.	.	PUNCT